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ABSTRACT 
CHRISTOPHER GILLETTE: The Effect of Risk, Side Effect, and Benefit 
Communication in Pediatric Asthma Visits on Asthma Control Medication Adherence, 
Caregiver- and Child- Reported Problems/Concerns about Side Effects 
(Under the direction of Dr. Betsy Sleath) 
A secondary analysis was conducted on child interview, caregiver questionnaire, 
and transcripts of audiotaped medical visit data collected in North Carolina clinics from 
2005-2009.  The data includes 35 providers and 295 children with persistent asthma.  
Qualitative analyses examined the content of control medication side effect, risk, and 
benefit discussions.  Generalized estimating equations were used to predict side effect, 
risk, and benefit discussions, medication adherence, and concerns about side effects. 
Results revealed that 4% of visits included side effect discussions. Side effect 
discussions were more likely with younger children.  Sixteen percent of visits included 
risk discussions.  Risks were more likely to be discussed when children were 
taking/prescribed an inhaled corticosteroid and during longer visits.  
Approximately 47% of visits included benefit discussions.  Benefits were more 
likely to be discussed when: the child was younger; the child was taking/prescribed an 
inhaled corticosteroid; and adherence was discussed.  
Average medication adherence was 85%.  Caregivers were more likely to report 
the child as 80% or more adherent when the: child took more control medications, visit 
was longer, and the child had seen the provider more.  Discussions of medication risks 
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were not associated with control medication adherence of at least 80%, contrary to our 
hypothesis. 
Approximately 37% of caregivers reported a concern about side effects.  
Caregivers were more likely to report a concern when the child had seen the provider 
less.  Discussions of risks were not associated with caregivers reporting a 
problem/concern about side effects, contrary to our hypothesis.   Approximately 33% of 
children reported a concern about side effects.  Children were more likely to report a 
concern about side effects when the: caregiver was not married, child did not take an 
inhaled corticosteroid, and they saw male providers.  Discussions of side effects and 
benefits were not associated with the child reporting a concern, contrary to the 
hypotheses.   
Study results showed that discussions of medication benefits were more frequent 
than discussions of side effects and risks, although less than half of visits had benefit 
discussions.  Future research should investigate how to improve communication in these 
areas.  
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CHAPTER ONE: BACKGROUND AND SIGNIFICANCE 
Overview and Organization 
The background and rationale for this project is presented in this chapter and is organized 
into four sections: (1) Pediatric Asthma Overview; (2) Risks, Side Effects, and Benefits 
of Asthma Control Medications; (3) Patient-Provider Communication; and (4) 
Conceptual Framework. 
 
The Pediatric Asthma Overview section provides a brief overview of asthma in children 
in the United States, including prevalence and outcomes, as well as introducing select 
topics from the national guidelines for the treatment of asthma that have been developed 
by the National Asthma Education and Prevention Program (NAEPP)[NAEPP, 2007].  
The Risks, Side Effects, and Benefits of Asthma Control Medications section outlines the 
role and importance of these medications in controlling the disease.  This section also 
outlines the potential risks and benefits that are associated with these medications, in 
addition to summarizing the literature on both adherence to asthma control medications 
and child- and caregiver-reported problems and concerns with side effects.  The Patient-
Provider Communication section provides an overview of the importance of good 
communication between the patient and provider, including some of the 
recommendations provided by the NAEEP (NAEPP, 2007).  This section also outlines 
previous research on risk communication between patients and providers.  Finally, the 
Conceptual Framework section presents the framework that was used to explore the
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 relationship between communication of risks, side effects, and benefits of asthma control 
medications, adherence to asthma control medications, and caregiver- and child-stated 
problems and concerns with side effects of asthma control medications.   
 
Pediatric Asthma Overview 
Introduction 
Asthma is a chronic disease, affecting more than nine million children in the United 
States (Butz, et. al. 2007). Asthma is characterized by inflammation and constriction of 
the airways, leading to breathing difficulties.  Since 1980 through the late 1990s, asthma 
prevalence more than doubled (Akinbami 2006).  Since the late 1990s the prevalence of 
asthma has been relatively stable in the United States.  However, since the plateau of 
asthma prevalence, ambulatory care use has continued to grow (Akinbami 2006).   
 
Health Outcomes and Healthcare Utilization 
Children diagnosed with asthma are likely to experience symptoms that negatively affect 
daily living.  The symptoms experienced may include: (a) wheezing, (b) coughing, (c) 
shortness of breath, or (d) chest pain/tightness.  The onset of symptoms can lead to 
limited daily functioning, decreased quality of life, missed school days, non-participation 
in physical activities, as well as negatively affecting caregiver work attendance and 
productivity (Diette et. al. 2000, et. al., Schmier et. al. 2007).  In 2004, asthma accounted 
for seven million outpatient visits for children.  Every year, pediatric asthma is 
responsible for 658,000 to 754,000 emergency department visits and almost 200,000 
hospitalizations (Coffman et. al. 2008).  The morbidity associated with asthma has a 
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greater impact than mortality although some people can suffer life-threatening asthma 
episodes.     
 
This increase in healthcare utilization leads to increased costs and lost wages for parents.  
Using data collected from the Medical Expenditures Panel Survey (MEPS) from 1996 
and converted into 2003 dollars, direct costs for asthma accounted for over $1 billion 
($401 per each child with asthma), which included payments for prescription 
medications, hospital inpatient stays, hospital outpatient visits, emergency department 
visits, and office – based visits (Wang et. al. 2005).  In addition to direct costs, asthma 
has significant indirect costs associated with it.  For example, in children, asthma is one 
of the leading causes of school absenteeism, accounting for 10 – 15 million missed 
school days each year (Wang et. al. 2005).  Children with asthma miss 1.5 – 2 more 
school days per year than children without asthma.  Asthma also affects quality of life for 
the child and the entire family, due to missed time from work for parents and inability to 
exercise and play for the asthmatic child (Wang et. al. 2005, Diette et. al. 2000, Schmier 
et. al. 2007).  Finally, parent lost productivity from asthma-related school absences is 
approximately $719.1 million (Wang et. al. 2005).  The total economic impact of 
childhood asthma is almost $2 billion in the United States alone (Wang et. al., 2005). 
 
National Guidelines 
National guidelines or clinical practice guidelines are developed to assist the practitioner 
in providing optimal care based on available evidence (NAEPP 2007).  An expert panel 
commissioned by the National Asthma Education and Prevention Program Coordinating 
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Committee, coordinated by the National Heart, Lung, and Blood Institute (NHLBI) of the 
National Institutes of Health (NIH), have developed Guidelines for the Diagnosis and 
Management of Asthma.  The Guidelines are now in their third edition (Expert Panel 
Report 3 or EPR-3), which was published in 2007.  Because the parent grant, upon which 
this dissertation is based, began prior to the EPR-3, this dissertation will reference the 
EPR-2 (NAEPP, 1997).  EPR-2 was developed prior to the parent grant and was the most 
current when data collection began for the parent grant.  Therefore, all references are to 
the EPR-2, unless otherwise noted.  The changes from the EPR-2 to the EPR-3 focus on 
different aspects of asthma diagnosis and management.  For example, the EPR-3 places a 
new emphasis on using FEV1/FVC in classifying severity in children because it may be a 
more sensitive measure than only FEV1 (NAEPP, 2007).   The EPR-3 guidelines also 
present information on new medications.  However, the communication 
recommendations were stable from EPR-2 to EPR-3.   
 
The NAEPP guidelines support four central tenets for managing long-term asthma and 
exacerbations: (1) assessment and monitoring, (2) patient education, (3) control of factors 
leading to asthma severity, and (4) pharmacologic treatment.  The guidelines provide 
comprehensive asthma management and treatment recommendations (NAEPP, 2007).  
Only those aspects that relate directly to this dissertation will be referenced. 
 
Disease Severity Classifications 
The 2007 guidelines classify asthma into four different severity levels that are based on 
several factors, including: symptoms, nighttime awakenings, short-acting beta agonist 
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use, and lung function.  The four severity classifications in order of increasing severity 
are: (1) intermittent, (2) mild persistent, (3) moderate persistent, and (4) severe persistent.   
 
Intermittent asthma is defined by the NAEEP as infrequent exacerbations separated by  
periods of no symptoms and normal pulmonary function.  This is defined as: (a) asthma 
symptoms occurring less than two days per week, or (b) less than 2 night awakenings 
from asthma symptoms per month, or (c) using a short-acting beta-agonist less than two 
days per week.  Mild persistent asthma is defined as: (a) asthma symptoms occurring 
more than two days per week but not daily, or (b) three to four nighttime awakenings 
from asthma symptoms per month, or (c) using a short-acting beta-agonist more than two 
days per week but not daily.  Moderate/severe persistent asthma is defined as: (a) daily 
asthma symptoms, (b) more than one nighttime awakening per week but not nightly, or 
(c) daily use of a short-acting beta-agonist.  Severe persistent asthma consists of: (a) 
symptoms occurring throughout the day, (b) being awakened by asthma symptoms often 
seven nights per week, or (c) using a short-acting beta-agonist several times through the 
day (NAEPP 2007).   
 
Medications 
Despite the fact that there is no known cure for asthma at the present time, asthma can be 
controlled with the proper use of medications.  The goal of pharmacologic treatment of 
asthma is to control symptoms and reduce exacerbations.  There are two main categories 
of medications that are used to treat asthma: “rescue” medications and “control” 
medications (NAEPP 2007).  “Rescue” medications are short-acting medications that are 
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used for acute exacerbations of symptoms, which include coughing, wheezing, shortness 
of breath, and chest pain/tightness. These “rescue” medications come from three classes, 
short-acting beta-agonists, anticholinergics, and systemic corticosteroids.  “Control” 
medications are used to maintain control of persistent asthma symptoms.  “Control” 
medications prevent or control inflammation or bronchospasms.  The classes of control 
medications are: (a) inhaled corticosteroids (ICS), (b) cromolyn sodium and nedocromil, 
(c) immunomodulators, (d) systemic corticosteroids, (e) leukotriene receptor antagonists 
(LTRAs), (f) 5-liopxygenase inhibitor, (g) long-acting beta-agonists, and (h) 
methylxanthines. Table 1 below lists the more common asthma “rescue” and control 
medications, compiled from the national guidelines and the medication list from the 
parent grant.  The table lists the generic name, the medication class, type, and brand name 
for each medication.    
Table 1: List of Common Asthma Rescue and Control Medications 
Class   
"Rescue" Medications Generic Name Brand Name(s) 
Short Acting Beta Agonists Albuterol Proventil, Ventolin 
  Pirbuterol  Maxair 
  Levalbuterol  Xopenex 
Anticholinergics Ipratropium Atrovent  
  Albuterol/Ipratropium Combivent 
Control Medications     
Inhaled Corticosteroids Beclomethasone Qvar 
  Fluticasone Flovent 
  Budesonide Pulmicort 
  Mometasone Asmanex 
Leukotriene Modifiers Montelukast Singulair 
Long Acting Beta Agonists Salmeterol  Serevent 
  Formoterol Foradil 
Inhaled Corticosteroids & 
Long Acting Beta Agonists Budesonide/Formoterol  Symbicort 
  Fluticasone/Salmeterol Advair 
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The NAEPP guidelines and the National Heart, Lung, and Blood Institute state that all 
people with persistent asthma should be treated with a daily control medication to  
achieve and maintain asthma control.  
 
NAEPP Guidelines Concerning Communication of Risks, Side Effects, and Benefits 
The guidelines address what medical providers should assess during a routine clinic visit.  
Medical providers should monitor pharmacotherapy by asking about specific side effects 
the patient may have experienced from any their daily medications.  Furthermore, the 
guidelines instruct medical providers to teach and reinforce the roles of short-acting beta-
agonists and long-term control medications at every opportunity.  This strategy aims to 
educate patients and their caregivers about the benefits of both “rescue” medications and 
long-term control medications.  Finally, the guidelines encourage open communication to 
ensure patient satisfaction and greater adherence to therapy.  This open communication 
should include having patients and caregivers weigh the risks and benefits of medications 
so that the provider addresses fears and concerns about medications.  Allaying the fears 
and concerns about the medications could potentially improve adherence, which should 
enhance patient outcomes.        
 
Summary 
In conclusion, asthma is a common and costly problem in the United States.  For the 
children who are affected by asthma, consequences of the disease may include lost time 
from school, not being able to play/exercise with friends, numerous outpatient visits, lost 
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time from work for parents, and in the most extreme cases, death (Wang et. al. 2005).  
The NHBLI continually updates national guidelines to assist medical providers in the 
diagnosis and management of asthma (NAEPP 2007).  For persistent asthma, control 
medications are used to increase quality of life and prevent symptoms.  The risks, side 
effects, and benefits of asthma control medications will be discussed in greater detail 
below.     
 
Risks, Side Effects, and Benefits of Asthma Control Medications 
Introduction 
This section will explain the adverse effects associated with regular use of asthma control 
medications.  Additionally, this section will explain the benefits of regular use of asthma 
control medications. For the purposes of this dissertation, risks were defined as potential 
adverse reactions that could occur as a result of using a medication, but have not yet been 
experienced by a patient using that medication.  Also, adverse effects that were discussed 
for medications the child had not yet taken were also defined as risks.  An example of a 
risk as defined in this dissertation would be the possible risk of stunted growth from 
inhaled corticosteroid (ICS) medications.  Side effects were defined as adverse reactions 
that the patient was experiencing on the day of the visit or had experienced prior to the 
audio taped visit.  An example of a side effect as defined in this dissertation would be 
oral thrush being experienced by the patient at the visit or sometime prior to the visit, 
since the patient’s susceptibility to experiencing the side effect is known.  Benefits were 
defined as positive outcomes, both potential and presently being experienced, that result 
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from using the medication. An example of a benefit of an ICS medication is the 
decreased need for short-acting beta-agonist medications.  
 
Risks Related to Asthma Control Medications 
Local and systemic adverse effects have been identified with use of asthma control 
medications, especially ICS medications and long-acting beta-agonists (LABA). Table 2 
lists the medication classes and potential adverse effects.  Systemic corticosteroids are 
included in this list, but can also be used as short-term “burst” therapy to gain prompt 
control of inadequately controlled persistent asthma. (NAEPP, 2007).  This section will 
address the most pertinent risks that have been associated with asthma control 
medications, with a focus on risks associated with ICS and LABA medications.  Some 
risks of control medications may only apply to adults or geriatric patients (e.g. 
osteoporosis) or medications that are not commonly used for asthma control (e.g. 
cromolyn sodium, immunomodulators, and Zafirlukast). 
Table 2: Asthma Control Medication Classes and Associated Adverse Effects 
Long-Term Asthma Control Medications and Potential Adverse Effects 
Class Name Potential Adverse Effects 
Inhaled Corticosteroids 
  
Cough 
Dysphonia 
Oral thrush 
In low to medium doses in children, growth 
suppression but may be transient 
In high doses:   Adrenal suppression 
Osteoporosis 
Skin thinning 
Easy bruising 
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Class Name Potential Adverse Effects 
Systemic Corticosteroids 
Short-term use: Reversible abnormalities in 
glucose metabolism 
                         Increased appetite 
                         Fluid retention 
                         Weight gain 
                         Mood alteration 
                         Hypertension 
                         Peptic ulcer 
                         Rarely aseptic necrosis 
Mast cell stabilizer 
Cough 
Irritation 
15-20% of patients report unpleasant taste 
    
Immunomodulators 
Pain and bruising at injection sites 
Anaphylaxis 
Leukotriene Receptor Antagonists With Zafirlukast: Reversible hepatitis 
  
                             Irreversible hepatic failure 
                             Death 
Long-Acting Beta Agonists 
Diminished bronchoprotective effect may 
occur within 1 week of initiating therapy 
Tachycardia 
Skeletal muscle tremor 
Hypokalemia 
Prolongation of QTc interval in overdose 
Uncommon severe, life-threatening or fatal 
exacerbation 
Methylxanthenes 
Insomnia 
Gastric upset 
Aggravation of ulcer or reflux 
Increase in hyperactivity of children 
   
 
 
 11
• Local Adverse Effects of ICS 
One of the most common adverse effects of ICSs is oral candidiasis or thrush.  Thrush is 
more common in adults than children.  There are prevention recommendations in addition 
to treatment recommendations for thrush (NAEPP 2007).  Dysphonia is another local 
adverse effect and can be prevented and treated as well (NAEPP 2007).  Reflex cough 
and bronchospasm are other local adverse effects (AE) that have been identified by the 
NAEPP guidelines (NAEPP, 2007).  Treatment and prevention is available for this local 
AE as well.    
• Systemic Adverse Effects of ICS 
The most pertinent systemic adverse effect of ICS medications is a reduction in linear 
growth and growth velocity for children (NAEPP 2007).  Research on ICSs effect on growth 
has shown that ICSs may impede growth velocity, but the effects are small and may be 
reversible (NAEPP 2007, Skoner, 2002).  For example, one study in Sweden found that ICS 
medications had no impact on final adult height (Norjavaara E. et. al. 2000).  However, that 
study did find that asthma severity was a major determinant of final adult height 
(Norjavaara et. al., 2000).  Since poorly controlled asthma may be a significant factor in final 
adult height and ICSs have not been shown to significantly reduce height, the benefits of 
ICSs outweigh the risks of reduced height (NAEPP 2007, Skoner 2002).  Other adverse 
effects that are thought not to be clinically significant in children are: (a) decreased bone 
mineral density, (b) glaucoma and cataracts, (c) impaired glucose metabolism, and (d) 
weakened hypothalamic pituitary adrenal axis function (NAEPP 2007).   
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• Risks of Long-Acting Beta-Agonists (LABAs) 
The NAEPP guidelines also address the risks of long-acting beta-agonist (LABA) 
medications (NAEPP 2007).  This class of medication is thought to increase the chances 
of asthma-related deaths and the FDA label for products containing LABA medications 
includes a ‘black box’ warning.  The guidelines recommend that LABAs be adjunctive 
therapy for those whose asthma is not well controlled with ICS alone (NAEPP 2007).  
The increased potential for asthma related deaths has resulted in LABAs not being 
recommended as monotherapy for asthma (NAEPP 2007).  The guidelines go on to state 
that the decision to increase the dose of ICS should be given equal weight to the addition 
of LABA medications.  Studies have shown that those who discontinue ICS after the 
addition of LABA may face the greatest risk of asthma-related death because LABAs do 
not treat inflammation, although they maintain lung function, which may cause patients 
to delay seeking treatment (NAEPP 2007).  
 
Other medications and medication classes that are used as long-term control therapy 
include: (a) mast cell stabilizers, (b) immunomodulators, (c) leukotriene receptor 
antagonists, (d) long-acting beta agonists, and (e) methylxanthenes.  Though the majority 
of identified adverse reactions for asthma control medications belong to the ICS and 
LABA classes, other medications that are used for long-term control of asthma have 
potential adverse effects as well. 
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Caregiver and Child Perceptions of Risks and Side Effects of Control Medications  
Previous studies have shown that caregivers of children with asthma have concerns about 
daily use of a control medication (Sleath et. al. 2010, Smith et. al. 2008, Conn et. al. 
2007, Conn et. al. 2005).  In two different samples, Conn found that 34% and 30% 
respectively, of caregivers reported strong concerns in using asthma control medications 
(Conn et. al. 2007, Conn et. al. 2005).  Concerns that were identified included concerns 
about dependency and adverse effects.  Furthermore, 17% of caregivers reported that 
concerns about their child’s medications exceeded the necessity scores.  Caregivers who 
scored higher on concerns about control medications were found to be more likely to 
under-use asthma control medications (Smith et. al. 2008). Sleath et. al. found that 31% 
of caregivers reported that side effects bothered their child a little or a lot (Sleath et. al. 
2010).  These studies collectively show that strong concerns about taking a daily 
medication for asthma may result in suboptimal adherence of control medications.  This 
dissertation is unique because it is the first study to assess the relationship between 
discussions about adverse effects (side effects and risks) and medication benefits and 
child- and caregiver-reported problems and concerns about adverse effects.  
 
Prior studies have found that asthmatic children also have concerns about using a control 
medication (Sleath et. al. 2010, Logan et. al. 2003).  Sleath and colleagues found that 
87% of children with persistent asthma cited at least one problem/concern in using 
asthma medications (Sleath et. al. 2010).  That same study also found that 40% of 
children cited side effects as a problem/concern.  Logan et. al. (2003) developed a scale 
with five factors for illness management for children with asthma.  The scale identifies 
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five domains as barriers, including medication regimen concerns and problems.  The 
scale was shown to correlate with self-reported medication adherence.  Problems and 
concerns that children reported with medications included: (1) regimen causes changes to 
my body that I don’t like, (2) doctors don’t understand how much the regimen impacts 
important things in life, (3) the regimen has side effects that I don’t like, and (4) 
following the regimen causes physical pain and discomfort.   
 
Naimi et. al. found that 45% of children did not like the taste of fluticasone/salmeterol 
but few reported that the taste of the medication discouraged them from using the 
medication.  Other concerns that teenagers had of asthma control medications were: fear 
of addiction, the medication gave them acne, or made them “stocky” (Naimi et. al. 2009).  
Further, Penza-Clyve et. al. found that children state their asthma control medications 
taste bad and they have concerns about adverse effects, such as becoming hyperactive, 
which may decrease children’s adherence to these medications (Penza-Clyve et. al. 
2004).         
 
Benefits of Asthma Control Medications 
All asthma control medications were developed to: (a) reduce symptoms, (b) improve 
asthma control, (c) improve quality of life, (d) prevent exacerbations, and (e) reduce the 
need for systemic corticosteroids, emergency department usage, and death due to asthma 
(NAEPP 2007).  The NAEPP states that ICSs are the most potent and most consistently 
effective asthma control medications available (NAEPP 2007).  ICSs are characterized by 
their anti-inflammatory activity, which may account for their efficacy in controlling 
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asthma.  The NAEPP also recommends ICSs over all other asthma control medications, 
including leukotriene receptor antagonists (LTRAs) (NAEPP 2007).  Those patients who 
are not well controlled on one asthma control medication may need adjunctive therapy.  
More specifically, adjunctive therapy is a combination of an ICS and LABA.  However, 
adjunctive therapy has not been well studied in children 5-11 years of age.  The research 
supports the use of adjunctive therapy in older children rather than increasing the dosage 
of an ICS or adding an LTRA (NAEPP, 2007).       
   
Non-Adherence to Asthma Control Medications 
Despite the availability of effective asthma control medications, non-adherence is a 
significant problem.  Studies have found that children only take approximately 50% of 
their regularly prescribed asthma medications (McQuaid et. al. 2003, Bender et. al. 1998, 
Penza-Clyve et. al. 2004, Jones et. al. 2003). Adherence has been shown to be related to: 
(a) age (older age is associated with poorer adherence), (b) route of administration 
(children taking tablets are more adherent than those using metered-dose inhalers), (c) 
regimen complexity (more medications result in poorer adherence), (d) minority status 
(minorities are less adherent), and (e) side effects (McQuaid et. al. 2003, Modi and 
Quittner 2006, Rau 2005, Chambers et. al. 2001).  Research has shown that effective 
communication between providers and patients may be an area that can significantly 
improve medication adherence in asthma, highlighting the importance of this dissertation 
(Rau 2005).  In one study of adherence in children with asthma by Kyngas and Rissanen, 
there was a correlation between medication adherence and perceived support from 
physicians.   Perceived support is evidenced by encouragement and positive feedback, 
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aspects of communication that may positively impact asthma medication adherence 
(Kyngas and Rissanen 2001).   
 
According to prior research, the general population is concerned about the safety of long-
term asthma control medications, which may predict poor adherence (Conn et. al. 2005, 
Conn et. al. 2007, Smith et. al. 2008, Le et. al. 2008, Choi et. al. 2008).  In a study of 
adults with asthma, patients who reported themselves as accepting and ambivalent about 
control medications had significantly higher adherence than those who were indifferent 
and skeptical about the need for preventer medications (Menckeberg et. al. 2008).  
Chambers et. al. (2001) recruited adults into a study that assessed their attitudes about 
regular use of ICS and found that fear of side effects was the most frequently cited reason 
for nonadherence.  Wroe (2002) found that intentional nonadherence (missing doses to 
suit one’s needs) was predicted by the individual’s weighing of the pros and cons for 
themselves based on the information they have at hand.  These findings suggest that an 
individual’s concerns about a medication may lead him/her to intentionally miss doses 
based on the information they can access.  However, providers are in an ideal position to 
communicate effectively about the nature and course of the disease to both children and 
their primary caregivers during a medical visit.  This communication can be used to 
educate both children and their caregivers so that adherence to these medications can be 
improved.  
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Child and Caregiver Reported Problems and Concerns with Asthma Medications 
There has been little research to determine the types of problems and concerns that 
children and their caregivers may have about asthma medications.  Only one paper has 
studied the problems that children report with their asthma medications (Sleath et. al. 
2010).  Approximately 40% of children reported a problem/concern with side effects of 
their asthma medication(s) and approximately 31% of caregivers reported that children 
were bothered a little or a lot by side effects.  Providers are in a crucial position to ask 
children and caregivers about problems/concerns with asthma medications during a 
medical visit and then educate and alleviate those concerns.  Alleviating concerns about 
side effects could result in better asthma control medication adherence in children.  
 
Other prior research has found that minorities tend to have lower asthma medication 
adherence than Caucasians.  Minorities also are more likely to have negative beliefs 
concerning asthma control medications.  Le and colleagues (2008) found that minorities 
were significantly more likely to hold more negative beliefs about asthma medication and 
also found that negative beliefs were associated with significantly lower adherence.  
Beliefs that Le (2008) cited included: (a) “using an inhaled steroid every day may cause 
long-term side effects and problems”, (b) “I don’t like the idea of using an inhaled steroid 
medicine,” and (c) “if I use my inhaled steroid every day it won’t work as well when I 
need it” (Le et. al. 2008).   
 
Further, communication in pediatrics has been shown to have a stronger relationship with 
adherence than in adults (Drotar and Bonner 2009).  The exact mechanism is unclear for 
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this stronger effect size in pediatrics.  This dissertation has the potential to inform future 
work in pediatric communication research by increasing understanding of how providers 
talk to children and their caregivers about the risks, side effects, and benefits of asthma 
control medications and the relationship between communication and asthma control 
medication adherence.  This dissertation also will examine the communication about 
risks, side effects, and benefits in-depth and how this communication impacts child and 
caregiver reported problems of side effects with their asthma medications.        
 
Summary  
Almost all long-term asthma control medications have potential risks associated with 
regular use and therefore it is important to understand how providers discuss the risks 
associated with daily treatment.  Caregivers and children alike report concerns and fears 
about side effects of their asthma control medications.  Prior research has found that 
caregivers and children may purposefully decrease their use of an asthma control 
medication because of concerns about adverse effects.  
 
Provider-Patient Communication   
Introduction  
Effective communication between providers and patients is associated with positive 
health outcomes, such as improved medication adherence (Janson et. al. 2003, Street et. 
al. 2008).  However, it is unknown through which explanatory mechanisms or why 
elements of provider-caregiver-child communication are associated with better health 
outcomes (Street et. al. 2008).  Provider-patient communication research about 
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medications has focused on many aspects, including: (a) shared decision making in 
depression (Young et. al. 2006), (b) discussion of costs of medications with rheumatoid 
arthritis patients (Beard et. al. 2010), (c) information providers give patients when 
prescribing antidepressants (Young et. al. 2008), and (d) discussions of complementary 
and alternative medicine with rheumatoid arthritis patients (Sleath et. al. 2008).  The 
objective of this study was to explore if communication about the risks, side effects, and 
benefits of asthma control medications is associated with adherence to these medications 
and determine if there is a relationship between this communication and reported 
concerns and problems with side effects of asthma control medications.  To our 
knowledge, no prior study has examined the relationship between the communication of 
risks, side effects, and benefits on asthma control medication adherence as well as child- 
and caregiver-reported problems and concerns about side effects of asthma control 
medications. 
 
Children’s Participation in Medical Visits    
Past research supports the notion that school-age children can participate in self-
management decisions and that they are accurate reporters of their asthma symptoms and 
health status (Butz et. al.  2007).  However, past research has found that providers speak 
little to children and that children are not often engaged in the medical visit (Butz et. al. 
2007, Wissow et. al. 1998).  Prior research has found that both caregivers and providers 
may, intentionally or not, restrict the child’s participation in a medical visit.  Caregivers 
are likely to speak for a child and providers tend to align with the caregiver through the 
course of the interaction (Tates et. al. 2002).  Prior research has also found that parents 
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often interfere when providers interact with the child in medical visits, and that children 
may not be socialized enough to participate in a medical visit (Tates et. al. 2002).  This 
deficit in socialization during a medical encounter has important implications.  However, 
increasing international attention has been paid to the ability of a child taking an active 
role in their own health care (Ulph et. al., 2009).  Therefore, this study is significant 
because it is the first to describe how children are participating in discussions of asthma 
medication risks and benefits with their medical providers and caregivers.  Given that 
improved health outcomes, such as medication adherence, can be positively influenced 
by provider-caregiver-children communication, this study was significant.     
 
Risk Communication and Medications  
Risk communication is a national research priority for the Food and Drug Administration.  
A 2006 report from the Institute of Medicine criticized the FDA because of drug 
withdrawals due to safety concerns (IOM 2006).  In response, the FDA established the 
Risk Communication Advisory Committee to investigate how to more effectively 
communicate the risks associated with medications.   
 
Approximately half of the patients in North America, Europe, and Japan fail to take their 
medications properly (Thurmann 2006).  One of the largest deficits in patient 
understanding is awareness and comprehension of the risks associated with medications 
(Vogt, 2002 and Thurman, 2006).  Thus, providers play a crucial role in helping both 
patients and their caregivers understand the risks that are associated with medications in 
treating persistent asthma.  However, Thurmann (2006) describes risk communication as 
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a two-way conversation, not just an explanation by the provider to the patient.  Further, 
research has shown that most patients are not well informed about the side effects of their 
medication and that 50-90% would like more information (Thurmann 2006).  Zeigler et. 
al. (2001) found that more than 76% of patients wanted to hear all adverse effects of their 
medications, no matter how rare.  Interestingly, those with higher education and younger 
age desired less information about adverse effects (Zeigler, 2001).    
         
Important Aspects of Risk Communication  
Medical practice is moving towards a patient-centered model of care.  However, research 
has shown that children participate very little during the clinic visit (Butz et. al. 2007, 
Wissow et. al. 1998).   Risk communication is multi-faceted and research in risk 
communication is currently in its infancy.  The FDA has focused particular attention to 
how providers communicate the inherent risks that are associated with medical treatment 
by instituting a risk communication advisory committee to reflect the FDA’s commitment 
to better understand risk communication.  Further, research has shown that people desire 
information about the potential adverse effects of their medications (Thurmann 2006).  
 
There are a number of frameworks that reflect basic dimensions of risk that should be 
addressed in a medical visit (Reyna and Brainerd 1995, Bogardus et. al. 1999, Makoul 
and Clayman 2006), but there is currently no consensus on how to communicate those 
risks. However, prior research has shown that the way in which providers frame the 
presentation of risk (verbal, numerical, graphical, one-on-one, etc.) has a significant 
effect on patient’s perception of risk (Edwards et. al. 2000, Zikmund-Fisher et. al.2008).  
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Therefore, the current study is innovative because it was the first to describe how 
providers communicate risks of asthma control medications to children and their primary 
caregivers by coding specifically for two aspects of how providers discuss the probability 
of a risk occurring: (1) qualitatively and (2) numerically.  A qualitative statement of the 
probability of a risk occurring uses words such as: likely, not likely, rare, etc. to convey 
the chances of a risk occurring while a numerical statement uses numbers or percentages 
such as 1% chance of Risk A occurring.  Bogardus’ framework (1999) and Makoul et. 
al.’s Shared Decision Making framework (2006) was used to guide this study.  Bogardus’ 
framework (1999) was designed to give providers a basic framework for how to discuss 
medication and medical procedure risks (such as surgery).  Makoul and colleagues’ 
framework (2006) was developed to define essential discussions that needed to be 
discussed between providers and patients for shared decision making to occur.  
Specifically, Bogardus’ (1999) framework was used in its entirety while Makoul et. al.’s 
SDM framework (2006) was narrowed down to the discussion of benefits and risks 
aspect that is essential for SDM to actually occur in medical treatment.  The two 
frameworks that were used in this dissertation will now be discussed in more detail.   
 
One framework that can be useful in researching communication of risk is the framework 
developed by Bogardus et. al (Bogardus 1999).  This framework was developed 
specifically to provide medical providers with the most basic way to discuss the adverse 
risks associated with any medical action the physician may take.  The framework is 
separated into five basic dimensions that the provider should discuss with the patient 
before any medical action is undertaken, such as discussing the risks associated with a 
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medication.  The five dimensions are: (1) identity, (2) permanence, (3) timing, (4) 
probability, and (5) value.  A brief description of each dimension follows. 
 
The first dimension that Bogardus addresses is identity.  This dimension involves 
identifying the pertinent unwanted outcomes for the medical action.  The second 
dimension is permanence, or how long the risk will affect the patient.  Providers should 
discuss this issue with patients and their caregivers so that children and their caregivers 
could have a different outlook about their asthma medications.  The third dimension is 
timing, or when is the risk likely to occur.  The fourth dimension of risk communication 
is probability, or how likely the unwanted outcome will occur.  Lastly, the final 
dimension is the value that the patient places on the risk.  This is defined as the level of 
importance the patient places on the risk for himself/herself or a child in their care.  
Bogardus states that providers should ask children and caregivers about concerns and 
values regarding the adverse effects of using medications.   
 
A second framework that is useful in risk communication research is the theory of shared 
decision-making (SDM) (Makoul et. al. 2006).  SDM is defined as the provider and 
patient interacting and sharing their thoughts and feelings regarding a medical event.  
There are many essential aspects of SDM that Makoul addresses (2006), but the element 
about risk/benefit communication is the most pertinent to this dissertation.  Makoul et. al. 
(2006) identified several elements they considered to be essential for SDM to occur.  
They defined these essential elements as basic topics that needed to be discussed in order 
for SDM to have occurred in an office visit.  Risk/benefit communication was defined as 
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an essential element of SDM by Makoul et. al. (Makoul et. al. 2006).  Providers should 
discuss different options, if they exist, with patients as well as the pros and cons of each 
option.  This discussion then would flow easily with patient values and preferences 
regarding treatment.  The discussion of pros and cons then should reflect higher patient 
knowledge about their treatment and lead to less concern about medications. 
 
How providers choose to discuss probability of a risk is directly mentioned by Bogardus 
(1999) and Makoul et. al. (2006) as important in a discussion of risks of a course of 
action.  Bogardus’ (1999) framework states that providers should discuss the probability 
of a risk occurring while Makoul et. al.’s framework (2006) states that providers should 
discuss the benefits and risks of a course of action in order for true shared decision 
making to occur.  Discussing not only what a risk is but also its chance of occurring is 
essential for both patients and providers in choosing the most appropriate treatment 
option.       
 
Conveying Risk Probability: Qualitatively  
One of the key issues in conveying risk information to children and adults is the concept 
of how well they understand probabilistic information.  The ability of children and adults 
to correctly understand probabilistic information will allow them to make better and more 
informed decisions about their own health care.  However, past and present research has 
failed to come up with a “gold standard” way of communicating probabilistic information 
(Bogardus 1999).   
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One way to convey probabilistic information about the risks of medications is presenting 
probability in a qualitative fashion.  Conveying probabilistic information this way has the 
advantage of using common words to describe the likelihood of certain events occurring 
(Lipkus 2007).  An example of qualitatively describing probabilities is: “One common 
side effect of using an inhaled corticosteroid is oral thrush.”  A disadvantage of using 
qualitative terms to describe risk is that there is no specific anchoring point for all people 
and words can be taken to convey different meanings from person to person (Visschers 
et. al. 2008, Lipkus 2007).  A prior study found that in over 73% of medical visits, family 
providers used qualitative ways of presenting probabilistic information, which was the 
most often used form of presenting risk information (Neuner-Jehle et. al. 2011).  
However, patient understanding was significantly higher in this study when the provider 
used visual aids (i.e. graphs) to communicate probabilistic information compared to 
qualitative methods of presenting risk information (Neuner-Jehle et. al. 2011).   
 
There are differences among medical providers and patients in how they would like risk 
information.  For example in one study, physicians preferred to use qualitative 
expressions of risk information while the general public found that numerical expressions 
of risk (e.g. 1% of side effect A occurring) were more helpful (Nelson et. al. 2008).       
 
As stated above, people desire probability information to be presented in different ways.  
For example, some prefer using only words to describe the likelihood of an event while 
some prefer the information to be presented using only numbers while others prefer a mix 
of words and numbers (Mazur and Hickam, 1991).  Research has shown that the severity 
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of the expected outcome, older age, and the scale of the probabilities (i.e. <1 out of 
1,000,000 vs. <1 out of 1,000) influence interpretations of verbal/qualitative risk terms, 
with older patients providing significantly higher estimations of a risk occurring than 
younger patients and the “rare” risk of death being rated as less likely than the “rare” risk 
of severe pneumonia (Mazur and Merz 1994).     
 
In 2006, the European Union issued guidelines concerning recommended descriptors for 
frequency of adverse drug reactions (Thurmann 2006).  These descriptors along with the 
probabilities that define each descriptor are: (a) very common = >10%; (b) common = 1-
10%; (c) uncommon = 0.1-1%; (d) rare = 0.01-0.1%; and (e) very rare = <0.01%. 
(Thurmann 2006).  However, research has consistently reported that people tend to 
grossly over-estimate the probability of a risk occurring when qualitative expressions are 
used (Thurmann 2006, Knapp et. al. 2009, Knapp et. al. 2004, Berry et. al. 2002, Berry 
et. al. 2003).      
 
Conveying Risk Probability: Numerically 
Another way to present risk likelihood is using numbers, such as frequencies and 
percentages.  A disadvantage of using numbers to convey such information is that many 
people lack numerical skills (Fagerlin et. al. 2005).  The advantage of using numbers to 
present risk probability is that many people have been found to be more accurate with 
their estimate of that risk (Waldron et. al. 2010, Knapp et. al. 2009, Berry et. al. 2002, 
Berry et. al. 2003).   
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Numeracy and Risk Communication 
Numerous studies have shown that many people lack skills to sufficiently understand 
numbers (numeracy) (Fagerlin, et. al. 2005).  Prior research has found that those with low 
numeracy are more likely to have negative outcomes associated with treatment, 
especially when that treatment is complicated (Estrada et. al. 2004).  However, because 
medical care is shifting towards shared decision-making, patients are more often asked to 
be involved in their own medical care.  This is especially evident in young children, who 
may also lack the numerical skills to understand probabilities.  Further, prior research has 
shown that those with low numeracy significantly over-estimated their risk of developing 
a disease while those with higher numeracy were more accurate (Fagerlin et. al. 2005).  
Zeigler also commented that those with low numeracy may be more willing to hear all 
adverse effects no matter how rare because they are uncomfortable dealing with numbers 
(Zeigler et. al. 2001).     
 
Research in children to examine numeracy and risk information is extremely limited.  
One study found that children from as young as seven years of age understand probability 
information but, like adults, the format used to communicate probabilistic information 
can significantly affect children’s accuracy making judgments about the likelihood of an 
event (Ulph et. al. 2009).  Schlottmann argues that children as young as five or six years 
of age can understand probabilistic information (Schlottmann 2001).  
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Summary: Using Words of Likelihood vs. Numbers 
Even though there is not a “gold standard” of the best way for providers to convey risk 
information (Bogardus 1999), an emerging body of evidence is starting to show that 
conveying risk information numerically may be superior to qualitative terms.  This may 
be because different people perceive words differently and people may tend to extremely 
over-estimate their chances of a risk occurring when qualitative forms of risk estimation 
are used (Thurmann 2006, Knapp et. al. 2009, Knapp et. al. 2004, Berry et. al. 2002, 
Berry et. al. 2003).        
 
This research coded for both ways in which providers may choose to present risk 
information to patients and their caregivers: qualitatively or numerically.  
 
Risk Communication Frameworks to Be Used in this Dissertation 
This dissertation was guided by Bogardus’ risk communication framework (Bogardus 
1999) and Makoul and Clayman’s model of shared decision-making (2006).  This 
dissertation coded for a discussion of all of Bogardus’ dimensions (2006) for both risks 
and side effects as well as coding for a discussion of benefits of asthma control 
medications.  In addition to coding whether or not a specific dimension was addressed, 
this dissertation also coded each statement of risk, side effect, and benefit verbatim that is 
discussed in the audiotaped medical visit.  Finally, this project also coded for whether 
providers discussed the likelihood of a risk occurring, and if so, did they discuss it in 
qualitative, numerical, or in both qualitative and numerical terms.     
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Makoul and Clayman’s (2006) model of shared decision-making was also used in guiding 
this dissertation.  This model states that providers should discuss not only the risks of the 
medication but that providers should also discuss the benefits of the medication.  This 
dissertation coded whether a discussion of the benefits of an asthma control medication 
occurred during the audio taped medical visit.    
 
Figure 1 shows the schematic of how both Makoul and Clayman’s (2006) model of 
shared decision making and Bogardus’ framework of risk communication (1999) 
provided the framework that was used in coding for risks, side effects, and benefits for 
this study.  The figure shows communication aspects that were coded from transcripts of 
audio taped medical visits in general pediatric practices in North Carolina, in addition to 
coding all of the statements and questions regarding risks, side effects, and benefits 
verbatim from the transcripts.  Each transcript was coded for: (1) the presence of a 
discussion of control medication benefit; (2) the presence of a discussion of control 
medication risk; (3) the presence of a discussion of control medication side effect; (4) the 
presence of a discussion of the identity of the risk of the control medication; (5) the 
presence of a discussion of the permanence of the risk; (6) the presence of a discussion of 
the probability of a risk; (7) the probability of timing of the risk; and (8) the presence of a 
discussion of the patient’s and caregiver’s values regarding the risk.  
 
For the purposes of this dissertation, risks were defined as potential adverse reactions that 
could occur as a result of using a medication, but have not yet been experienced by a 
patient using that medication.  An example of a risk as defined in this dissertation would 
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be the risk of oral thrush from ICS medications, as long as the patient has not experienced 
oral thrush in the past.  Side effects were defined as adverse reactions that the patient was 
experiencing on the day of the visit or had previously experienced prior to the audio 
taped visit.  An example of a side effect as defined in this dissertation would be oral 
thrush being experienced by the patient at the visit or sometime prior to the visit, since 
the patient’s susceptibility to experiencing the side effect is known.  Benefits were 
defined as positive outcomes, both potential and presently being experienced, that may or 
will occur as a result of using the medication. An example of a benefit of an ICS 
medication is the decreased need for short-acting beta-agonist medication use as a result 
of using the ICS medication.    
 
Figure 1: Framework Used in Coding Communication 
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The framework for the conceptual model that shows the relationships between 
characteristics of the child, caregiver, provider, and medication influence discussion of 
the risks, side effects, and benefits of asthma control medications and medication 
adherence and concerns about side effects of asthma medications will be presented in the 
next section.  
 
Conceptual Model Used in this Dissertation 
Figure 2 presents the conceptual model for the study that links side effect, risk, and 
benefit communication aspects described above to caregiver-reported medication 
adherence and caregiver and child-reported problems and concerns with side effects one 
month following the medical encounter.  The model suggests that characteristics of the 
child, caregiver provider, and medication are related to communication between 
pediatricians, caregivers, and children about the risks, benefits, and side effects of a  
control medication.  The model also suggests that communication about the risks, side 
effects, and benefits of asthma control medications are related to caregivers and 
children’s concerns about side effects of their control medication and medication 
adherence one month later.   
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Figure 2: Conceptual Model Linking Characteristics to Communication and 
Outcomes
 
 
Patient and Caregiver Characteristics  
Medical communication research has shown that characteristics of the child and caregiver 
both play an important role in more parent and child involvement in a medical encounter.  
Cox et. al. found that passive involvement of parents in a medical encounter was less 
likely when both parents were present, compared to when mothers who were present 
(Cox et. al. 2007). Other variables that may affect communication during the medical 
visit as well as medication adherence are: (1) age of the child; (2) age of the parent, (3) 
race, (4) income, (5) how long the child has lived with asthma, and (6) asthma severity 
[Rau 2005].  Additionally, caregivers who are less educated and have lower incomes may 
also have low numeracy, which could explain why these people may want to know the 
potential for all adverse effects since they may be uncomfortable dealing with numbers 
(Zeigler et. al. 2001).        
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Physician Characteristics   
The pediatric medical communication literature suggests that communication between 
providers, caregivers, and children are a function of characteristics of not only children 
and their caregivers, but also of providers.  Research has shown that children and parents 
speak longer and are more active in visits with female providers (Bernzweig et. al. 1997).  
Also, passive involvement of parents was less likely with physicians who have been in 
practice longer and with longer medical visits (Cox et. al. 2007).  Further, studies have 
consistently shown that different communication styles are predictors of improved health 
outcomes, such as reassurance, patient – centered questioning techniques, as well as time 
spent in information and education (Drotar et. al. 2009).  Higher treatment adherence has 
been found among children whose physicians who were viewed more supportive and 
more interested in the child (Kyngas and Rissanen 2001).  
  
Medication Characteristics   
Research has shown that a medication’s delivery device may affect treatment adherence 
among patients with asthma.  For example, past research supports the notion that children 
may adhere better with oral medications (i.e. Singulair) than with metered-dose inhalers 
(Carter and Ananthakrishnan 2003 and Sherman 2001).  Additionally, the complexity of 
the medication regimen may also affect adherence (Rau 2005).  The author of this 
dissertation hypothesized that medication characteristics, such as mode of administration 
and medications that contain inhaled steroids may impact discussions of risks, side 
effects, and benefits of these medications.  These discussions could potentially impact 
medication adherence as well as concerns about side effects of control medications.       
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Communication between physicians, caregivers, and children   
For this study, discussion of risks, benefits, and side effects were variables of interest in 
assessing the impact of parent, child, physician, and medication characteristics on 
provider-caregiver-child communication.  One study found that more time allotted during 
the medical visit for risk communication significantly increased the patient’s intention to 
adhere to chosen treatment (Edwards et. al. 2004).    Further, questions and statements by 
children, caregivers, and physicians about risks, benefits, and side – effects are all 
considered important since improved outcomes have been found to be associated with 
less passive involvement from children and caregivers (Cox et. al. 2007).  Finally, the 
manner in which providers communicate about the probability of risk is an area of 
interest because the risk communication literature suggests that how the risk is 
communicated can impact patient understanding.  Furthermore, there is no consensus 
about how to communicate inherent medical risks (Bogardus 1999).  This research used 
qualitative and numerical statements of risk as a means of assessing risk communication.   
 
Provider-patient communication about medication side effects, risks, and benefits and the 
potential outcomes that may be associated with this communication make this 
dissertation practical and important.  One of the FDA’s research priorities is to 
investigate how to communicate the risks of medications to the public (US FDA, 2007).  
This dissertation will increase knowledge about how general medical providers who treat 
pediatric patients may be discussing asthma control medication-related risks to children 
and their caregivers as well as present information on the extent to which providers are 
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discussing risks.  The specific aims that this research will address are provided below 
along with the hypotheses for each aim and the methods used to accomplish each aim.   
 
Specific Aims 
1. To examine the association between provider, caregiver, and child characteristics and 
communication about risks, side effects, and benefits of asthma control medications 
during audiotaped pediatric visits.  
H1: Discussions of asthma control medication side effects will be more likely to 
be discussed when more than one caregiver is present during the audiotaped 
medical visit. 
H2: Discussions of asthma control medication risks will be more likely to occur 
when caregivers have lower incomes. 
H3: Discussions of asthma control medication risks will be more likely to occur 
when there is more than one caregiver present during the audiotaped medical 
visit. 
H4: Discussions of asthma control medication risks will be more likely to occur 
when caregivers are less educated. 
H5: Discussions of asthma control medication benefits will be more likely to be 
discussed when the child has moderate/severe persistent asthma.  
 
 
 
 36
2. To analyze predictors of caregiver-reported adherence to the child’s asthma control 
medications one month after the audiotaped medical visit. 
H6: Caregivers are more likely to report their child as adherent to their asthma 
control medications if risks were discussed in the medical visit.  
H7: Caregivers are more likely to report their child as adherent to their asthma 
control medications when the control medication was only montelukast.   
H8: Caregivers are more likely to report their child as adherent to their asthma 
control medications when the child is not taking an inhaled corticosteroid AND a 
tablet as asthma control medications.  
3. To examine the association between risk, side effect, and benefit communication and 
caregiver- and child-reported problems and concerns about asthma medication side 
effects one month after the audiotaped medical visit. 
H9: Caregivers are less likely to report problems and concerns about side effects 
with their child’s asthma medications if risks were discussed during the medical 
visit. 
 H10: Caregivers are less likely to report problems and concerns about side effects 
with their child’s asthma medications if the asthma control medication does not 
contain an inhaled corticosteroid. 
H11: Children are less likely to report problems and concerns about side effects 
with their asthma control medications if side effects were discussed during the 
medical visit. 
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H12: Children are more likely to report problems and concerns about side effects 
with their asthma control medications if benefits were discussed during the 
medical visit.  
4. To qualitatively describe all control medication risks, side effects, and benefits that 
are discussed during the audiotaped asthma visits.   
 
Summary and rationale  
Asthma is one of the most common chronic diseases in childhood and the research 
investigating provider–caregiver–patient communication is limited.  This dissertation is 
the first study to examine the actual content of the discussions about asthma control 
medication-related side effects, risks, and benefits.  This dissertation also contributes to 
the literature by examining factors that are associated with communication of risks, side 
effects, and benefits of asthma control medications.  Finally, this dissertation contributes 
to the literature by examining if discussions about side effects, risks, and benefits are 
associated with caregiver-reported medication asthma control medication adherence and 
child- and caregiver-reported problems/concerns about side effects of control 
medications.  
 
The findings from this study can be used to develop communication strategies directed 
toward providers, caregivers, and children with persistent asthma so that asthma 
outcomes can be improved.  The field of risk communication about medications is 
currently in its infancy, therefore this research will contribute to a better understanding of 
risk communication about control medications during pediatric asthma visits.  
CHAPTER TWO: METHODS FOR QUANTITATIVE ANALYSIS (AIMS 1-3) 
 
Overview 
This study is a cross-sectional secondary analysis of data collected from a previous 
NHLBI funded study examining physician-caregiver-child communication about asthma 
communication in primary care visits.  The data were collected from June 2006 through 
October 2009.  The study sample includes 296 pediatric patients with persistent asthma 
and 35 medical providers from North Carolina.  Study data includes de-identified clinic 
visit audiotapes, child interviews, and caregiver surveys.  The University of North 
Carolina-Chapel Hill Institutional Review Board approved this study.   
 
Medical providers, children, and caregivers provided consent/assent for the parent study.  
The aims of this research were developed after patient enrollment was completed under 
the protocol of the parent grant.  Providers, children, and caregivers were therefore 
blinded to the specific aims outlined in this research.   
 
Study Setting 
Providers, children, and their primary caregivers were recruited from five primary care 
pediatric clinics, all of which are located in North Carolina. Thirty-five providers from 
the five offices agreed to participate in the study.  Providers were eligible to participate if 
they regularly treated pediatric asthma patients. Written consent was obtained from each
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participating provider. All of the clinics accepted Medicaid in addition to private 
insurance; this is advantageous because offices that accept Medicaid are more likely to 
serve a racially and economically diverse patient population (Dubay, 2002).  
 
Patient Enrollment and Eligibility 
Patients were eligible for the study if they were: (1) between the ages of 8 and 16, (2) had 
a prior diagnosis of asthma, (3) read and spoke English, and (4) classified by a research 
assistant as having mild or moderate/severe persistent asthma based on medications and 
symptom-frequency over the past year. Mild persistent asthma was defined as: (1) the 
child is on one control medication (e.g. montelukast) and/or (2) the child has experienced 
asthma symptoms (e.g. coughing or wheezing) more than two times per week, but not 
every day for the past year.  Moderate/severe persistent asthma was defined as: (1) the 
child is on two control medications (e.g. fluticasone/salmeterol combination) and/or (2) 
the child has experienced at least one asthma symptom every day for the past year 
(NAEPP, 2002).  Each child and caregiver dyad completed an eligibility screener before 
enrollment into the parent study.  Research assistants obtained written assent/consent 
from each child and his/her caregiver.   
  
Data Collection and Variables 
Data Collection Procedures 
Clinic staff identified children with asthma who had an upcoming office visit; the clinic 
staff called caregivers the day prior to their visit to remind them of the visit and to briefly 
describe the parent study.  On the day of the visit, clinic staff referred interested patients 
and caregivers to research staff, who described the study in more detail.  If the patient and 
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caregiver were willing to participate in the study and met all eligibility criteria, then the 
research assistant enrolled them in the waiting room prior to the patient being called to 
see the provider.  Before the provider entered the exam room, a research assistant set up a 
digital audio-recorder and microphone, started recording, and exited the room.  When the 
physician was finished with the visit, the research assistant then re-entered the room and 
stopped the recorder.  The research assistant then moved both the child and caregiver to 
another room within the clinic.  The caregiver then completed a questionnaire while the 
research assistant interviewed the child.  Approximately one month after the initial clinic 
visit, the research assistant went to the child’s residence and interviewed the child again 
while the parent completed a questionnaire. As part of both the initial clinic visit and 
home visit, the research assistant recorded self-reported medication adherence for control 
medications from both the child and caregiver.  Children and their caregivers were given 
$15 each at both the initial clinic and home visits.  
 
Data 
The majority of the data for this research came from three primary sources: (1) transcripts 
from the audio taped medical visits; (2) interviews administered to the child by a research 
assistant at the conclusion of the medical visit and one month after the audio taped 
medical visit; and (3) questionnaires completed by the caregiver immediately after the 
medical visit and one month after the medical visit.  Additional data came from the 
eligibility screeners and a survey completed by the providers when they agreed to 
participate in the parent study.   
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All communication variables were coded from the transcriptions of the audiotapes. The 
Primary Coding Instrument (PCI) was developed under the protocol of the parent study. 
The Supplemental Coding Instrument (SCI) was developed for this research.   
 
Transcript Generation 
All audiotapes were transcribed under the protocol of the parent grant.  Transcribing 
occurred under the supervision of the principal investigator of the parent grant.  
Transcriptions of audiotapes make the coding of the audiotapes more reliable (Waitzkin 
1990 and Mishler 1984).  The principal investigator of the parent grant had previously 
used the transcribing rules that were used in the parent study.  The transcribing rules were 
adapted from transcribing rules used by previous researchers in physician-patient 
communication (Waitzkin 1990 and Mishler 1984).  All identifiers were removed when 
the audiotapes were transcribed.  The transcriptionists were blinded to the study 
hypotheses.   
 
Coding:  Primary Coding Instrument (PCI) 
The Primary Coding Instrument (PCI) was developed as part of the parent grant.  The 
principal investigator trained research assistants how to code the transcripts using the 
PCI.  Coders were trained using 12 transcripts from a pilot study.  During training, the 
minimum accepted level for inter-rater reliability was 0.80.  Practice and training 
continued until this minimum level of reliability was achieved.  After coders achieved 
this minimal level of reliability, they started coding the transcripts from the parent study.  
All coders blindly coded 20 of the same transcripts to ensure the minimum level of 
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reliability.  To assure that reliability levels were maintained, the principal investigator 
conducted spot checks of coder performance throughout the coding process.  If there was 
a problem in the coder’s performance, the coder was immediately stopped from coding 
more transcripts and re-trained until the minimum reliability level of 0.80 was achieved.  
Like the transcriptionists, the coders were blinded to the parent study’s hypotheses.  This 
dissertation did not use any communication variables from the PCI.     
 
Coding: Supplemental Coding Instrument (SCI) 
The transcripts were also coded using a supplemental coding instrument that was 
developed specifically for this research.  The rules that were followed by the coders can 
be found in Appendix A and the actual coding tool can be found in Appendix B.  The 
author of this dissertation developed a draft of the supplemental instrument, which was 
refined and tested during the initial part of this study.  Another coder was trained to code 
the transcripts using ten transcripts from a pilot study.  Using the coding tool for 
transcribed medical visits, coders recorded the following: (1) the verbatim questions that 
providers, caregivers, and children asked about asthma control medication side effects, 
risks, and benefits; (2) the number of questions that each participant asked about asthma 
control medication side effects, risks, and benefits; (3) the verbatim statements that 
providers, caregivers, and children made about asthma control medications side effects, 
risks, and benefits; (3) the number of statements that each participant made about asthma 
control medication side effects, risks, and benefits; (4) the initiator of each conversation 
about asthma control medication side effects, risks, and benefits, (5) the end-of-visit plan 
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for each medication discussed during the medical visit; and (6) whether there was more 
than one caregiver present during the medical visit.  
 
The principal investigator of this dissertation trained another coder to ensure that the 
results of this dissertation was more reliable and reproducible.  After initial training, both 
coders coded 20 of the same transcripts throughout the coding period to assess inter-
coder reliability using Cohen’s kappa coefficient.  The kappa coefficient for inter-coder 
reliability was 1.00 for discussion of side effect, 1.00 for discussion of risk, and 0.80 for 
discussion of benefit.   
 
The coders met once weekly to discuss the coding of transcripts as well as to define the 
categories of questions and statements about side effects, risks, and benefits.  The name  
of each category is meant to reflect the general concept assessed by each question and 
statement  
 
Measurement 
Table 3 describes all of the outcome measures that were used in this research.  All 
variables are defined below.  The outcome measures that were used in this study came 
from three sources: (1) transcripts of the audio tapes of the medical visits; (2) interviews 
completed by children one month after the audiotaped medical visit; and (3) 
questionnaires completed by one month after the audiotaped medical visit;  
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Table 3: Outcome Variables, Source, and Range 
 
Variable Outcomes Source Range 
Adherence score to asthma 
control medications one month 
after visit 
Caregiver 
Questionnaire 
Continuous; 
Range = 0-100.0 
Adherent to asthma control 
medications one month after 
visit 
Caregiver 
Questionnaire 
Adherence score of at least 
80% indicates child was 
adherent (1); adherence 
score of less than 80% 
indicates child was not 
adherent (0) 
Caregiver Side Effects Concern 
about asthma control 
medications one month after 
visit 
Caregiver 
Questionnaire 
1=yes; 0=no 
Child Side Effects Concern 
about asthma control 
medications one month after 
visit 
Child Interview 1=yes; 0=no 
 
 
Outcome Variables (From Caregiver Questionnaire and Child Interview at Home Visit) 
       Adherence Score: This continuous variable indicates the child’s adherence to 
asthma control medications as a percentage with values ranging from 0% to 100%.  
Adherence from caregiver self-report data was measured using the following formula: 
adherence = (number of doses used during the past week divided by the number of 
prescribed doses) multiplied by 100.  Children who were on more than one asthma 
control medication had an average adherence score calculated. 
 
      Adherent: This dichotomous variable indicates whether the caregiver reported 
whether the child was adherent to their asthma control medications.  “Yes” (1) indicated 
the child had an adherence score (or average adherence score) of at least 80%.  “No” (0) 
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indicated the child had an adherence score (or average adherence score) that was less than 
80%.  Eighty percent has been used in many prior studies as reflective of adequate 
adherence (Karve et. al. 2009).    
 
 Caregiver Side Effects Concern: This variable indicates the level of 
problems/concerns about side effects that caregivers reported at the home visit.  Options 
for caregivers in the parent study were: 0=none, 1=a little, and 2=a lot.  This variable was 
taken from the caregiver’s home visit questionnaire.  The answers to this question in the 
parent study were skewed to the left because of numerous values where the caregiver 
reported no concern/problem about side effects; consequently, this variable was 
transformed into a dichotomous variable.  “Yes” (1) indicates that the child’s caregiver 
reported a little or a lot of concern about their child’s asthma medication and “No” (0) 
indicates that the caregiver chose “None” on the survey about concern/problem of side 
effects from their child’s asthma medication. 
 
      Child Side Effects Concern: This variable indicates the level of problems/concerns 
about side effects that children reported at the home visit.  Options for children were 
0=none, 1=a little, and 2=a lot in the parent study.  This variable was taken from the 
child’s home visit interview.  The answers to this question in the parent study were 
skewed to the left because of numerous values where the child reported no 
problem/concern about side effects; consequently, this variable was transformed into a 
dichotomous variable.  “Yes” (1) indicates the child reported a little or a lot of concern 
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with side effects from their asthma control medication and “No” (0) indicates that the 
child did reported no concern about side effects of their asthma medication. 
 
Communication, Medical Visit, and Medication Variables (Based on Coding of 
Transcripts of Audiotapes) 
This section describes the variables that were measured as aspects of both the 
communication that occurred during the medical visit and aspects of the actual medical 
visit.  Table 4 presents the communication and medical visit variables that were used in 
this dissertation, including the name of the variable as well as the range.  All of the 
variables presented in Table 4 came from the secondary coding tool.     
 
Table 4: Communication, Medical Visit, and Medication Variables 
Communication & Medical Visit 
 
Range 
Benefits discussed of asthma control 
medications 
1=yes; 0=no 
Side effects of control medications discussed  1=yes; 0=no 
Risks of control medications discussed  1=yes; 0=no 
Number of caregiver statements about 
benefits of asthma control medications 
Discrete (0-7) 
Number of caregiver questions about benefits 
of asthma control medications 
Discrete (0-1) 
Number of provider statements about benefits 
of asthma control medications 
Discrete (0-9) 
Number of provider questions about benefits 
of asthma control medications 
Discrete (0-8) 
Caregiver States Side Effects of asthma 
control medications 
1=yes; 0=no 
Child State Side Effects of asthma control 
medications 
1=yes; 0=no 
Number of child statements about side effects 
of asthma control medications 
Discrete (0-1) 
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Communication & Medical Visit Range 
Number of child questions about side effects 
of asthma control medications 
Discrete (0) 
Number of caregiver statements about side 
effects of asthma control medications 
Discrete (0-2) 
Number of caregiver questions about side 
effects of asthma control medications 
Discrete (0-1) 
Number of provider statements about side 
effects of asthma control medications 
Discrete  (0-4) 
Number of provider questions about side 
effects of asthma control medications 
Discrete (0-3) 
Risk identified 1=yes; 0=no 
Risk permanence 1=yes; 0=no 
Risk timing 1=yes; 0=no 
Probability discussed 1=yes; 0=no 
Numerical statements about probability of 
risk from asthma control medications 
1=yes; 0=no 
Qualitative statements about probability of 
risk from asthma control medications 
1=yes; 0=no 
Child values discussed about risks of asthma 
control medications 
1=yes; 0=no 
Caregiver values discussed about risks of 
asthma control medications 
1=yes; 0=no 
Number of child statements about risks with 
medications 
Discrete (0) 
Number of child questions about risks with 
medications 
Discrete (0-1) 
Number of caregiver statements about risks 
with medications 
Discrete (0-2) 
Number of caregiver questions about risks 
with current medications 
Discrete (0-2) 
Number of provider statements about risks 
with medications 
Discrete (0-6) 
Number of provider questions about risks 
with medications 
Discrete (0-2) 
Medication Characteristics  
Corticosteroid 1=yes; 0=no 
Number of Asthma Control Medications 
Discussed 
Discrete (0-4) 
Number of Asthma Control Medications 
Started 
Discrete (0-2) 
Number of Asthma Control Medications 
Continued 
Discrete (0-3) 
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Medication Characteristics Range 
Number of Asthma Control Medications 
Discontinued 
Discrete (0-2) 
Child Taking Singulair and an Inhaled 
Corticosteroid  
1=yes; 0=no 
Child Taking Singulair Only 1=yes; 0=no 
 
 Benefits of asthma control medications discussed: This dichotomous variable 
indicates whether there was a discussion of benefits of an asthma control medication. 
“Yes” (1) indicated that there was a discussion of benefits of an asthma control 
medication and “No” (0) indicated there was not a discussion of the benefits of an asthma 
control medication.  Examples of benefits of an asthma control medication could be 
“prevents wheezing” and/or “less frequent use of a rescue medication.”    
 
 Side Effects Discussed: This dichotomous variable indicates whether there was a 
discussion about the side effects of the current asthma control medication(s) being taken.  
If the child was not on an asthma control medication on the day of the visit, then this 
variable did not apply.  “Yes” (1) indicates that there was a discussion of side effects and 
“No” (0) indicates that there was not a discussion of side effects.  A side effect was 
defined as an adverse reaction that the patient/child was experiencing at the time of the 
visit or has been experienced in the past from a medication that the child was taking or 
had taken in the past.  An example of a side effect is “bad taste from a metered dose 
inhaler.”  
 
 Risks Discussed: This dichotomous variable indicates whether there was a discussion 
of the risks of an asthma control medication. “Yes” (1) indicates that there was a 
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discussion of risks and “No” (0) indicates there was not a discussion of risks.  A risk was 
defined as an adverse reaction that the patient/child had not experienced yet while taking 
an asthma control medication.  A risk was also defined as an adverse reaction that the 
child may experience before starting a new asthma control medication.  An example of a 
risk would be the potential for a corticosteroid metered-dose inhaler to potentially cause 
oral candidiasis (oral thrush), but the child had not experienced that adverse reaction 
previously.     
  
 Length of visit: This discrete variable indicates the length in seconds of the 
audiotaped visit.    
    
 Number of statements of benefits of asthma control medications: There were 
three separate discrete variables that measured the number of statements about benefits 
that were made during the audiotaped medical visits.  There was a variable that measured 
the number of statements about benefits made by providers, another variable that 
measured the number of statements about benefits made by caregivers, and the last 
variable that measured the number of statements about benefits made by children.     
 
 Number of questions about benefits of asthma control medications: There were 
three separate discrete variables that measured the number of questions about benefits 
that were made during the audiotaped medical visits.  One variable measured the number 
of questions about benefits that providers asked, another variable that measured the 
 50
number of questions about benefits that caregivers asked, and the last variable that 
measured the number of questions about benefits that children asked.  
    
 Number of statements of side effects of asthma control medications: There were 
three separate discrete variables that measured the number of statements about side 
effects that were made during the audiotaped medical visits.  One variable measured the 
number of statements about side effects that providers made, another variable that 
measured the number of statements about side effects that caregivers made, and the last 
variable measured the number of statements about side effects that children made.  
  
 Number of questions about side effects of asthma control medications: There 
were three separate discrete variables that measured the number of questions about side 
effects that were made during the audiotaped medical visits.  One variable measured the 
number of questions about side effects asked by providers, another variable that 
measured the number of questions about side effects asked by caregivers, and the last 
variable that measured the number of questions about side effects asked by children.   
 
 Risk Identified: This dichotomous variable indicates whether the provider stated any 
risks of an asthma control medication.  “Yes” (1) indicates that the provider did identify a 
risk associated with an asthma control medication and “No” (0) indicates the provider did 
not identify a risk.  An example of a provider identifying a risk would be: “There are 
some risks. What risks?  There are some studies that say using long-acting beta agonists 
increase the risk of asthma-related death.”   
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 Permanence of Risk Discussed: This dichotomous variable indicates whether the 
provider made any statements about how long each stated risk would affect the child.  
“Yes” (1) indicates that there was a discussion of the permanence of a risk and “No” (0) 
indicates there was not a discussion.  An example of this type of communication would 
be the provider discussing: is the risk temporary or permanent (reduced height from ICSs 
may be temporary). 
  
 Timing of Risk Discussed: This dichotomous variable indicates whether there was a 
discussion of when the risk is likely to occur.  “Yes” (1) indicates that timing of a risk 
was discussed and “No” (0) indicates that it was not discussed.  Examples that would lead 
to a coding of “Yes” (1) would be the provider addressing: (a) when the risk is likely to 
occur (i.e. how long it will take for child to experience oral candidiasis), and (b) 
discussing and weighing of risks that may happen now versus later on in the treatment 
process (reduced height from asthma severity versus potential for reduced height from 
using ICSs).   
 
 Probability Discussed: This dichotomous variable indicates if the provider 
communicated any probability of the child experiencing a risk and/or side effect.  “Yes” 
(1) indicates the provider did use at least one type of probability statement and “No” (0) 
indicates the provider did not state any type of probability.  An example of a probability 
statement would be: “There is a rare chance of oral thrush from an inhaled 
corticosteroid.”  
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 Numerical statements: This dichotomous variable indicates if the provider used any 
numerical statements of risk during the audiotaped medical visit.  “Yes” (1) indicates the 
provider did use a numerical statement of risk and “No” (0) indicates the provider did 
not.  Examples of numerical statements of risk would be a provider stating the child has a 
2% risk of developing oral thrush from using a fluticasone (Flovent) metered-dose inhaler 
and/or a provider telling a child and caregiver that there is a 1.8% risk of drowsiness 
when taking montelukast (Singulair).  
 
 Qualitative statements: This dichotomous variable indicates whether the provider 
used any qualitative statements, such as words to communicate risk, during the 
audiotaped medical visit.  “Yes” (1) indicates the provider used a qualitative statement of 
risk and “No” (0) indicates the provider did not. Any statement of risk that includes 
words instead of numbers to indicate the probability of a risk occurring was coded as 
“Yes” (1).  Examples of qualitative statements of risk would be the use of these words to 
describe the probability of a risk occurring: (a) rare, (b) often, (c) not common, (d) 
unknown risk, (e) high risk, (f) low risk, etc.  All qualitative statements were coded 
verbatim from the transcripts.     
 
 Child values addressed: This dichotomous variable indicates the presence of a 
discussion about the child’s values regarding the risks of their asthma control medication.  
“Yes” (1) indicates that there was a discussion of the child’s values regarding the risk of 
the asthma control medication and “No” (0) indicates there was not a discussion.  An 
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example of this type of communication would be the provider asking the child if he/she 
felt like it was beneficial to take an asthma control medication based on the risks 
discussed. 
 
 Caregiver values addressed: This dichotomous variable indicates the presence of a 
discussion about the caregiver’s values regarding the risks of the asthma control 
medication.  “Yes” (1) indicates that there was a discussion of the caregiver’s values 
regarding the risk and “No” (0) indicates that there was not a discussion.  An example of 
this type of communication would be the provider asking the caregiver if he/she felt 
comfortable with the child taking a certain asthma control medication based on the risks 
associated with the medication. 
     
  Number of statements of risks: There were three separate discrete variables that 
measured the number of statements about asthma control medication risks that were made 
during the audiotaped medical visits.  One variable measured the number of statements 
about risks made by providers, another variable that measured the number of statements 
about risks made by caregivers, and the last variable that measured the number of 
statements about risks made by children.    
  
 Number of questions about risks: There were three separate discrete variables that 
measured the number of questions about risks that were asked during the audiotaped 
medical visits.  One variable measured the number of questions about risks asked by 
providers, another variable that measured the number of questions about risks asked by 
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caregivers, and the last variable that measured the number of questions about risks asked 
by children.   
  
 Qualitative Coding of Risks, Side Effects, and Benefits: This dissertation also 
coded all statements and questions of risks, side effects, and benefits made by providers, 
caregivers, and children.  All statements and questions of risks, side effects, and benefits 
were coded from the transcripts.  Statements and questions posed by providers, 
caregivers, and children were coded.  A draft of the SCI is included in Appendix A.  
 
 Inhaled Corticosteroid: This dichotomous variable indicated whether any of the 
child’s asthma control medications contained an inhaled corticosteroid.  “Yes” (1) 
indicated that at least one of the child’s asthma control medications contained an inhaled 
corticosteroid and “No” (0) indicated that none of the child’s asthma control medications 
contained an inhaled corticosteroid, meaning that the child was only on Singulair or was 
not taking any control medications.     
  
 End of Visit Plan: These variables indicated the end-of-visit plan for each asthma 
control medication discussed during the medical visit.   These variables were a series of 
separate dichotomous variables for each asthma control medication discussed.  The 
options for these variables were: (1) start, (2) continue, (3) discontinue, and (4) not start. 
If the provider started a new asthma control medication or changed the dosage on an 
asthma control medication, then the Start variable was coded “Yes” (1) and all other End 
of Visit variables would be coded “No” (0).  If the provider continued an asthma control 
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medication, then the Continue variable was coded “Yes” (1).  If the provider discontinued 
an asthma control medication, then the Discontinue variable was coded “Yes” (1).  If the 
provider discussed an asthma control medication but did not start the medication, then the 
Not Start variable was coded “Yes” (1). 
  
 Child Taking Montelukast and an Inhaled Corticosteroid as Asthma Control 
Medications: This dichotomous variable measured whether children were taking a 
medication with an inhaled corticosteroid AND a tablet (i.e. Singulair) as their asthma 
control medications.   
 
 Number of Asthma Control Medications Discussed: This discrete variable 
measured how many asthma control medications were discussed during the medical visit.   
 
 Number of Asthma Control Medications Started: This discrete variable measured 
how many asthma control medications were started during the medical visit.   
 
 Number of Asthma Control Medications Continued: This discrete variable 
measured how many asthma control medications were continued during the medical visit. 
 
 Number of Asthma Control Medications Discontinued: This discrete variable 
measured how many asthma control medications were discontinued during the medical 
visit.  
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 Child Only Taking Montelukast: This dichotomous variable measured whether the 
child was only taking Singulair as the asthma control medication.  This variable was 
conceptualized as identifying children who only took tablets as their asthma control 
medication versus children who used other devices or a combination of other devices 
along with tablets.  “Yes” (1) indicated the child was only taking Singulair at the time of 
the home visit and “No” (0) indicated the child did not take Singulair at all, or took 
Singulair as part of a combination of oral and inhaled pharmacotherapy for asthma.   
 
Child, Caregiver, and Provider Variables 
This section describes the variables that were measured for the child, caregiver, provider, 
and asthma control medications.    Unless otherwise noted in Table 5, all of these 
variables were obtained through the child interview or caregiver and provider 
questionnaire.  Table 5 presents these variables, including the variable name, source, 
type, and range.  
Table 5: Child, Caregiver, Provider, and Medication Variables 
Child Characteristics Source Type (Range) 
Gender Child Interview 1=male; 0=female 
Age Child Interview Continuous (8-16) 
Race/ethnicity Child Interview 1=white; 0=non-white  
How long child has lived with 
asthma 
Child Interview Continuous 
Asthma severity Child Interview 1=moderate/severe 
persistent; 0=mild 
persistent  
Child on Medicaid  Caregiver 
Questionnaire 
1=yes; 0=no 
Number of Prior Visits with 
Study Provider 
Caregiver 
Questionnaire 
Discrete (0-70) 
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Caregiver characteristics Source Type (Range) 
Gender Caregiver 
Questionnaire 
1=male; 0=female 
Age Caregiver 
Questionnaire 
Continuous (26-80) 
Education Caregiver 
Questionnaire 
Continuous (2-20) 
Income Caregiver 
Questionnaire 
1=Less than $10,000 
2=Between $10,000 and 
$19,999 
3=$20,000 through 
$29,999 
4=$30,000 through 
$49,999 
5=$50,000 through 
$69,999 
6=$70,000 or more 
Presence of 2 caregivers Coding Tool 1=yes; 0=no 
Provider characteristics Source Type (Range) 
Gender Provider 
Questionnaire 
1=male; 0=female 
Age Provider 
Questionnaire  
Continuous (29-69) 
How long has practiced 
medicine 
Provider 
Questionnaire 
Continuous (1-43) 
Race Provider 
Questionnaire 
1=white; 0=non-white 
 
 
Child Variables (Obtained from the Child Interview at Initial Visit and Home Visit) 
      Gender: This dichotomous variable measures whether the child was either male or 
female, reported by the child. 
       
       Age: This continuous variable measures the age of the child in years, reported by the 
child. 
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        Race/ethnicity: This variable was originally reported by children as: White, African 
– American, Native American, Asian, and Other.  Race was recoded as a dichotomous 
variable for analyses, measuring whether the patient was White or Non-White.  “Yes” (1) 
indicates the child was white and “No” (0) indicates the child was not White.   
       
 Number of Prior Visits with Study Provider: This discrete variable indicated the 
number of times the child had previously seen the provider that was seen as part of the 
medical visit.  This variable was caregiver-reported.   
 
 Asthma severity: This dichotomous variable indicates the severity of the child’s 
asthma.  Mild persistent asthma was coded (0) and moderate/severe persistent asthma 
was coded (1).  This variable is based on the parent study’s eligibility screener which 
classified children’s severity based on two methods: asthma symptoms and medication 
use.  Any child receiving a single asthma control medication was classified as mild 
persistent.  Any child receiving more than one asthma control medication was classified 
as moderate/severe persistent.  Any subject that reported symptoms occurring two or 
more times a week but not daily or waking up more than two or more times a month, but 
not nightly, was classified as mild persistent.  Any subject that reported symptoms 
occurring every day or waking up more than five times a month was classified as 
moderate/severe persistent (NAEPP, 2002).  
 
 Child on Medicaid: This dichotomous variable indicates whether the child had 
Medicaid at the time of the audiotaped medical visit.  Insurance type was originally a 
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categorical variable in the parent study, using the following categories: None, Private, 
Medicaid, North Carolina Health Choice, and Other.  The majority of children were using 
Medicaid, with smaller amounts of children being covered by private insurance and 
North Carolina Health Choice (NCHC) so this variable was transformed into a 
dichotomous variable for the bivariate and multivariate analyses.  “Yes” (1) indicates the 
child had Medicaid and “No” (0) indicates the child did not.     
 
Caregiver Variables 
      Gender: This dichotomous variable indicates whether the caregiver present during 
the audiotaped visit was male or female.  If more than one caregiver was present, this 
variable indicates the gender of the caregiver who filled out the questionnaire. 
       
       Age: This continuous variable indicates the age in years of the caregiver present 
during the audiotaped visit.  If more than one caregiver was present, this variable 
indicates the age in years of the caregiver who filled out the questionnaire. 
       
      Education: This discrete variable indicates the number of years the caregiver has 
spent in formal education, reported by the caregiver. 
       
      Income: This variable indicates the amount of income in US dollars the household 
receives.  The categories are: (a) less than $10,000, (b) $10,000 - $19,999, (c) $20,000 - 
$29,999, (d) $30,000 - $49,999, (e) $50,000 - $69,999, or (f) $70,000 or more.  For the 
bivariate and multivariate analyses, total household income was dichotomized, $19,999 
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or less versus $20,000 or more.  This was chosen because $20,000 or less was classified 
as the federal poverty level in 2006, when data collection commenced for the parent 
study (US Department of Health and Human Services, 2006).  The variable was coded as: 
(1) for families that made at least $20,000 and (0) for families that made less than 
$20,000.    
  
      Presence of two caregivers: This dichotomous variable indicates whether there was 
more than one caregiver present during the audio – taped visit and were taken from the 
transcripts of the visit. 
 
Provider Variables (Obtained from the Provider Questionnaire) 
      Gender: This dichotomous variable indicates whether the provider is male or female.  
This measure was self-reported by the provider. 
       
 Race: This variable indicates the provider’s race.  The original categories for this 
variable in the parent study were: White, African American, Native American/American 
Indian, or Other (includes categories of Hispanic, Asian American, other).  This variable 
was transformed into a dichotomous variable for the analyses where providers who were 
White were coded (1) and providers who were Non-White were coded (0) because of low 
frequencies of non-white races.   
  
 Age: This continuous variable measured how old the provider was in years at the time 
of provider enrollment. 
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 How long practiced medicine: This discrete variable indicates how many years it 
had been since the provider graduated from medical school.  The year of graduation was 
subtracted from the year that the provider completed the provider survey.  
 
Creation of Composite Variables 
 Racial Concordance: A new variable, Racial Concordance, was created to indicate 
medical visits in which the race of the child matched the race of the provider.  This 
variable was created because of the importance of race concordance on medical visit 
communication and medication outcomes (Johnson et. al. 2004).  Specifically, provider-
patient communication may be improved when the patient’s race matches the provider’s 
race (Johnson et. al. 2004).  Racial concordance between providers and patients is also 
significantly related to improved patient outcomes (LaVeist and Nuru-Jeter 2002).   
 
The next section is a discussion of the calculation of the sample size that was used in this 
study to make sure there was adequate power to detect meaningful conclusions. 
 
Sample Size and Statistical Power 
This research used an estimate of sample size that was described by Bentler et. al (1976).   
This heuristic is a general method of determining the number of subjects that are needed 
for a study.  This heuristic suggests that when regression analyses are used a sample size 
of: 80+20*sqrt(number of independent variables). The largest numbers of variables were 
in the analyses for Aim 2 (n=21) and therefore 172 persons were estimated to be able to 
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detect a significant difference (80+20*4.6).  Therefore, 295 subjects provided adequate 
statistical power for the current study. 
 
The next section is a discussion of missing data and the methods employed to remedy the 
problems caused by missing data.  
  
Missing Data 
The data were next examined for the presence of missing data.  The patterns of missing 
data are reviewed next, which determined the method for addressing the problem.  Table 
6 below shows the variables that were missing along with the frequency and percent 
missing.   
Table 6: Variables with Missing Data (N=295) 
Variable Name Frequency Missing (%) 
Child has Medicaid as Insurance 9 (3.1%) 
Caregiver is Married 3 (1.0%) 
Asthma Reason for Medical visit 2 (0.7%) 
Child is Hispanic 6 (2.0%) 
Child is white 6 (2.0%) 
Caregiver Gender 1 (0.3%) 
Caregiver Age 14 (4.7%) 
Caregiver Years of Education 4 (1.4%) 
Total household income 7 (2.4%) 
Number of prior visits with study provider 36 (12.2%) 
Adherent 59 (20.0%) 
Caregiver Concern about Side Effects 37 (12.5%) 
Child Concern about Side Effects 40 (13.6%) 
 
The missing data can be attributed to at least three causes: (a) improper following of skip 
patterns, (b) willful incompletion of the items, and (c) children who were lost to follow-
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up or dropped out of the study.  One patient did not have any baseline information, which 
left a baseline sample of 295 children.   
 
There was no way to evaluate whether the data were missing at random, since this would 
require knowledge of the missing values.  However, Faris and colleagues (2002) showed 
that even when there are violations of the missing at random assumption, that the bias 
that is introduced to regression coefficients was minimal.  Therefore, a conservative 
approach to analyze the missing data was chosen and the data was assumed to be missing 
at random (MAR).  For this study, multiple imputation methods were utilized to address 
the missing data in the predictor variables.  Multiple imputation models using the Markov 
Chain Monte Carlo (MCMC) algorithm method with five imputed datasets were created.   
 
Generalized estimating equation (GEE) models for each of the communication outcome 
variables (Side Effects Discussed, Risks Discussed, and Benefits Discussed) were 
constructed for the multiply-imputed dataset and for the complete case dataset using 
listwise deletion.  There were few differences in the coefficients and no differences in the 
variables that were of statistical significance when comparing the multiply-imputed 
dataset and the complete case dataset using listwise deletion.  Results from the complete 
cases are presented in the results.  The sample size for the GEE model predicting risk and 
benefit discussion was 255. 
 
There were also missing variables on three of the outcome variables, adherence, and 
whether the caregiver and child had any concerns or fears about side effects.  In total, 260 
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children and caregivers had home visits; therefore, 88% of the final sample completed 
both data points for the study.  There is debate around imputing outcome variables, thus 
the decision was made to use complete case analysis using listwise deletion of missing 
values on outcome variables.  Listwise deletion removes subjects from the analysis if 
there is a missing value on any of the variables that were included in the model.    
 
The listwise deletion left a sample of 229 caregivers that answered the home visit 
variable, adherence.  The sample size for the adherence outcome variable was 214 after 
accounting for missing data in the independent variables.  The sample size for the 
caregiver concern at home visit outcome variable was 215 and the sample size for the 
child concern at home visit outcome variable was 240.  Even though these sample sizes 
did decrease the overall power of this dissertation, the sample sizes were still well above 
the minimum amount of patients needed to detect significant differences (n=172).       
 
Data Analysis 
All study data were entered into SPSS 14.0 and converted to SAS 9.2 for analysis.  In 
addition, codes were entered into Excel 2011 from the qualitative analysis. 
 
Descriptive Data Analysis 
First, descriptive statistics were calculated for the child, caregiver, provider, medication, 
and communication variables.  Frequencies and percents were used to describe 
categorical and dichotomous variables.  Means and standard deviations were used to 
describe continuous variables.  For all discrete and count variables, the data was plotted 
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to examine the structure.  As an example, the child question asking about risks variable 
was skewed to the left because of numerous zero values, therefore it was dichotomized. 
 
Bivariate Data Analysis   
Bivariate relationships among the independent variables were examined using Pearson 
correlation coefficients.  Table 18 in CHAPTER FOUR presents the correlations for the 
independent variables that were used in this dissertation.      
 
After the bivariate relationships among the independent variables were examined, the, 
bivariate relationships between all of the outcome variables and child, caregiver, 
provider, medication, visit, and communication characteristics were examined.  Table 19 
in CHAPTER FOUR presents the correlations among the independent variables with 
each outcome variable used in this dissertation.  Table 19 shows Pearson correlation 
coefficients.     
 
After examining the Pearson correlation coefficients between the independent variables 
and the outcome variables, chi-square statistics were calculated to test the association 
between each of the outcome variables and categorical independent variables.  Two-tailed 
t-tests were calculated to test the association between communication outcome variables 
and discrete variables.  All analyses were conducted with an alpha level of 0.05 and 
performed in SAS 9.2.  
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Multicollinearity Among Independent Variables 
As expected, there was significant multi-collinearity between the caregiver-reported race 
variable and the child-reported race variable (r=0.81, p<0.0001).  Thus, only child-
reported race was used in the bivariate and GEE analyses.  There was also significant 
multi-collinearity between the provider’s age and the length of time that the provider had 
spent in medical practice (r=0.92, p<0.0001).  Therefore, only provider age was used in 
the bivariate and GEE analyses for all outcome variables.   
 
There was multicollinearity between the number of control medications discussed and the 
number of control medications that the child was taking or prescribed at the end of the 
visit (r=0.74, p<0.0001).  This correlation is intuitive because the number of medications 
that were discussed during the visit would be the exact same or very close to the number 
of control medications that were continued or prescribed.  Another set of variables that 
breached the r=0.70 threshold for multicollinearity were the number of control 
medications that the child was taking or prescribed at the end of the visit and the number 
of control medications that were continued during the visit (r=0.76).  There was also 
significant multicollinearity between the variable that measured patients who were taking 
inhaled corticosteroids and the number of medications the patient was taking (r=0.62, 
p<0.0001).  This relationship did not meet the r=0.70 threshold (Slinker and Glantz 1985) 
but the relationship was approaching the threshold.  The decision was made to drop the 
number of medications the child was taking or prescribed at the end of the visit for all 
primary analyses except the analysis that focused on medication adherence.  For the 
medication adherence analysis, the number of medications that the child was taking was 
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used and the variable that measured whether the child was taking an inhaled 
corticosteroid was dropped.   
 
To remedy this multicollinearity, the decision was made to drop the number of the 
number of medications the child took or was prescribed to take at the end of the visit and 
number of control medications that were continued during the visit, in favor of keeping 
the number of medications discussed during the visit variable for the primary analyses.    
 
Another set of variables that resulted in multicollinearity was the family income variable 
and the child on Medicaid variable.  While these two variables did not reach the r=0.70 
threshold to indicate that multicollinearity would be a problem in the multivariate 
analyses there was a strong, direct correlation between the two variables (phi=0.59, 
p<0.0001).  This correlation was the third highest correlation among independent 
variables and was reaching the r=0.70 correlation threshold that may have resulted in 
multicollinearity problems.  
 
The next section discusses the methods that were used for hypothesis testing using 
generalized estimating equations for each of the outcome variables.   
 
 
 
 
 
 68
Analysis by Aim 
Specific Aim #1: To examine the association between provider, caregiver, and child 
characteristics and communication about risks, side effects, and benefits of asthma 
control medications during audiotaped pediatric visits.  
H1: Discussion of asthma control medication side effects will be more likely to be 
discussed when there is more than one caregiver is present during the audio-taped 
medical visit. 
H2: Discussions of asthma control medication risks will be more likely to occur when 
caregivers are less educated. 
H3: Discussion of asthma control medication risks will be more likely to occur when 
caregivers have lower incomes. 
H4: Discussion of asthma control medication risks will be more likely to occur when 
there is more than one caregiver present during the audio-taped medical visit.  
H5: Discussion of asthma control medication benefits will be more likely to occur when 
the child has moderate/severe persistent asthma.  
 
These hypotheses were tested using generalized estimating equations (GEE).  GEE 
allows for nesting by provider.  GEE models were not constructed for the side effects 
variable because there was not enough variation to run an appropriate specified GEE 
model.  Only 4% of visits included a discussion about side effects of asthma control 
medication.   
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The independent variables for the risk discussion GEE model were: child race, child age, 
child gender, asthma severity, whether the child was taking an inhaled corticosteroid, 
caregiver age, caregiver gender, caregiver education, family income, provider gender, 
provider age, provider race, length of visit, adherence was discussed, presence of second 
caregiver in room, reason for visit, whether the caregiver was married, the number of 
prior visits with study provider, and the racial concordance variable.   
  
A separate GEE model was then run to examine the impact of the independent variables 
on the presence of discussions about the benefits of asthma control medications.  The 
independent variables for this GEE model were: child race, child age, child gender, 
asthma severity, whether the child was taking or prescribed an inhaled corticosteroid, 
caregiver age, caregiver gender, family income, provider gender, provider age, provider 
race, length of visit, whether adherence was discussed, presence of second caregiver in 
room, reason for visit, whether the caregiver was married, the number of prior visits with 
the study provider, and the racial concordance variable.   
 
Specific Aim #2: To analyze predictors of caregiver-reported adherence to the child’s 
asthma control medications one month after the audiotaped medical visit. 
 
H6: Caregivers are more likely to report their child being adherent to their asthma control 
medications if risks were discussed in the medical visit.  
H7: Caregivers are more likely to report their child being adherent to their asthma control 
medications when the control medication was only Singulair.   
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H8: Caregivers are more likely to report their child being adherent to their asthma control 
medications when the child is taking only one asthma control medication or one 
combination asthma control medication.  
 
The analysis of this aim focused on using generalized estimating equations (GEE) to 
examine how patient, caregiver, provider, communication, and asthma control medication 
characteristics was associated with: caregivers reported their child as adherent to their 
asthma control medications.  As discussed above, an adherence score of at least 80% was 
defined as adherent.  Only children who took asthma control medications were included 
in the Aim 2 analyses.     
 
We constructed a GEE model to test the association of the measured variables to the 
caregiver-reported adherence variable.  The independent variables for this GEE model 
were: child race, child age, child gender, asthma severity, count of asthma control 
medications, caregiver education, caregiver gender, whether benefits were discussed 
during the audio-taped visit, whether risks were discussed during the audio-taped visit, 
whether side effects were discussed during the audiotaped visit, family income, whether 
the child was taking only one asthma control medication, provider gender, provider age, 
provider race, length of visit, whether adherence was discussed during the audio-taped 
visit, whether the caregiver was married, number of prior visits with the study provider, 
the reason for the visit, and whether the child was only taking Montelukast.   
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Specific Aim #3: To examine the association between risk, side effect, and benefit 
communication and caregiver- and child-reported problems and concerns about asthma 
medication side effects one month after the audiotaped medical visit. 
 
H9: Caregivers are less likely to report problems and concerns about side effects with 
their child’s asthma medications if risks were discussed during the medical visit. 
 H10: Caregivers are less likely to report problems and concerns about side effects with 
their child’s asthma medications if the asthma control medication does not contain an 
inhaled corticosteroid. 
H11: Children are less likely to report problems and concerns about side effects with their 
asthma control medications if side effects were discussed during the medical visit. 
H12: Children are more likely to report problems and concerns about side effects with 
their asthma control medications if benefits were discussed during the medical visit.  
 
To accomplish this aim, there was a single variable on both the child home visit interview 
and the caregiver home visit survey that asked how much concern or fear that children 
and caregivers had of the asthma control medication causing side effects.  A plot of the 
variable revealed a large proportion of “None” answers for this question.  The decision 
was then made to collapse the three categories into a dichotomous variable, where 1=a 
little or a lot of concern about side effects or 0=no concern about side effects.   
 
Finally, GEE models were constructed to test the association between patient, caregiver, 
provider, medication, and communication characteristics on caregiver- and child-report 
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of a problem/concern of side effects of asthma control medication(s).  The dependent 
variable in hypotheses nine and ten was caregiver report of fear/concern of side effects 
and the dependent variable in hypotheses eleven and twelve was child report of 
fear/concern of side effects. 
 
The independent variables for the caregiver side effects concern GEE model were: child 
race, child age, child gender, asthma severity, whether the child was taking an inhaled 
corticosteroid, caregiver age, caregiver gender, family income, whether side effects were 
discussed, provider gender, provider age, provider race, length of visit, reason for visit, 
whether the caregiver was married, risks discussed during the medical visit, benefits were 
discussed during the medical visit, the number of prior visits with the study provider, 
whether the child only took Singulair as his/her asthma control medication.  
 
The independent variables for the child side effects concern GEE model were: child race, 
child age, child gender, asthma severity, whether the child was taking an inhaled 
corticosteroid, caregiver age, caregiver gender, provider gender, provider age, provider 
race, length of medical visit, whether the caregiver was married, whether the child was 
only taking Montelukast as his/her asthma control medication, family income, whether 
risks were discussed during the medical visit, whether benefits were discussed in the 
medical visit, whether side effects were discussed, and the reason for the medical visit.  
CHAPTER THREE: METHODS FOR QUALITATIVE ANALYSIS (AIM 4) 
 
Overview 
This chapter presents the methods used to qualitatively analyze the transcripts of the 
medical visits for discussions about side effects, risks, and benefits of asthma control 
medications.  Specific Aim 4 is: To qualitatively describe all control medication risks, 
side effects, and benefits that are discussed during the audiotaped asthma visits.   
  
The chapter is organized into three parts. First, the chapter describes the methods and 
theory utilized to discern the context of these discussions. Second, the chapter presents 
the categories that were revealed in the process of the qualitative analysis and the 
definition for each category, along with some examples of questions and statements that 
would fit into each category.  
 
Content Analysis of the Medical Visit Transcripts 
In this study, to complete the qualitative analysis of discussions about side effects, risks, 
and benefits, all transcripts were first reviewed to determine the presence of 
communication about risks, side effects, and benefits.  
 
Content analysis of the transcripts was performed using the following process: processing 
the raw data, data reduction, data display, conclusion drawing, and then verification 
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(Strauss and Corbin 1998).  The general description of this process is as follows: (1) 
reading and examining the transcripts to identify questions and statements that convey a 
single meaning or idea, (2) grouping together and labeling units conforming to themes, 
(3) data organization, and (4) validating themes.   
 
While completing the coding tool, both coders copied and pasted the text of the entire 
discussion about side effects, risks, and benefits from the transcripts of the medical visits 
into the tool.  Upon completion of cutting of excerpts from the medical visit transcripts, 
codes were generated to describe the discovered concepts.  The coders carefully reviewed 
each question and statement to identify the main idea behind the question or statement.  
By identifying the main topic of each question and statement, both coders began to 
develop categories.  The categories were intended to reflect the main idea of the question 
and statement.  The coders coded 20 of the same transcripts to check for reliability for 
discussions about side effects, risks, and benefits.    
 
By closely examining the discussion data, both coders were able to identify concepts that 
were then examined more closely to develop categories; words, phrases, and subject 
matter that were found to be similar were then grouped into distinct categories.  In this 
analysis, categories described subject matter, such as specific risks that were discussed in 
the transcripts.  As each category was created, a process of constant comparison was 
employed in assigning new codes, so that text and subject matter that were considered the 
same were assigned to the same category.  This process continued throughout the coding 
process.  
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Through category refinement, the definition and conceptualization of the themes of side 
effect, risk, and benefit communication emerged from the transcripts.  Categories were 
refined until the concepts were not repeated and no new categories were being created, 
which indicated the analysis reached saturation.   
 
Several steps were undertaken to improve coding reliability and validate the concepts that 
were discovered in the analysis.  First, as previously mentioned, a process of constant 
comparison was employed so that each new assignment of a code initiated a brief review 
of previous uses of the same category to ensure that the content of the category addressed 
the same concept.  Next, a second coder was used to double-code 10% (n=30) of the 
transcripts and assign categories while being blinded to the principal investigator’s 
assignment of categories.  The purpose of having a second coder was to check and 
validate the principal investigator’s assignment of categories based around the concepts 
of the discussions.  While none of these actions guarantee valid results, it is believed that 
the steps taken indicate a rigorous approach to the conduct of the qualitative analysis and 
improve the validity of the findings.   
 
The goal of the qualitative analysis was to more fully understand the nature of how 
providers discussed side effects, risks, and benefits of asthma control medications with 
children and their caregivers.  An additional aspect of risk communication that was 
examined was how comprehensive providers were in the discussions about risks.  This 
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study used Bogardus’ dimensions of risk communication (1999) to examine this aspect of 
risk communication.   
Qualitative Analysis of Side Effect Discussions 
Questions about Side Effects of Asthma Control Medications 
Table 7 presents all of the categories that questions about side effects fell into, along with 
each category’s definition and an example.  
 
There were five categories of questions that were asked about side effects from providers 
and caregivers.  Children did not ask any questions about side effects during these clinic 
visits.  General questions about side effects was the category that was most often used by 
providers, and caregivers asked one question each from the Asking for Clarification, Bad 
Taste, Weight Gain, and Cough categories.   
 
Table 7: Categories of Questions about Side Effects of Asthma Control Medications 
 
Category Definition Example 
General 
A question that asks about side effects 
that may have been experienced but 
does not state a specific side effect 
D: “…She didn’t have 
no bad reaction to it or 
anything like that?” 
Asking for 
Clarification 
A question that is a follow-up 
question of a statement that was 
previously made about side effects 
C: “You don’t think so?” 
Bad Taste Questions that were asked about the taste of an asthma control medication C: “Is it sour?” 
Weight Gain  
Questions asking if the child was 
experiencing weight gain from using 
an asthma control medication 
C: “Do you think it’s 
[weight gain] because of 
the medicine or because 
he hasn’t felt like 
playing?” 
Cough 
Questions asking if the child was 
experiencing cough from a result of 
using an asthma control medication 
C: “Won’t be like the 
cough we have now?” 
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Statements about Side Effects of Asthma Control Medications 
Table 8 presents all of the categories of statements about side effects that were made by 
participants during the clinic visits.  
 
There were seven categories of statements about side effects during these clinic visits.  
The category that was most often used by providers was the Assurance category while 
caregivers made the most statements about General side effects and Headaches.  
Children did make statements about side effects, but always spoke after their caregiver, 
repeating what the caregiver said about side effects. 
 
Table 8: Categories of Statements about Side Effects of Asthma Control 
Medications 
 
Category Definition Example 
Assurance 
Statements made to assure that a 
certain side effect that the child was 
experiencing was not because of the 
asthma control medication 
D: "“Ah, I wonder if 
the reason he’s tired in 
the morning is not so 
much the Advair…” 
Thrush 
Statements about the child 
experiencing thrush after taking an 
asthma control medication 
C: “Actually, he was 
using the Advair every 
day twice a day like he 
was supposed to been 
and he started 
complaining of a sore 
throat” 
Bad Taste Statements made about the bad taste 
of an asthma control medication P: “It tastes nasty” 
Unaware of Side 
Effects Caused by 
Medication 
Statements made about children 
experiencing side effects that the 
provider had not seen or heard 
before 
D: “…and I’ve just not 
ever seen that but I 
guess you know every 
medicine is different in 
every kid’s body” 
Headaches 
Statements made about the child 
experiencing headaches from using 
an asthma control medication 
C: “Well I mean he 
used to take Singulair, 
but he got really bad 
headaches" 
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Category Definition Example 
General 
Statements made that indicated the 
child had experienced a side effect, 
but did not state a specific side 
effect 
C: “We did Advair one 
time and I didn’t like 
that at all".   
Drowsiness 
Statements made that indicated the 
child had experienced drowsiness 
after using an asthma control 
medication 
C: “Let me tell you 
something about that, 
ah, that, that makes him 
sleepy”. 
 
The next section presents the risk discussion categories, along with a definition of each 
category and an example of each category.    
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Qualitative Analysis of Risk Discussions  
Questions About Risks of Asthma Control Medications 
Table 9 presents the categories of questions that were asked about risks during these 
clinic visits.  
 
Providers asked two questions about risks, one each in the General category and the 
Steroid Causing Harm category.  When the provider asked questions about risks, the 
provider used those questions to begin the medication risk discussion.  Caregivers asked 
the most questions in the Steroid Causing Harm category and children asked one 
question each in the Steroid Causing Harm, Anabolic Steroid Risks, and Bad Taste 
categories. 
Table 9: Categories of Questions about Risks of Asthma Control Medications 
Category Definition Example 
Steroid Causing 
Harm 
Questions made that indicated that an 
asthma control medication might harm 
a child 
P: “It won’t hurt me will 
it?” 
General 
Questions made asking about potential 
risks of an asthma control medication, 
but did not state a specific risk 
C: “Okay, so what are 
the side effects from the 
Singulair?”   
Drug-Drug 
Interaction 
Questions about the risk of two drug 
interacting and causing an adverse 
effect on the child 
C: “And it’s safe 
together [Singulair and 
anti-histamine]?”  
Dose 
Questions made about the risks 
associated with the dose of an asthma 
control medication being too high 
C: “Okay, that’s not too 
much?”   
Probability of Risks 
Occurring 
Questions made asking about the 
probability of a risk occurring 
C: “So it’s not 
common?”   
Anabolic Steroid 
Risks 
Questions asking that compares the 
risks of anabolic steroids with inhaled 
corticosteroids 
P: “Wait, does steroids 
um, cut off my fat or 
something?”.   
Bad Taste Questions that indicated the asthma 
control medication may taste bad 
P: “Is it going to taste 
better?”. 
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Statements about Risks of Asthma Control Medications 
Table 10 presents the categories of statements about risks of asthma control medications 
during these clinic visits.  Table 10 also lists the definition of each category as well as 
one example of each statement.     
 
Overall, there were 16 different categories of statements about the risks of asthma control 
medications.  The category that was most often spoken about was General statements 
about risks, which were statements where a specific risk was not identified.  Children did 
not make any statements about asthma control medication risks during these clinic visits.   
 
Table 10: Categories of Statements about Risks of Asthma Control Medications 
 
Category Definition Example 
Safety 
Statements that indicated the asthma 
control medication was safe or lacked 
risks 
D: “Those have really 
got a great safety 
profile”.   
Thrush 
Statements made about the possibility 
of the child getting thrush after using 
the asthma control medication 
D: “Occasionally, 
people get a little sore 
throat”.  
Bad Taste Statements that indicated the asthma 
control medication may taste bad 
D: “It doesn’t have that 
powdery taste”.   
Drowsiness 
Statements made that indicated the 
asthma control medication may or 
may not cause drowsiness 
D: “The Singulair can 
be given at any time of 
day because it doesn’t 
cause sleepiness”.  
Concerns in Media 
Statements about risks stated in 
popular media, such as newspapers, 
television, the internet, etc. 
D: “Somebody 
rehashed it on TV and 
every time it happens I 
have a kid, ah, family 
call me up, we’re 
stopping the medicine 
because we’re scared of 
it”.   
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Category Definition Example 
Anabolic Steroid 
Risks 
Statements that compare the risks of 
anabolic steroids with inhaled 
corticosteroids 
D: “Well, remember 
that the football players 
are not inhaling 
steroids, they’re taking 
shots of testosterone 
that’s very dangerous”.   
Hyper-Activity 
Statements made about an asthma 
control medication causing hyper-
activity in children 
D: “The only side 
effect as far as that 
goes sometimes it 
hypes them up”.   
Steroid Causing 
Harm 
Statements made about an asthma 
control medication that may or may 
not cause harm to the child 
D: “And there were 
actually some, with one 
study showed that 
increased risk of dying 
from asthma with 
people taking Serevent 
alone”.   
Reduction in 
Growth Velocity 
Statements made that indicated an 
asthma control medication may or 
may not cause a reduction in growth 
velocity or final adult height 
D: “So you’re not 
affecting his growth 
pattern, you will read in 
the package insert that 
they say oh, this can 
affect growth patterns”.   
Reduced Immunity 
Statements made that an asthma 
control medication may cause a 
reduction in immunity 
D: “It won’t make him 
more susceptible to you 
know, getting 
infections”.   
General 
Statements about risks of asthma 
control medications, but does not 
state a specific risk 
D: “And it tends not to 
have an effect all over 
the body because we 
don’t want that”.   
Dose 
Statements made about the risk of 
dosages of an asthma control 
medication 
D: “No, Advair twice a 
day is fine, you don’t 
want to do more than 
twice a day”.   
Feels like Taking 
Albuterol 
Statements made that an asthma 
control medication may make a child 
feel like (s)he has just taken 
Albuterol 
D: “Occasionally 
people will feel little 
bit like they took 
Albuterol”.   
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Category Definition Example 
Long-Term Effects 
Statements made about the long-term 
risks of a child taking an asthma 
control medication 
C: “Yeah because I 
worry about the long 
term”.   
Drug-Drug 
Interaction 
Statements about the risk of two 
drugs interacting and causing an 
adverse effect on the child 
D: “Get back on 
Claritin and then do the 
Singulair, you can take 
them both at the same 
time and it’s no big 
deal”.   
Assurance 
Statements made to assure caregivers 
and children that a condition the child 
may experience is not related to the 
child's asthma control medication 
D: “It’s not from that 
[nosebleeds from 
Singulair]”.   
Nosebleeds 
Statements made that the child may 
experience a nosebleed from taking 
an asthma control medication 
C: "But still he gets 
nosebleeds" 
 
The next section discusses the categories from the qualitative discussions about the 
benefits of asthma control medications.   
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Qualitative Analysis of Benefit Discussions 
Questions about Benefits of Asthma Control Medications 
Table 11 presents the categories of questions that were asked about the benefits of 
asthma control medications.  
 
There were eight different categories of questions that were asked about the benefits of 
asthma control medications.  The most often discussed category of questions was 
Symptom Control/Prevention.  Both caregivers and children asked very few questions 
about asthma control medication benefits.   
Table 11: Categories of Questions about Benefits of Asthma Control Medications  
Category Definition Example 
Symptom 
Control/Prevention 
Questions that asked if the asthma 
control medication was controlling 
and preventing asthma symptoms 
D: “Advair?  How is 
that working for you?”  
Ease of Use 
Questions about the ease of use of 
an asthma control medication or 
device, including the time it would 
take for the child to use the asthma 
control medication or device 
D: “How long is it 
going to take him to do 
the Pulmicort in the 
inhaler?” 
Quality of Life 
Questions made that indicated that 
the asthma control medication 
would improve one of the 
following: asthma symptoms, 
activity limitation, and negative 
emotions 
D: “Are you worried 
she is going to get sick 
and have to come in?” 
Adherence 
Questions asked about the child's 
adherence or lack of adherence and 
the resulting benefit from an 
asthma control medication 
D: “If you take it, does 
it work?” 
Re-iteration 
Questions that restated what the 
caregiver or child said about the 
control medication benefits 
D: “It works good?” 
General 
Questions that were made that 
asking specific benefits the asthma 
control medication would provide 
C: “He seems to be 
doing a lot better with 
the Singulair than 
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without, you know?” 
Category Definition Example 
Teach-Back Questions using the Teach-Back 
method of ensuring understanding 
D: “To keep it away so 
you don’t have to use 
your?” 
Potency  
Questions that asked about the 
effectiveness or lack of 
effectiveness of the asthma control 
medication 
D: “You started two 
weeks ago, and it’s 
such a strong medicine 
that you’re already 
better right?”    
 
 
Statements about Benefits of Asthma Control Medications 
Table 12 presents the categories of statements that were made about asthma control 
medication benefits.  
 
Overall, there were 21 categories of statements about the benefits of asthma control 
medications.  The most frequently discussed category was Symptom Control/Prevention.   
 
Of note, the Quality of Life category was defined as statements that referenced at least 
one of three concepts: negative emotion, symptoms, and activity limitation.  Specifically, 
these statements indicated that the asthma control medication would improve at least one 
of the following: asthma symptoms, activity limitation, and negative emotions.  The three 
domains were taken specifically from the Pediatric Asthma Quality of Life Questionnaire 
(PAQLQ) (Juniper, et. al. 1996), which is a patient and caregiver- reported quality of life 
measure.  It has been shown to be both reproducible and reliable.  
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Table 12: Statements about Benefits of Asthma Control Medications 
Category Definition Example 
Adherence 
Statements about the child's 
adherence or lack of adherence and 
the resulting benefit from an asthma 
control medication 
P: “Yeah, usually when 
I take it, I wait a couple 
minutes and then I have 
no more asthma for the 
rest of the day”    
Potency 
Statements about the effectiveness or 
lack of effectiveness of an asthma 
control medication 
P: “Umm, it helps a 
little bit but not much”   
General 
Statements made about benefits of 
asthma control medications but do 
not name a specific benefit, 
describing the medication in a 
positive way 
P: “That’s why I 
haven’t had as much 
problems probably 
since I started taking the 
Singulair” 
Teach-Back Statements using the Teach-Back 
method to ensure understanding 
P: “To keep it situated” 
 
Multiple Indications 
Statements made about an asthma 
control medication having more than 
one indication, i.e. control of asthma 
and allergy symptoms 
D: “Singulair is really 
good for allergies and 
also asthma preventive 
medications so I do 
think Singulair is a 
good idea”   
Decreases 
Inflammation in 
Lungs 
Statements that indicate the asthma 
control medication will decrease 
inflammation in the lungs 
D: So we got 
inflammation, we got 
spasm, you want to use 
Pulmicort to get rid of 
that inflammation”  
Consequences of 
Not Treating 
Statements made indicating that not 
treating the child with an asthma 
control medication may result in 
short- and long-term consequences 
for the child's health 
D: “They have long 
issue problems even in 
long, later on in life, 
you know like COPD or 
emphysema even 
without smoking ever in 
their life, you know so 
there are consequences 
to not treating”   
 86
Category Definition Example 
Symptom 
Control/Prevention 
Statements indicating that using an 
asthma control medication would 
result in improved asthma symptom 
control and prevention of asthma 
symptoms 
D: “And the 
Singulair…these are to 
prevent and control her 
symptoms”   
Quality of Life 
Statements made indicating that an 
asthma control medication would 
improve one of the following: 
asthma symptoms, activity 
limitation, and/or negative emotions 
D: “A child should be 
able to go outside and 
play as hard and as long 
as they want and not 
have to come in and get 
her inhaler, she should 
be able to go to a 
birthday party and blow 
up balloons just like all 
the other kids”. 
Pulmonary Function 
Statements made indicating that an 
asthma control medication would 
improve lung function for the child 
D: “Okay so that this is 
(unclear) asthma and 
improve lung function”   
Reduced Need for 
Rescue Medication 
Statements that indicated that an 
asthma control medication would 
reduce the child's need for an asthma 
rescue medication 
P: “It helps me not to 
use it [Albuterol] as 
much”  
Acute 
Symptoms/Prior to 
Exercise 
Statements about the benefit or lack 
of benefit an asthma control 
medication would bestow during 
acute symptoms and immediately 
prior to exercise 
D: “It does not help in 
an acute attack, it’s not 
meant to do that” 
Length of Time 
Medication Works 
Statements made indicating the time-
frame the asthma control medication 
would work in the child's body 
D: “Advair, the purple 
disk, when you brush 
your teeth in the 
morning, it does have a 
long acting steroid in it 
and a long-acting 
Albuterol so the benefit 
is it hangs out in the 
lungs over a 12 hour 
period”  
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Category Definition Example 
Goals of Treatment 
Statements made about different and 
separate benefits in the same 
statement about the specific goals of 
treating children with an asthma 
control medication 
D: “And that’s one of 
the ways how we judge 
if it is working for you 
whether you are 
needing your Albuterol, 
are you able to sleep 
through the night 
without coughing, are 
you able to exercise, 
you know run around 
play without coughing”   
Improvement Time-
Table 
Statements made about the time-
frame the caregiver and child could 
expect to see improvement of asthma 
symptoms, asthma control, and 
prevention of symptoms 
D: “Give it a good try 
for four weeks and I 
really think you will 
find it is well worth it”     
Ease of Use 
Statements about the low difficulty 
of the use of an asthma control 
medication or device; Statements 
could also include the time it would 
time for a child to take a dose of the 
medication 
D: “Well let’s do the 
Claritin, the Flonase, 
and the Singulair 
because that’s as easy 
as it gets”   
Dose 
Statements about how well the 
asthma control medication works at 
different dosages 
D: “Well the interesting 
thing about Advair 
(unclear) is there is a 
dose at which you don’t 
get much of a response 
after you get there”   
Prevention of Bad 
Asthma Outcomes 
Statements made about asthma 
control medications preventing bad 
asthma outcomes and referenced at 
least one of the following outcomes: 
missing school days, emergency 
room visits, hospitalizations from 
asthma, pulmonary function testing, 
and chronic asthma exacerbations 
D: “That medicine has 
saved a lot of people 
from being sick and 
having to go to the 
emergency room and all 
that sort of stuff”.  
Inhalation 
Technique 
Statements about the asthma control 
medication benefit that was 
dependent on the child's inhalation 
technique 
D: “Yeah it won’t work 
if you don’t do it right 
so you’ve got to do it 
the right way” 
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Category Definition Example 
Anticipating Benefit 
Statements about anticipating 
benefits from using an asthma 
control medication 
C: “It seems like a 
really good direction to 
go in because…when 
the steroids were in 
her…she had really 
good health”.   
Bronchitis 
Statements that indicated that an 
asthma control medication has 
improved a child's bronchitis 
symptoms 
C: “Well he hasn’t had 
anything to do with 
bronchitis since May of 
last year” 
 
The next chapter describes the results from the quantitative analysis.
CHAPTER FOUR: QUANTITATIVE RESULTS 
 
Children with Asthma and Caregiver Characteristics of Total Sample 
 
Patient characteristics for the full sample of 295 children are presented in Table 13.  
Approximately 59% (n=173) of the children’s visits were asthma-related.  The average 
age of children is 11.1 (SD=2.4; range 8-16).  The majority of children were male (54%).  
Most patients were classified as having moderate-severe persistent asthma (72%).  
Almost all patients had some type of health insurance, with Medicaid as the most 
prevalent type of insurance (52%).  Only 4.1% of children were of Hispanic origin.  The 
number of prior visits with the study provider had large variability, with a mean of 11.1 
(SD=11.5; range 0-70).  Finally, almost one-third of children (n=83) reported a problem 
or concern about side effects of their asthma control medication one month after the 
medical visit.   
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Table 13: Characteristics of Children with Asthma in Total Sample (N=295) 
Characteristics Percentage (N) 
Age, mean (standard deviation) (range) 11.1 (2.4) (8-16) 
Child Gender-Male 53.7 (153) 
Race   
Black 30.1 (89) 
White 61.5 (182) 
American Indian/Alaskan Native 10.1 (30) 
More than One Race 10.1 (31) 
Native Hawaiian or Other Pacific Islander 1.0 (3) 
Asian  0.3 (1) 
Other 4.7 (14) 
Hispanic  4.1 (12) 
Asthma Severity   
Mild Persistent 28.0 (83) 
Moderate-Severe Persistent 72.0 (213) 
Medical Insurance   
None 1.0 (3) 
Private 26.5 (78) 
Medicaid 52.0 (153) 
NC Health Choice 17.7 (52) 
Other 2.7 (8) 
Reason for Visit-Asthma 59.0 (173) 
Number of prior visits with study provider, mean 
(standard deviation) (range) 11.1 (11.5) (0-70) 
Child-reported Problems and Concerns About Side 
Effects of Asthma Control Medication 32.6 (83) 
 
Table 14 shows the caregiver’s characteristics from the sample.  The majority of 
caregivers were female (85.8%) and were married (58.4%).  The mean age of caregivers 
in this sample was 41 years (SD=8.4; range=26-80).  The mean years of education for 
caregivers were 12.8 years (SD=2.5; range=2-20).  Most caregivers had an annual income 
between $30,000 and $49,999 (23.9%).   
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Caregiver-reported average adherence for children taking control medications was 84.6% 
(standard deviation=25.9) with a range of 0-100.  Caregivers reported that almost 60% of 
children had an average adherence score of at least 80%, classified as adherent to their 
asthma control medication(s).  About 37% (n=96) of caregivers reported a problem or 
concern about side effects of their child’s asthma control medication one month after the 
audio-taped medical visit.       
Table 14: Characteristics of Caregivers of Children with Asthma in Total Sample 
(N=295) 
 
Caregiver Characteristics Percentage (N) 
Caregiver Age, mean (standard deviation) (range) 41.0 (8.4) (26-80) 
Caregiver Gender-Female 85.8 (253) 
Marital Status   
Never Married 16.4 (48) 
Married 58.4 (171) 
Widowed 3.1 (9) 
Separated 9.6 (28) 
Divorced 12.6 (37) 
Years of Education, mean (standard deviation) (range) 12.8 (2.5) (2-20) 
Family Income   
Less Than $10,000 21.5 (62) 
Between $10,000 and $19,999 20.1 (58) 
Between $20,000 and $29,999 13.8 (40) 
Between $30,000 and $49,999 23.9 (69) 
Between $50,000 and $69,999 8.7 (25) 
$70,000 or More 12.1 (35) 
Caregiver-Reported Child Adherence Score, mean 
(standard deviation) (range) 84.6 (25.9) (0-100) 
Child Adherence Score of at Least 80% 59.2 (138) 
Caregiver-Reported Problem/Concern About Side 
Effects of Asthma Control Medication 37.2 (96) 
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Provider Characteristics 
The characteristics for the full sample of 35 providers are presented in Table 15.  The 
majority of providers were female (51.4%) and classified as physicians (88.6%).  The 
mean age for providers was 44 years (SD=9.3; range=29-69).   
Table 15: Characteristics of Medical Providers (N=35) 
Characteristics of Provider  Percentage (N) 
Provider Gender- Female 51.4 (18) 
Provider Type   
Physician 88.6 (31) 
Physician Assistant/Nurse Practitioner 8.6 (3) 
Nurse 2.9 (1) 
Age, mean (standard deviation) (range) 44 (9.3) (29-69) 
 
 
Medical Visit Communication Characteristics 
This section describes the characteristics of the office visit, specifically the 
communication variables and associated variables that came from the coding of the 
audiotape transcripts.  Each of the following is described separately: side effects 
discussion, risk discussion, and benefit discussion.  Information on the communication 
variables and associated variables are presented in Table 16 for the entire sample.   
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Table 16: Medical Visit Communication Characteristics (N=295) 
Medical Visit Communication Characteristics Percentage (N) 
Length of Visit with Provider in seconds, mean (SD) 
(range) 915 (509.9) (139-2743) 
Number of Control Medications Discussed, mean 
(standard deviation) (range) 1.3 (0.8) (0-4) 
Second Caregiver in Room 7.4 (22) 
Side Effects Discussed 4.1 (12) 
Caregiver Starts Side Effect Discussion 2.0% (6) 
Provider Starts Side Effect Discussion 2.0% (6) 
Risks Discussed 15.9 (47) 
Caregiver Starts Risk Discussion 4.4 (13) 
Provider Starts Risk Discussion 10.5 (31) 
Child Starts Risk Discussion 1.0 (3) 
Benefits Discussed 47.3 (140) 
Caregiver Initiates Benefit Discussion 5.4 (16) 
Provider Initiates Benefit Discussion 87.1 (122) 
Child Initiates Benefit Discussion 0.7 (2) 
Adherence to Control Medication Discussed 46.8 (138) 
 
The mean length of visits with providers was 915 seconds (SD=509.9) with a range of 
139 seconds to 2743 seconds.  Therefore the average visit length was 15 minutes, with a 
range of approximately two minutes to approximately 46 minutes.  The mean number of 
asthma control medications discussed was 1.3 (standard deviation=0.8) with a range of 0-
4.  Seven percent of medical visits included more than one caregiver (n=22).   
 
Side effects of asthma control medications were discussed during approximately 4.1% 
(n=12) of the visits.  Asthma control medication risks were discussed during 
approximately 16% (n=47) of the visits.  The benefits of asthma control medications were 
discussed during 47.3% (n=140) of the visits.  There was a discussion about adherence to 
asthma control medications during approximately 47% (n=138) of the visits.   
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Both risks and benefits were discussed together during approximately 11.9% (n=35) of 
medical visits.  Side effects and benefits were discussed together during approximately 
1.7% (n=5) of medical visits.  There were no visits where risks and side effects were 
discussed together without a discussion of benefits.  Finally, approximately 0.7% (n=2) 
of medical visits included a discussion of side effects, risks, and benefits together.    
 
Characteristics of Medications Discussed During Medical Visits 
Table 17 shows the percentage of medical visits where each asthma control medication 
was discussed.  Singulair was the asthma control medication that was most often 
discussed.  More than 44% (n=132) of medical visits included a discussion about 
Singulair.  Advair was the next most often discussed asthma control medication, with 
42.4% (n=125) of medical visits in which it was discussed.  More than 16% (n=48) of 
medical visits did not include any discussion about asthma control medications.   
Table 17: Medications Discussed during Medical Visits (N=295) 
Medications Discussed in Medical Visits Percentage (N) 
Singulair 44.7% (132) 
Advair 42.4% (125) 
Pulmicort 15.9% (47) 
Flovent 14.9% (44) 
Asmanex 4.4% (13) 
Qvar 1.0% (3) 
Symbicort 1.0% (3) 
Serevent 0.3% (1) 
Number of Visits Where An Asthma Control Medication was 
not Discussed 16.3% (48) 
Children Taking Singulair Plus Inhaled Corticosteroid 29.2% (86) 
Children Only Taking Singulair  11.9% (35) 
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Of the 295 patients in the study, 25% of children were prescribed at least one new asthma 
control medication during the medical visits.  The mean number of asthma control 
medications that each child was taking or prescribed was 1.14 (SD = 0.71), with a range 
of 0-3.  Almost 72% of children were currently taking or had at least one inhaled 
corticosteroid prescribed.  Approximately 12% (n=35) of children only took Singulair as 
their asthma control medication after the medical visit.  Approximately 29% of children 
took Singulair and an inhaled corticosteroid as their asthma control medications.  
 
Bivariate Results Among Independent Variables  
Table 18 presents the bivariate associations between the independent variables as a 
correlation matrix.  White children were significantly more likely to see White providers 
(r=0.21, p=0.0004).  Children taking inhaled corticosteroids were significantly more 
likely to have Moderate/Severe Persistent Asthma (r=0.32, p<0.0001).  Children who 
were taking inhaled corticosteroids were significantly more likely to have a higher count 
of medications (r=0.62, p<0.0001).  Adherence was significantly more likely to be 
discussed when the child took a higher number of asthma control medications (r=0.33, 
p<0.0001), when the child was taking an inhaled corticosteroid (r=0.34, p<0.0001), and 
when the visit was for asthma (r=0.20, p=0.0004).    
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Table 18: Correlation Matrix Between Independent Variables (N=295) 
  White Child Age 
Child 
Gender 
Asthma 
Severity-
Moderate
/Severe 
Persistent 
Income 
Above 
$20,000 
# Asthma 
Medications 
Patient 
Taking 
ICS 
Length 
of Visit 
Adherence 
Discussed-
Yes 
Asthma 
Visit 
# 
Prior 
Visits 
Child 
Taking 
Singulair 
Only-Yes 
White 1.00 
Child Age -0.03 1.00 
Child 
Gender-
Female 0.17* 0.05 1.00 
Asthma 
Severity-
Moderate/
Severe 
Persistent -0.04 0.09 0.01 1.00 
Income 
Above 
$20,000 0.23 0.01 -0.01 -0.08 1.00 
#Asthma 
Medication 
-0.08 -0.17* -0.06 0.27* -0.10 1.00 
Patient 
Taking 
ICS -0.01 -0.11* -0.03 0.32* -0.04 0.62* 1.00 
Length of 
Visit -0.01 0.01 0.00 0.07 0.10 0.11 0.12* 1.00 
Adherence 
Discussed 0.00 0.04 -0.06 0.15* -0.08 0.33* 0.34* 0.02 1.00 
Asthma 
Visit  -0.22* -0.12* -0.10 0.13* -0.13* 0.32* 0.28* -0.03 0.20* 1.00 
# Prior 
Visits  0.02 -0.13* -0.05 0.02 -0.01 -0.02 0.03 -0.04 0.02 -0.03 1.00 
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 White Child Age 
Child 
Gender 
Asthma 
Severity= 
Moderate/ 
Severe 
Persistent 
Income 
Above 
$20,000 
# Asthma 
Medications 
Patient 
Taking 
ICS 
Length 
of Visit 
Adherence 
Discussed-
Yes 
Asthma 
Visit 
# Prior 
Visits 
Child 
Taking 
Singulair 
Only -0.04 0.01 -0.09 -0.21* 0.02 -0.09 -0.59* 0.03 -0.05 -0.01 -0.08 1.00 
Child 
Taking 1 
Asthma 
Control 
Medication 0.06 0.01 -0.13* -0.08 0.10 -0.21* 0.13* 0.07 0.11* 0.03 0.07 0.32* 
 
*p<0.05
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Bivariate Results Among Independent Variables and Outcome Variables 
Table 19 presents the correlation matrix between the independent and dependent 
variables.  Each independent variable is listed as rows in Table 19 and the outcome 
variables are listed in the columns of Table 19.  Below also discusses bivariate results 
using t-tests or Pearson chi-squares if appropriate.  
 
Children whose visits included a discussion about side effects were younger on average 
(9.6 years old versus 11.0 years old) than children whose visits did not include a 
discussion about side effects (t=-2.02, p=0.04).   
 
Risks were significantly more likely to be discussed when: the child took a higher 
number of asthma control medications on average (1.45 versus 1.08, t=4.28, p<0.0001), 
when the child was taking or prescribed an inhaled corticosteroid (Chi-square=5.2, 
p=0.02), and when the visit was longer on average (1335.3 seconds versus 858.2 seconds, 
t=6.01, p<0.0001).   
 
Benefits were significantly more likely to be discussed when: the child was younger on 
average (10.7 years versus 11.4 years, t=-2.53, p=0.01), the child was classified as having 
moderate/severe persistent asthma (Chi-square=4.92, p=0.03), when the child took a 
higher number of asthma control medications on average (1.4 versus 0.9, t=6.09, 
p<0.0001), when the child was taking or prescribed an inhaled corticosteroid during the 
visit (Chi-square=39.11, p<0.0001), when the visit was longer on average (988.3 seconds 
versus 849.7 seconds, t=2.35, p=0.02), when control medication adherence was discussed 
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(Chi-square=17.66, p<0.0001), and when the visit was asthma-related (Chi-square=8.88, 
p=0.003).   
 
Caregivers were significantly more likely to report their child as at least 80% adherent to 
their asthma control medications when: the child took a higher number of asthma control 
medications on average (1.3 versus 1.1, t=1.97, p=0.05), when the child was taking or 
prescribed an inhaled corticosteroid (Chi-square=4.11, p=0.04), when the visit was longer 
on average (991 versus 810.2, t=2.84, p=0.01), and when the child had seen the provider 
(s)he saw during the study more times on average (13.3 versus 8.4, t=3.2, p=0.00).   
 
Caregivers were significantly more likely to report a problem/concern about side effects 
one month after the audiotaped medical visit when the child had seen the provider (s)he 
saw during the study less times on average (8.4 versus 13.1, t=-3.52, p=0.000).   
 
Children were significantly more likely to report a problem/concern about side effects 
one month after the audiotaped medical visit when: the child was Non-White (Chi-
square=4.27, p=0.04), when the child was not taking an inhaled corticosteroid (Chi-
square=4.58, p=0.03), when the caregiver was not married (Chi-square=6.24, p=0.01), 
and when the child was only taking Singulair as their asthma control medication (Chi-
square=5.08, p=0.02).  
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Table 19: Correlation Matrix Between Independent and Outcome Variables 
  
Side Effects 
Discussed-Yes 
Risks 
Discussed-
Yes 
Benefits 
Discussed-Yes 
Caregiver 
Adherence of 
At Least 80%-
Yes 
Caregiver 
Concern 
About Side 
Effects-Yes 
Child 
Concern 
About Side 
Effects-Yes 
Child Race-
White 0.08 -0.03 0.01 0.01 -0.03 -0.13* 
Child Age -0.13* -0.06 -0.15* -0.09 0.02 -0.06 
Child Gender-
Female -0.05 -0.07 -0.10 0.04 0.05 0.02 
Asthma Severity-
Moderate/Severe 
Persistent 
0.02 0.07 0.13* 0.04 0.06 -0.02 
Caregiver 
Education 0.04 0.01 0.03 0.05 0.10 0.09 
Caregiver 
Gender-Female 0.08 -0.03 -0.04 0.03 0.09 0.07 
Income of At 
Least $20,000 0.04 0.00 0.03 -0.03 0.05 0.04 
Count of Asthma 
Medications -0.04 0.19* 0.33* 0.13* 0.02 -0.07 
Patient Taking 
Inhaled 
Corticosteroids-
Yes 
0.05 0.23* 0.36* 0.13* 0.07 -0.13* 
Provider 
Gender-Female 0.04 0.04 -0.04 -0.09 -0.01 -0.11 
Provider Race-
White -0.05 -0.08 0.05 0.02 -0.10 -0.01 
Provider Age -0.01 -0.09 -0.01 0.03 0.04 0.03 
Length of Visit 0.01 0.36* 0.14* 0.18* 0.10 -0.04 
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Side Effects 
Discussed-Yes 
Risks 
Discussed-
Yes 
Benefits 
Discussed-Yes 
Caregiver 
Adherence of 
At Least 80%-
Yes 
Caregiver 
Concern 
About Side 
Effects-Yes 
Child 
Concern 
About Side 
Effects-Yes 
Caregiver 
Married -Yes 0.07 0.07 0.04 -0.05 -0.03 -0.16* 
Adherence 
Discussed-Yes -0.06 0.00 0.24* 0.03 0.07 0.08 
Reason for Visit-
Asthma 0.10 0.06 0.17* 0.01 -0.01 0.06 
Number of Prior 
Visits 0.09 -0.05 0.02 0.21* -0.20* 0.00 
Child Taking 
Singulair Only-
Yes 
0.03 -0.10 -0.07 -0.08 -0.10 0.14* 
Child Taking 1 
Asthma Control 
Medication-Yes 
0.09 -0.08 -0.04 -0.06 -0.03 0.08 
 
 
*p<0.05 
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Multivariate Analyses 
Specific Aim #1: To examine the association between provider, caregiver, and child 
characteristics and communication about risks, side effects, and benefits of asthma 
control medications during audiotaped pediatric visits.  
 
This section describes the results of the examination of the patient, caregiver, provider, 
medication, and visit characteristics that are associated with communication about asthma 
control medication risks and benefits.  This section also describes the results of the 
examination of caregivers who reported their child as 80% or more adherent, caregiver-
reported problems/concerns about side effects, and child-reported problems/concerns 
about side effects of asthma control medications.  Results in this section are based upon 
the patients for which data were available on the outcome variables.   
 
Communication about Medication Side Effects by Child, Caregiver, Provider, 
Medication, and Other Communication Characteristics 
 
H1: Discussions of asthma control medication side effects will be more likely to be 
discussed when there is more than one caregiver is present during the audiotaped medical 
visit. 
 
Communication about Asthma Control Medication Side Effects 
There was insufficient variation to run a GEE model predicting side effect discussion, 
because approximately 4% of medical visits included a discussion of side effects. 
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Hypothesis one was rejected based on the bivariate results for the side effect discussion 
variable (Fisher’s Exact Test p=0.62).  This finding should be interpreted with caution 
however, because discussions of side effects rarely occurred. 
 
Communication about Medication Risks by Child, Caregiver, Provider, Medication, and 
Other Communication Characteristics 
H2: Discussions of asthma control medication risks will be more likely to occur when 
caregivers have lower incomes. 
H3: Discussions of asthma control medication risks will be more likely to occur when 
there is more than one caregiver present during the audio-taped medical visit. 
H4: Discussions of asthma control medication risks will be more likely to occur when 
caregivers are less educated. 
 
Table 20 shows the results from the GEE with the Risk Discussion variable as the 
dependent variable.  Hypotheses two through four were all rejected based on the Risk 
Discussion GEE model’s results.  The variable that measured caregiver income less than 
$20,000 had an adjusted beta=0.12, p=0.79.  The variable that measured a second 
caregiver in the medical visit had an adjusted beta=-0.10, p=0.90.  The variable that 
measured caregiver education had an adjusted beta=-0.15, p=0.07.    
 
Risks were significantly more likely to be discussed during visits with children who were 
taking or prescribed an inhaled corticosteroid (Adjusted Beta=2.94, p=0.001) and when 
the length of the visit was longer (Adjusted Beta=0.002, p<0.0001).   
 104
Table 20: GEE Predicting Risk Discussions Results (N=255) 
Independent Variable Adjusted Beta Robust SE p-value 
Child Race-White -2.04 1.68 0.21 
Child Age -0.05 0.11 0.66 
Child Gender-Female -0.63 0.55 0.25 
Asthma Severity-Moderate-
Severe Persistent -0.01 0.48 0.98 
Child Taking an Inhaled 
Corticosteroid 2.94* 0.90 0.001 
Caregiver Age -0.02 0.02 0.40 
Caregiver Gender-Female 0.05 0.47 0.92 
Caregiver Education -0.15 0.08 0.07 
Family Income of at Least 
$20,000 0.12 0.46 0.79 
Provider Gender-Female 0.00 0.51 1.00 
Provider Age -0.02 0.02 0.31 
Provider Race-White -1.20 0.81 0.14 
Length of Visit 0.002** 0.00 <0.0001 
Adherence Discussed -0.39 0.48 0.41 
Second Caregiver in Room -0.10 0.77 0.90 
Reason for Visit-Asthma 0.50 0.56 0.37 
Caregiver Married 0.23 0.49 0.64 
Number of Prior Visits with 
Study Provider -0.02 0.02 0.22 
Racial Concordance for Child 
and Provider 2.20 1.69 0.19 
 
*p<0.05; **p<0.0001 
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Communication about Medication Benefits by Child, Caregiver, Provider, Medication 
and Other Communication Characteristics 
H5: Discussions of asthma control medication benefits will be more likely to be 
discussed when the child has moderate/severe persistent asthma.  
 
Table 21 shows the results from the GEE with the Benefit Discussion variable as the 
dependent variable.  Hypothesis five was rejected based on the Benefit Discussion GEE 
model.  The variable that measured the child’s asthma severity had an Adjusted 
Beta=0.22, p-value=0.47.  This could have occurred because child age and medication 
adherence being discussed may account for more of the variance when all three are 
included in the same model.   
 
Benefits were significantly more likely to be discussed when the child was younger 
(Adjusted Beta=-0.19, p=0.012), when the child was taking or prescribed an inhaled 
corticosteroid (Adjusted Beta=1.20, p=0.0004) and when control medication adherence 
was discussed during the visit (Adjusted Beta=1.00, p=0.002).  
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Table 21: GEE Predicting Benefit Discussions Results (N=255) 
Independent Variable Adjusted Beta Robust SE p-value 
Child Race-White -0.002 0.65 1.00 
Child Age -0.19* 0.07 0.01 
Child Gender-Female -0.39 0.33 0.23 
Asthma Severity-Moderate-
Severe Persistent 0.18 0.28 0.53 
Child Taking an Inhaled 
Corticosteroid 1.20* 0.34 0.0004 
Caregiver Age -0.01 0.02 0.44 
Caregiver Gender-Female -0.76 0.46 0.10 
Caregiver Education -0.10 0.05 0.07 
Family Income of at Least 
$20,000 0.30 0.30 0.32 
Provider Gender-Female 0.18 0.52 0.73 
Provider Age 0.01 0.02 0.78 
Provider Race-White 0.42 0.62 0.50 
Length of Visit 0.00 0.00 0.19 
Adherence Discussed 1.00* 0.32 0.002 
Second Caregiver in Room .0.56 0.48 0.24 
Reason for Visit-Asthma 0.31 0.32 0.33 
Caregiver Married 0.12 0.36 0.74 
Number of Prior Visits with 
Study Provider -0.00 0.01 0.65 
Racial Concordance for 
Child and Provider -0.06 0.71 0.93 
  
 *p<0.05 
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Specific Aim #2 Results  
Caregiver-Reported Adherence of At Least 80% 
H6: Children are more likely to report being adherent to their asthma control medications 
if risks were discussed in the medical visit.  
H7: Children are more likely to report being adherent to their asthma control medications 
when the control medication was only Singulair.   
H8: Children are more likely to report being adherent to their asthma control medications 
when the child is taking only one asthma control medication.  
 
Table 22 presents the results of the GEE model for caregiver-reported adherence of at 
least 80%.  As previously stated, Hypotheses six through eight were all rejected based on 
the GEE results. The variable that measured whether risks were discussed had an adjusted 
beta=0.39 with a p-value=0.38.  The variable that measured whether Singulair was the 
child’s only asthma medication had an adjusted beta=-0.53 with a p-value=0.19.  Finally, 
the variable that measured whether children were on one asthma control medication had 
an adjusted beta=0.13 and a p-value=0.69.       
 
Caregivers were significantly more likely to report their child being 80% or more 
adherent to their asthma control medications when the medical visit was longer (Adjusted 
Beta=0.001, p=0.003), when the child took a higher number of asthma control 
medications (Adjusted Beta=0.72, p=0.002), and when the child had more prior visits 
with the study provider (Adjusted Beta=0.05, p=0.007).    
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Table 22: GEE Results Predicting Caregiver-Reported Adherence of at least 80% 
(N=214) 
 
Independent Variables Adjusted Beta Robust SE p-value 
Child Race-White 0.01 0.35 0.99 
Child Age -0.05 0.06 0.46 
Child Gender-Female 0.22 0.28 0.43 
Asthma Severity-Moderate-
Severe Persistent -0.00 0.40 0.99 
Count of Asthma Control 
Medications 0.72* 0.23 0.002 
Caregiver Education-Years 0.03 0.07 0.63 
Caregiver Gender-Female 0.20 0.51 0.69 
Benefits Discussed -0.65 0.42 0.13 
Risks Discussed 0.39 0.45 0.38 
Family Income of At Least 
$20,000 -0.34 0.36 0.35 
Side Effects Discussed 0.90 0.65 0.17 
Child Taking 1 Asthma 
Control Medication 0.13 0.32 0.69 
Provider Gender-Female --0.54 0.38 0.15 
Provider Age 0.02 0.02 0.35 
Provider Race-White 0.18 0.44 0.68 
Length of Visit 0.001* 0.00 0.003 
Adherence Discussed -0.15 0.35 0.67 
Caregiver Married -0.55 0.45 0.23 
Number of Prior Visits with 
Study Provider 0.05* 0.02 0.007 
Reason for Visit-Asthma -0.24 0.38 0.54 
Child only taking 
Montelukast -0.53 0.41 0.19 
 
*p<0.05 
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Specific Aim #3 Results 
Caregiver-Reported Problems and Concerns about Side Effects of Asthma Control 
Medications 
H9: Caregivers are less likely to report problems and concerns about side effects with 
their child’s asthma medications if risks were discussed during the medical visit. 
 H10: Caregivers are less likely to report problems and concerns about side effects with 
their child’s asthma medications if the asthma control medication does not contain an 
inhaled corticosteroid. 
 
Table 23 presents the results of the GEE model where caregivers reported a problem and 
concern about their child’s asthma control medication.  Again, Hypotheses nine and ten 
were both rejected based on the GEE results.  The variable that measured discussions of 
medication risk had an adjusted beta=-0.08, p=0.85.  The variable that measured whether 
children were taking an inhaled corticosteroid had an adjusted beta=-0.16, with a p-
value=0.70.   
 
Caregivers were significantly more likely to report a problem and concern about the side 
effects of their child’s asthma medication when the child had fewer prior visits with the 
study provider (Adjusted Beta=-0.04, p=0.005). 
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Table 23: GEE Results Predicting Caregiver-reported Problems and Concerns with 
Side Effects of Child’s Asthma Control Medication (N=215) 
 
Independent Variable Adjusted Beta Robust SE p-value 
Child Race-White -0.20 0.43 0.64 
Child Age 0.02 0.06 0.73 
Child Gender-Female 0.18 0.29 0.52 
Asthma Severity-Moderate-
Severe Persistent 0.23 0.34 0.50 
Child Taking an Inhaled 
Corticosteroid --0.13 0.45 0.77 
Caregiver Age 0.00 0.02 0.94 
Caregiver Gender-Female 0.55 0.57 0.34 
Family Income of at Least 
$20,000 0.31 0.36 0.39 
Side Effects Discussed -0.15 0.53 0.78 
Provider Gender-Female -0.14 0.44 0.76 
Provider Age 0.01 0.02 0.67 
Provider Race-White -0.47 0.43 0.27 
Length of Visit 0.00 0.00 0.28 
Reason for Visit-Asthma 0.02 0.32 0.94 
Caregiver Married -0.32 0.32 0.32 
Risks Discussed -0.03 0.44 0.94 
Benefits Discussed 0.30 0.30 0.32 
Number of Prior Visits with 
Study Provider -0.04* 0.02 0.005 
Child Taking Only 
Montelukast as Asthma 
Control Medication 
-0.66 0.54 0.22 
 
*p<0.05 
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Child-Reported Problems and Concerns about Side Effects of Asthma Control 
Medications 
H11: Children are less likely to report problems and concerns about side effects with their 
asthma control medications if side effects were discussed during the medical visit. 
H12: Children are more likely to report problems and concerns about side effects with 
their asthma control medications if benefits were discussed during the medical visit.  
 
Table 24 presents the results of the GEE model where children reported a problem and 
concern about their asthma control medication.  Hypotheses eleven and twelve were 
rejected based on the GEE results.  The variable that measured discussions about side 
effects had an adjusted beta=-0.91 and a p-value=0.23.  The variable that measured 
discussions about benefit had an adjusted beta=0.32 with a p-value=0.27.   
 
Children were significantly more likely to report a problem and concern about side 
effects of their asthma control medication when the caregiver was not married (Adjusted 
Beta=-1.08, p=0.006), when the child did not take an inhaled corticosteroid (Adjusted 
Beta=-0.94, p=0.026), and when the provider was male (Adjusted Beta=-0.61, p=0.02).  
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Table 24: GEE Results Predicting Child-reported Problems and Concerns about 
Side Effects of Asthma Control Medications (N=240) 
 
Independent Variable Adjusted Beta Robust SE p-value 
Child Race-White -0.17 0.28 0.56 
Child Gender-Female 0.28 0.30 0.35 
Child Age -0.07 0.07 0.33 
Asthma Severity-Moderate-
Severe Persistent 
0.43 0.26 0.10 
Child Taking an Inhaled 
Corticosteroid  
-0.94* 0.42 0.026 
Caregiver Age -0.01 0.02 0.56 
Caregiver Gender-Female 0.61 0.60 0.31 
Provider Gender-Female -0.61* 0.27 0.02 
Provider Age -0.00 0.01 0.83 
Provider Race-White 0.02 0.42 0.96 
Length of Visit -0.00 0.00 0.66 
Caregiver Married -1.08 0.40 0.006 
Risks of Asthma Control 
Medication Discussed 
0.25 0.35 0.46 
Benefits of Asthma Control 
Medicaid Discussed 
0.32 0.29 0.27 
Side Effects Discussed -0.91 0.76 0.23 
Child Only Taking 
Montelukast as Asthma 
Control Medication 
0.86 0.57 0.13 
Family Income of Least 
$20,000 
0.60 0.36 0.09 
Reason for Visit-Asthma 0.0.50 0.29 0.09 
 
*p<0.05
CHAPTER FIVE: QUALITATIVE RESULTS (AIM 4) 
 
Overview 
This chapter presents the results of the qualitative analysis of the audiotape recorded 
medical visits.  The results of this chapter specifically refer to Aim 4 which stated the 
objective was: to qualitatively describe all control medication risks, side effects, and 
benefits that are discussed during the audiotaped asthma visits.  This analysis focused on 
the actual content of the discussions about asthma control medication side effects, risks, 
and benefits.  The chapter is organized into three sections, presenting the frequency of the 
discussions as well as examples of the actual discussion content for each section.  First, 
the results will show the extent and content of discussions about asthma control 
medication side effects.  Second, the results will present the extent and the content of the 
discussions about asthma control medication risks.  This section will also present the 
results of how often providers addressed each of Bogardus’ dimensions of risk.  Finally, 
the third section will present the results of asthma control medication benefits.     
 
 
Side Effects of Asthma Control Medications Discussion Content 
 
This section describes the results of the analysis of the content of communication about 
asthma control medication side effects in the 4% (n=12) of medical visits where side 
effects were discussed.  
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Provider Questions about Side Effects of Asthma Control Medications 
 
Under the major category questions about side effects from providers, two categories 
emerged from the content analysis of the medical visit communication.  The first 
category was General questions about if the child/patient had experienced any side 
effects from the asthma control medication.  The second category was Asking for 
Clarification from caregivers and children.  The sections below describe the categories in 
detail and provide illustrative excerpts from the transcripts.  Actual transcript data and 
direct participant quotes are used as much as possible.  To preserve confidentiality, all 
direct quotations from the transcripts are presented by noting whether it is a provider, 
caregiver, patient, or other family member speaking.  All proper names of people and 
places are omitted and a generic Dr ____ was used to replace any mention of a specific 
doctor’s name.   
 
 
Table 25 presents the extent to which providers asked caregivers and children questions 
about side effects of asthma control medications.  Four visits included providers asking 
General questions and one visit where a provider asked Clarification questions.  The 
range for provider questions about side effects was 0-3.  In total, providers asked 
questions about side effects during 2% (n=5) of medical visits and asked a total of 7 
questions.  Table 26 presents the actual questions that providers asked about side effects.   
 
 
 
 
 
 
 115
Table 25: Percentage of Visits Where Providers Asked Questions about Side Effects 
of Asthma Control Medications (N=295) 
 
Category Percentage of Visits (N) 
General 1.4% (4) 
Asking for Clarification 0.3% (1) 
Bad Taste 0 (0) 
Weight Gain 0 (0) 
Cough 0 (0) 
 
 
Table 26: Actual Provider Questions about Side Effects of Asthma Control 
Medications  
 
Category Actual question from provider 
General 
No problems with that? 
No problems with that? 
She didn't have no bad reaction to it or anything like that? 
So you emailed me that you are concerned that __ 
Singulair gave him kind of these funky side effects? 
Asking for Clarification 
It does? 
Um, does it really slow him down a lot? 
I mean like, in the mornings too? 
 
 
 
 
Provider Statements about Side Effects of Asthma Control Medications 
 
Under the major category statements about side effects from providers, four categories 
emerged from the analysis: Assurance, Thrush, Bad Taste, and Unaware of Side Effects 
Caused by Medication.  
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Table 27 presents the frequencies of provider statements about side effects of asthma 
control medications.  Three providers made Assuring statements, one provider made 
statements about Thrush, two providers made Taste statements, and one provider made 
Unaware statements.  The range of provider statements about side effects was 0-4.  In 
total, providers made statements about side effects during 2% (n=7) of visits and made a 
total of 14 statements.   
 
Table 27: Percentage of Visits Where Providers Made Statements about Side Effects 
of Asthma Control Medication (N=295) 
 
Category Percentage of Visits (N) 
Assurance 1.0% (3) 
Thrush 0.3% (1) 
Bad Taste 0.7% (2) 
Unaware of Side Effects Caused by 
Medication 0.3% (1) 
Headaches 0 (0) 
General 0 (0) 
Drowsiness 0 (0) 
    
Table 28 presents examples of the actual statements that providers made about side 
effects.  
 
Table 28: Actual Provider Statements about Side Effects of Asthma Control 
Medications  
 
Category Actual statement from Provider 
Assurance 
Not related to her asthma medicine. 
I don't think it's the medicine 
There shouldn't be anything in there to make him… 
Ah I wonder if the reason he's tired in the morning is not so much 
the Advair, um, I'd try it this summer…when he's at home 
Yeah I don't think it's the Advair then because that would happen 
every time you gave it.  
No I don't, maybe related to allergies or something like that 
Thrush 
Then you need to make sure that you rinse out your mouth after 
you use the Advair, right afterwards. 
 117
Category Actual Statement from Provider 
Bad Taste 
Ok, so big long breath, it tastes worse, but the longer you go the 
better it tastes 
Yea, but if you did it really short, it'll taste even worse 
Well you shouldn't be able to taste it at all anyway, it should be 
tasteless 
…sometimes if you get a little of the powder inside of your mouth 
it's almost grapefruity, kind of sour 
Unaware of Side 
Effects Caused 
By Medication 
and I've just not ever seen that but I guess you know every 
medicine is different in every kid's body 
 
  
 
Caregiver Questions about Side Effects of Asthma Control Medications 
 
This section describes the results of the analysis of the communication content about 
asthma control medication side effects from caregivers.  Under the major category 
questions about side effects from caregivers, four categories emerged from the content 
analysis of caregiver questions during the medical visit: Clarification, Bad Taste, Weight 
Gain, and Cough.  
 
Table 29 presents the frequencies of caregiver questions about side effects of asthma 
control medications.  There was one visit where a caregiver asked a Clarification 
question, one visit where the caregiver asked a question about Bad Taste, one visit where 
the caregiver asked if the child was experiencing weight gain as a side effect and one visit 
where the caregiver asked if the child was experiencing cough as a side effect of the 
asthma control medication.  The range for caregiver questions about side effects was 0-1.  
In total, caregivers asked questions about side effects during 1% (n=4) of clinic visits and 
a total of four questions were asked by caregivers.   
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Table 29: Percentage of Visits Where Caregivers Asked Questions about Side 
Effects of Asthma Control Medications (N=295) 
 
Category Percentage of Visits (N) 
General 0 (0) 
Asking for Clarification 0.3% (1) 
Bad Taste 0.3% (1) 
Weight Gain 0.3% (1) 
Cough 0.3% (1) 
 
 
Table 30 presents the actual questions made by caregivers to both providers and children 
about side effects. 
Table 30: Actual Caregiver Questions about Side Effects of Asthma Control 
Medications 
 
Category Actual Questions from Caregivers 
Clarification You don't think so? (headaches from control 
medications) 
Bad Taste Is it sour? 
Weight Gain Do you think it's because of the medicine or because he hasn't felt like playing? 
Cough Won't be like the cough we have now? 
Clarification You don't think so? (headaches from control 
medications) 
Bad Taste Is it sour? 
Weight Gain Do you think it's because of the medicine or because he hasn't felt like playing? 
Cough Won't be like the cough we have now? 
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Caregiver Statements about Side Effects of Asthma Control Medications 
 
Under the major category caregiver statements about side effects, four categories 
emerged from the content analysis of the caregiver statements made during the medical 
visit: Headaches, General, Thrush, and Drowsiness.  
 
Table 31 presents the frequencies of visits where caregivers made statements about side 
effects.  There were three visits in which caregivers made statements about the child 
experiencing Headaches after taking an asthma control medication, three visits in which 
caregivers made statements about General statements about side effects, one visit in 
which a caregiver made a statement about Thrush, and one visit in which a caregiver 
made statements about Drowsiness from an asthma control medication.  The range for 
caregiver statements was 0-2.  In total, caregivers made statements about side effects 
during 3% (n=8) of clinic visits and a total of ten statements were made by caregivers 
regarding side effects of asthma control medications. 
 
Table 31: Percentage of Visits Where Caregivers Made Statements about Side 
Effects of Asthma Control Medications (N=295) 
Category Percentage of Visits (N) 
Assurance 0 (0) 
Thrush 0.3% (1) 
Bad Taste 0 (0) 
Unaware of Side Effects Caused 
by Medication 0 (0) 
Headaches 1.0 (3) 
General 1.0 (3) 
Drowsiness 0.3% (1) 
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Table 32 presents the actual statements made by caregivers about side effects.   
 
Table 32: Actual Caregiver Statements about Side Effects of Asthma Control 
Medications 
  
Category Actual statements From Caregivers 
Headaches 
I took his Singulair away, he has not 
complained to me about headaches 
She gets to many headaches though, it's driving 
us crazy. 
Well I mean he used to take Singulair but he 
got really bad headaches 
General 
I'm interested to see that one of the side effects 
they mention in this book is (unclear) 
We did Advair one time and I didn't like that at 
all 
That's the only thing I could pin it on 
Thrush 
Actually he was using the Advair every day 
twice a day like he was supposed to been and 
he started complaining of a sore throat. 
Drowsiness 
Let me tell you something about that, ah, that, 
that, that makes him sleepy 
In the morning, like if I give it to him in the 
morning, ah, you know his teacher complains 
about you know sluggish or dragging but when 
I don't give it, I give it to him when he comes 
home from school and then before he goes to 
bed he's fine 
 
 
Children’s Questions about Side Effects of Asthma Control Medications 
Children did not ask any questions about side effects during these medical visits.  
 
 
Children’s Statements about Side Effects of Asthma Control Medications 
Under the major category children statements about side effects, two categories emerged 
from the analysis of the medical visit transcripts: Thrush and Bad Taste.  
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Table 33 presents the extent to which children/patients made statements about side 
effects during the clinic visits.  One clinic visit included a child making a statement about 
thrush and two clinic visits included children making statements about Bad Taste.  In 
total, children made statements regarding side effects during 1% (n=2) of clinic visits and 
children made a total of two statements during the audiotaped medical visits. 
 
Table 33: Percentage of Visits Where Children Made Statements about Side Effects 
of Asthma Control Medications (N=295)  
 
Category Percentage of Visits (N) 
Assurance 0 (0) 
Thrush 0.3% (1) 
Bad Taste 0.3% (1) 
Unaware of Side Effects Caused by 
Medication 0 (0) 
Headaches 0 (0) 
General 0 (0) 
Drowsiness 0 (0) 
 
Table 34 presents the actual statements made by children about side effects.   
 
Table 34: Actual Child Statements about Side Effects of Asthma Control 
Medications 
 
Category Actual statement 
Thrush Like I couldn't swallow or nothing 
Bad Taste It tastes nasty 
 
Discussions about Side Effects of Asthma Control Medications Conclusion 
Side effects were discussed during 4% (n=12) of clinic visits.  In this sample, providers 
asked the most questions to caregivers and children about whether the child had 
experienced any side effects from using their asthma control medication.  Providers also 
made the most statements to reassure caregivers and children that the child was not 
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experiencing a side effect in response to caregivers made a statements or questions about 
side effects.  When caregivers asked questions about side effects, they asked more 
questions to the provider about whether or not their child was experiencing a side effect.  
When caregivers made statements to providers, they made the most statements about 
their children experiencing headaches from their asthma control medication.  Children 
did not ask any questions about side effects but did make statements about the Bad Taste 
of their medication and Thrush after using the asthma control medication.  
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Risks of Asthma Control Medications Discussion Content 
This section describes the results of the analysis of the content of communication about 
asthma control medication risks.  Overall, 16% (n=47) of visits included a discussion 
about risks of asthma control medications.  
 
Provider Questions about Risks of Asthma Control Medications 
Under the major category, provider questions about risks, there were two categories that 
emerged from the analysis of the transcripts of the medical visits: Steroid causing harm 
and General.  
 
Table 35 presents the extent to which providers asked questions about risks of asthma 
control medications.  There was one clinic visit in which a provider asked questions 
about Steroids causing harm and the same clinic visit in which the provider asked a 
question in the General category.  There was only one provider (n=35) that asked 
questions about risks during these clinic visits and there was only one question asked in 
each category.   
Table 35: Percentages of Visits of Provider Questions about Risks of Asthma 
Control Medications (N=295) 
 
Category Percentage of Visits (N) 
Steroid Causing Harm 0.3% (1) 
General 0.3% (1) 
Drug-Drug Interaction 0 (0) 
Dose 0 (0) 
Probability of Risks Occurring 0 (0) 
Anabolic Steroid Risks 0 (0) 
Bad Taste 0 (0) 
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Table 36 presents the actual questions made by providers about risks. 
 
Table 36: Actual Provider Questions about Risks of Asthma Control Medications 
 
Category Actual question 
Steroid causing harm Now you think oh, steroids, steroids are bad 
right? 
General So what, what risks are associated with this 
medicine? 
   
 
Provider Statements about Risks of Asthma Control Medications 
Under the major category, provider statements about risks, there were 16 categories that 
emerged from the analysis of the medical visit transcripts.  Providers were most likely to 
make statements about General risks, with statements about Safety and Thrush being the 
next highest categories that providers made statements about.   
 
Table 37 presents the extent to which providers made statements about risks of asthma 
control medications.  There were 4% (n=12) of clinic visits in which providers made 
statements in the General category of risks.  Providers also made statements in the Safety 
category during 3% (n=8) of clinic visits and providers made statements in the Thrush 
category during 2% (n=6) of clinic visits.  The range for provider statements about risks 
was 0-6.  In total, providers made statements about risks during 15% (n=45) of all clinic 
visits and made a total of 85 statements about risks. 
Table 37: Percentage of Visits of Provider Statements about Risks of Asthma 
Control Medications (N=295) 
 
Category Percentage of Visits 
(N) 
Safety 2.7% (8) 
 125
Category Percentage of Visits 
(N) 
Thrush 2.2% (6) 
Bad Taste 1.7% (5) 
Drowsiness 1.0% (3) 
Concerns in Media 0.3% (1) 
Anabolic Steroid Risks 1.0% (3) 
Hyper-Activity 0.7% (2) 
Steroid Causing Harm 1.7% (5) 
Reduction in Growth Velocity 1.4% (4) 
Reduced Immunity 0.7% (2) 
General 4.1% (12) 
Dose 1.0% (3) 
Feels like Taking Albuterol 0.3% (1) 
Long-Term Effects 0.7% (2) 
Drug-Drug Interaction 0.3% (1) 
Assurance 0.3% (1) 
Nosebleeds 0 (0) 
 
Table 38 presents examples of actual statements about risks that providers made during 
these clinic visits.  
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Table 38: Actual Provider Statements about Risks of Asthma Control Medications 
 
Category Actual Provider Statement 
Safety 
Those have really got a great safety 
profile 
And being on the daily inhaled 
medicine is, is quite safe 
It's safer for your body to be on that 
than taking Albuterol every time you're 
exercising 
Thrush 
Because that's a steroid so they can get 
irritation in the mouth 
Occasionally, people get a little sore 
throat 
It's important that you rinse your 
mouth because you don't want to get a 
yeast infection in your throat 
Bad Taste 
It doesn't have that powdery taste 
Shouldn't taste bad 
Hey may but it may have a bad taste to 
it 
Drowsiness 
The Singulair can be given at any time 
of day because it doesn't cause 
sleepiness 
Tachyphylaxis 
Some kids who use Advair, sometimes 
they get what's called tachyphylaxis, it 
kind of works for a while and then 
causes them not to respond very well 
Concerns in Media 
I've had….people hear about these 
things on TV…those concerns come 
out on TV…every couple of years 
Somebody rehashed it on TV and 
everytime it happens I have a kid, ah, 
family call me up and say, we're 
stopping the medicine because we're 
scared of it 
Anabolic Steroid Side Effects 
The steroids don't make you grow hair 
and muscles, it's just anti-inflammatory 
Well remember…football players are 
not inhaling steroids, they're taking 
shots of testosterone, that's very 
dangerous 
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Category Actual Provider Statement 
Hyper-activity 
I've had a couple, you take it at night 
before you go to bed. There are a 
couple of people I've had that have 
been hyped up on it and to stop it. 
The only side effect as far as that goes, 
sometimes it hypes them up 
Steroids Causing Harm 
It’s, it’s not gonna be harmful 
No, it’s not going to hurt him at all 
And there actually were some, with 
one study showed that increased risk of 
dying from asthma with people taking 
Serevent alone 
Reduction in Growth Velocity 
And the steroid, if you're doing that it's 
not gonna interfere with growth 
…some children that don't grow quite 
as fast, but when they hit teenage 
years, then they just make up for it 
Reduced immunity 
Because the steroid cause, um, your 
immune system not to work as well 
It won't make him more susceptible to 
you know getting infections 
General 
I'm looking for no side effects from the 
medicines 
Because all medicines do have some 
side effects 
And it tends not to have an effect all 
over the body because we don't want to 
do that 
Dose 
No, Advair twice a day is fine, you 
don't want to do more than twice a day 
But the inhaled ones there's less than 5 
percent that gets absorbed into the 
circulation and already you are starting 
at such a minimal dose 
Uh huh yep well the Singulair it goes 
by age so we would go up 
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Category Actual Provider Statement 
Feel like taking Albuterol Occasionally, people will feel little bit like they took Albuterol 
Long-term effects 
I'm not worried about the long term 
effects of these medicines 
Yeah, oh Advair we don't, I don't 
worry too much about long term 
because it's got that low (unclear) 
Drug-Drug Interaction 
Get back on Claritin and then do the 
Singulair, you can take them both at 
the same time and it's no big deal 
Assurance it's [nosebleeds] not from that 
 
Bogardus Dimensions of Risk Communication 
Table 39 presents the extent to which providers discussed each dimension in the 
Bogardus dimensions of risk, with the added dimension of severity of risk.  There were 
32 instances where there was a specific risk addressed, such as thrush or reduction of 
growth velocity.  There were eight instances of a discussion about probability of a risk 
occurring, with seven instances of providers using the following words to convey 
probability: some, not common, a couple, most, rare few, and occasionally.  There was 
only one instance of a provider using a quantitative method in discussing probability, 
saying: “…I think maybe three people I can think of…that stopped it for some reason.”   
 
Table 39: Bogardus Dimensions of Risks Discussed in Medical Visits (n=295) 
 
Bogardus Dimension of Risk Discussed Frequency (N) 
Identity 10.8% (32) 
Permanence 0.7% (2) 
Timing 0.7% (2) 
Probability 2.7% (8) 
Qualitative Discussion of Risk 2.4% (7) 
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Bogardus Dimension of Risk Discussed Frequency (N) 
Quantitative Discussion of Risk 0.3% (1) 
Values  0.3% (1) 
Severity 0.3% (1) 
 
Caregiver Questions about Risks of Asthma Control Medication 
Under the major category, caregiver questions about risks, there were five categories that 
emerged from analysis of the transcripts: Steroid Causing Harm, Drug-Drug Interaction, 
Dose, Probability of Risks Occurring, and General.  Caregivers were most likely to ask if 
the steroids caused harm to the child.   
 
Table 40 presents the extent to which caregivers asked questions about the risks of 
asthma control medications.  Caregivers asked about steroids causing harm in 1% (n=3) 
of all clinic visits.  Caregivers asked about drug-drug interactions during 0.3% of clinic 
visits (n=1).  Caregivers asked about the strength of the dose being too high during 1% 
(n=2) of clinic visits and also asked about risks during 1% (n=2) of clinic visits.  The 
range for caregiver questions about risks was 0-2.  In total, caregivers asked questions in 
4% (n=11) of clinic visits and asked a total of 12 questions.   
 
Table 40: Percentage of Visits of Caregiver Questions about Risks of Asthma 
Control Medications (N=295) 
 
Category Percentage of Visits (N) 
Steroid Causing Harm 1.7% (5) 
General 0.7% (2) 
Drug-Drug Interaction 0.3% (1) 
Dose 0.7% (2) 
Probability of Risks Occurring 0.3% (1) 
Anabolic Steroid Risks 0 (0) 
Bad Taste 0 (0) 
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Table 41 presents the actual questions caregivers asked during these clinic visits. 
 
Table 41: Actual Caregiver Questions about Risks of Asthma Control Medications 
 
Category Actual Question from Caregiver 
Steroid Causing Harm 
There is not any kind of danger in that 
Advair is they? 
Ok, but I remember you telling me once 
before that could be dangerous doing this/ 
And it's not tough on the liver? 
Drug-Drug Interaction And it's safe together? (Singulair and 
antihistamine) 
Dose 
Ok, that's not too much? 
And it wouldn't hurt him? 
And the dose he is taking is still ok? 
Probability of Risks Occurring So it's not common 
General Ok, so what are the side effects from the Singulair? 
General 
That medicine he's taking, does it do 
anything to his (unclear)? 
So the medicine don't have nothing to do 
with that? 
 
Caregiver Statements about Risks of Asthma Control Medications 
Under the major category, caregiver statements about risks, there were six categories that 
emerged from the transcript analysis: General Nosebleeds, Long-Term Effects, Bad Taste, 
Thrush, and Concerns in Media.  Caregivers were most likely to ask questions in the 
General category.   
 
Table 42 presents the extent to which caregivers made statements about risks of asthma 
control medications during these clinic visits.  Caregivers made statements in the General 
category during 1% (n=3) of all clinic visits.  Caregivers made one statement (0.3% of all 
clinic visits) each in these categories: Nosebleeds, Long-Term Effects, Bad Taste, Thrush, 
and Concerns in Media.  The range for caregiver statements about risks was 0-2.  In total, 
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caregivers made at least one statement during 3% (n=8) of all clinic visits and made a 
total of ten statements.   
 
Table 42: Types and Frequencies of Caregiver Statements about Risks of Asthma 
Control Medications (N=295) 
 
Category Percentage of Visits (N) 
Safety 0 (0) 
Thrush 0.3% (1) 
Bad Taste 0.3% (1) 
Drowsiness 0 (0) 
Concerns in Media 0.3% (1) 
Anabolic Steroid Risks 0 (0) 
Hyper-Activity 0 (0) 
Steroid Causing Harm 0 (0) 
Reduction in Growth Velocity 0 (0) 
Reduced Immunity 0 (0) 
General 1.0% (3) 
Dose 0 (0) 
Feels like Taking Albuterol 0 (0) 
Long-Term Effects 0.3% (1) 
Drug-Drug Interaction 0 (0) 
Assurance 0 (0) 
Nosebleeds 0.3% (1) 
 
Table 43 presents the actual statements made by caregivers about the risks of asthma 
control medications during these visits. 
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Table 43: Actual Caregiver Statements about Risks of Asthma Control Medications 
 
Category Actual Statements 
General 
(unclear) research on it I did not want him, I 
didn't feel like his symptoms were strong enough 
to risk the side effects of that  
But I'm just worried about all these steroids that 
we keep pumping into him 
Yeah I give it to him when, when I see that it is 
getting to that point but I don't want to give it to 
him every night just because it's a steroid but I do 
give it to him and it relieves his… 
Nosebleeds 
 
 
But still he gets nosebleeds 
Well he gets nosebleeds 
Long-Term Effects Yeah, because I worry about the long term 
Bad Taste Yeah, it will taste better 
Thrush I was really concerned he was gonna get the yeast in his mouth and all this stuff 
Concerns in Media I heard on the TV you know they say all kinds of things on it 
 
 
Children’s Questions about Risks of Asthma Control Medications 
Under the major category, child questions about risks, there were three different 
categories that emerged after analysis of the transcripts.  The categories were: Anabolic 
Steroid Side Effects, Steroid Causing Harm, and Bad Taste.  Each type of question 
occurred in one visit (Table 44).   
 
Table 44 presents the extent to which children asked questions about risks of asthma 
control medications.  Children asked one question in each of the three categories, totaling 
three questions during the clinic visits.   
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Table 44: Types and Frequencies of Child Questions about Risks of Asthma Control 
Medications (N=295) 
 
Category Percentage of Visits (N) 
Steroid Causing Harm 0.3% (1) 
General 0 (0) 
Drug-Drug Interaction 0 (0) 
Dose 0 (0) 
Probability of Risks Occurring 0.3% (1) 
Anabolic Steroid Risks 0.3% (1) 
Bad Taste 0.3% (1) 
 
Table 45 presents the actual questions made by children about the risks of their asthma 
control medications during the audiotaped medical visits.   
Table 45: Actual Child Questions about Risks of Asthma Control Medications  
 
Category Actual Questions 
Anabolic Steroid Side Effects Wait, does steroids um, cut off my fat or 
something? 
Medication Causing Harm It won't hurt me will it? 
Bad Taste Is it going to taste better? 
 
Children’s Statements about Risks of Asthma Control Medications 
Children did not make any statements about risks during these clinic visits.  
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Discussions about Risks of Asthma Control Medications Conclusion 
Risks were discussed during 16% (n=47) of all clinic visits.  There was one provider that 
asked questions about risks and there were two instances of providers asking about risks 
to children and caregivers.  Providers were most likely to make statements about General 
risks and statements about the safety of the asthma control medication.  Caregivers were 
most likely to ask questions about the control medication causing harm to his/her child 
and were most likely to make General statements about risks, much like providers.  
Children asked questions that compared anabolic steroid side effects to inhaled 
corticosteroid side effects, the medication causing them harm and the Bad Taste of the 
medication.     
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Benefits of Asthma Control Medications Discussion Content 
This section describes the results of the analysis of asthma control benefit discussions in 
the 47% (n=140) of medical visits where benefits were discussed.   
 
Provider Questions about Benefits of Asthma Control Medications 
Under the major category, questions about benefits of asthma control medications, 
questions from providers fell into one of eight categories.  Providers were most likely to 
ask questions about symptom control and prevention (N=25).  
 
Table 46 presents the extent to which providers asked questions about benefits of asthma 
control medications.  As stated earlier, providers were most likely to ask questions about 
symptom control and prevention (n=25), asking a total of 33 questions about it.  The 
range for provider questions about benefits was 0-8.  In total, providers asked questions 
about the benefits of asthma control medications during 32 clinic visits and made a total 
of 49 statements.     
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Table 46: Percentage of Visits of Provider Questions about Benefits of Asthma 
Control Medications (N=295) 
 
Category Percentage of Visits (N) 
Symptom Control/Prevention 8.5% (25) 
Ease of Use 0.3% (1) 
Quality of Life 0.3% (1) 
Adherence 0.7% (2) 
Re-iteration 0.3% (1) 
Teach-Back 1.0% (3) 
General 0 (0) 
Potency 1.4% (4) 
   
 
Table 47 presents the actual questions made by providers during these clinic visits.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 137
 
Table 47: Actual Provider Questions about Benefits of Asthma Control Medications  
 
Category Actual Questions 
Symptom Control/Prevention 
Good, can you tell a difference? 
So it has improved? 
Did it seem to help when we did take something 
everyday 
Ease of Use How long is it going to take him to do the Pulmicort in the inhaler? 
Quality of Life Are you worried she is going to get sick and have to 
come in? 
Adherence When he takes his Asmanex, does he stay clear most 
of the time? 
Re-iteration It works good? 
Teach-Back 
And hopefully doing this, what are we going to 
watch for? 
Now I've got a question for you, what does that 
mean? 
To keep it away so you don't have to use your? 
Potency 
You started two weeks ago, and it's such a strong 
medicine that you're already better right? 
Okay, and that's even using your Advair, it doesn't 
help with that? 
 
 
Provider Statements about Benefits of Asthma Control Medications 
Under the major category, provider statements about benefits, statements fell into one of 
20 categories.  Providers were most likely to make statements about symptom control and 
prevention (n=66) as well as general benefits (n=44). 
 
Table 48 presents the extent to which providers made statements about asthma control 
medication benefits.  Providers also made frequent statements about the benefits of 
control medication adherence (n=22), as well as quality of life (n=19), and a time-table 
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for when caregivers and children could expect to realize benefits (n=19).  The range for 
provider statements about benefits of asthma control medications was 0-9.  Providers 
made a total of 338 statements about the benefits of asthma control medications during 
128 medical visits.   
Table 48: Percentage of Visits of Provider Statements about Benefits of Asthma 
Control Medications (N=295) 
 
Category Percentage of Visits (N) 
Adherence 7.4% (22) 
Potency 7.1% (21) 
General 14.9% (44) 
Teach-Back 0 (0) 
Multiple Indications 4.7% (14) 
Decreases Inflammation in Lungs 3.0% (9) 
Consequences of Not Treating 0.7% (2) 
Symptom Control/Prevention 22.3% (66) 
Quality of Life 6.8% (20) 
Pulmonary Function 0.3% (1) 
Reduced Need for Rescue Medication 5.4% (16) 
Acute Symptoms/Prior to Exercise 3.0% (9) 
Length of Time Medication Works 0.7% (2) 
Goals of Treatment 1.7% (5) 
Improvement Time-Table 6.4% (19) 
Ease of Use 3.0% (9) 
Dose 0.3% (1) 
Prevention of Bad Asthma Outcomes 1.0% (3) 
Inhalation Technique 0.7% (2) 
Anticipating Benefit 0.3% (1) 
Bronchitis 0 (0) 
 
Table 49 presents examples of the actual statements that providers made about the 
benefits of asthma control medications. 
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Table 49: Actual Provider Statements about Benefits of Asthma Control 
Medications 
 
Category Actual Statement 
 
 
 
Adherence 
 
 
 
 
You do it in the morning and at night and it will 
make a big difference 
So think of it like birth control, you want to do it 
everyday, if it is going to work you gotta do it 
everyday 
But you've got to take it everyday for it to work 
Potency 
The Flovent is dynamite 
Advair is the strongest thing for asthma 
It's not like using the Albuterol inhaler when you use 
it and in a few minutes you can tell a difference but it 
is much more powerful 
Multiple Indications 
Singulair is a medicine that can be used for both 
allergies and asthma 
Singulair helps with asthma and helps allergies and 
can be used in addition to the Zyrtec that he is 
already on 
Singulair is an allergy medicine and I chose it 
because it also helps with asthma 
Decreases Inflammation in 
Lungs 
Advair you know when she's another inhaler which 
decreases the inflammation in your lungs 
So it can be used long-term but it is only acting 
locally to get rid of the inflammation with her 
asthma 
Then it helps to kind of control some of the 
inflammation, some of the irritation of the lungs 
 
 
 
General 
 
 
 
 
Advair is good 
See, we're having less and less spells which is good 
It just has the steroid in it but it's a good one, it's one 
puff twice a day 
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Category Actual Statement 
 
 
 
 
 
 
Consequences of Not 
Treating 
 
 
 
 
 
 
 
 
Children who have untreated you know especially if 
there's evidence of asthma in the lung function that 
we do okay then um, then those children just don't 
feel healthy 
They have long issue problems even in long, later on 
in life you know like COPD or emphysema even 
without smoking ever in their life you know so there 
is consequences to not treating 
Like she say, you know they don't concentrate as 
well 
Symptom 
Control/Prevention 
The goal is to use the preventatives, the Advair, 
alright and completely control your symptoms so 
that you don't need to use the Albuterol 
The Pulmicort is there to prevent the symptoms 
Used to control and prevent, your word, you said 
prevention earlier, would prevent his coughing, 
wheezing, with trouble with play, exercise, recess, 
sneeze, mucus, trouble with sleep, ok that's the 
Pulmicort 
Quality of Life 
I want her not to cough and she needs to run and be 
able to play 
Oh, you better believe it, I want you to run like the 
wind 
I mean that worry, I mean we get rid of that worry 
that would be great 
Lung Function Ok, so that this is (unclear) asthma and improve lung function 
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Category Actual Statement 
Reduced Need for Rescue 
Medication 
He should be on enough maintenance medicine you 
know occasionally, once in a while, yeah he is going 
to need Albuterol but we hope not everyday 
That's our goal is to get him to the point where he 
doesn't need the Albuterol everyday 
Yeah I think the Advair is gonna prevent him from 
needing the Albuterol at least I hope 
 
 
 
 
Acute Symptoms/Prior to 
Exercise 
 
 
 
 
 
 
Now the steroid is not helpful for acute episodes 
when he is wheezing ok 
Now this one will not help you when you are 
wheezing 
That is what Advair is, it wouldn't make a difference 
right away within period of 30 minutes prior to 
exercise 
Length of Time Medication 
Works 
Advair, the purple disk, when you brush your teeth 
in the morning, it does have a long-acting steroid in 
it and a long-acting Albuterol so the benefit is it 
hangs out in the lungs over a 12 hour period 
But then it also has a long-acting Albuterol in it that 
helps kind of open the airways and works for about 
10-12 hours 
 
 
 
 
 
 
Goals of Treatment 
 
 
 
 
 
 
Okay but our goal is not to need it, no cough at night, 
no cough with exercise, no shortness of breath with 
exercise, no missed school, and no side effects from 
the medicine 
And that's one of the ways how we judge if it is 
working for you, whether you are needing your 
Albuterol, are you able to sleep through the night 
without coughing, are you able to exercise, you 
know run around, play without coughing 
Our goal is to make it so she will be able to run and 
play and laugh and be excited and not have trouble 
breathing 
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Category Actual Statement 
Improvement Time-Table 
So the fact is we still don't have perfect, it's still 
going to take two more weeks before we have 
perfect control with that Asmanex 
And it takes a while to see some effect 
And the Advair helps get things back to normal 
because you're, you know  you're not wheezing right 
now but your lungs are still damaged and the Advair 
helps repair that but it takes time 
 
 
 
 
Ease of Use 
 
 
 
 
And if you can do it, it's a lot easier than the 
Pulmicort you're taking, it's faster and it's easier 
Singulair is easy because you take it once a day and 
it will help that nose too 
A lot easier to use than having to use the Flovent 
Dose 
Well the interesting thing about Advair (unclear) is 
there is a dose at which you don't get much of a 
response after you get there 
And interestingly with the medicine that's in Advair, 
uh, the one that they change the dosing on the 100, 
the 250, the 500, that medicine itself, once you get to 
just a little bit over 100, you get very little 
improvement with 
Prevention of Bad Asthma 
Outcomes 
 
 
The medicines that are in Advair have been shown to 
keep kids out of the hospital, prevent death from 
asthma, prevent hospital admissions from asthma, 
prevent asthma attacks so you have to take your 
good with the bad 
That medicine has saved a lot of people from being 
sick and having to go to the emergency room and all 
that sort of stuff 
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Category Actual Statements 
Prevention of Bad Asthma 
Outcomes 
…The Flovent more than Singulair has been actually 
improve pulmonary function testing and prevent 
these chronic asthma exacerbations, prevent people 
from getting bad enough to go into the hospital or go 
to the emergency room 
Technique 
Yeah, it won't work if you don't do it right so you've 
got to do it the right way 
Here's the other thing with your Advair, you've got 
to use it the right way. If you don't do it the right way 
it won't work well 
If you don't…you go (quick breath) the medicine 
stops right here, never gets to your lungs and it won't 
work. For the medicine to work it has to get where 
you want it 
Anticipating Benefit and I'd love to hear that 
 
 
Caregiver Questions about Benefits of Asthma Control Medications 
Under the major category, questions about benefits, caregiver questions fell into one of 
three categories.  The categories were: Symptom Control/Prevention, Quality of Life, and 
General.  Caregivers were almost equally likely to ask questions about all three 
categories, as discussed below.   
 
Table 50 presents the extent to which caregivers asked questions about benefits of 
asthma control medications.  Caregivers asked questions about symptom 
control/prevention (n=1), quality of life (n=2), and general questions about benefits 
(n=2).  The range for caregiver questions about benefits of asthma control medications 
was 0-1.  In total, caregivers asked five questions about benefits during five medical 
visits.   
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Table 50: Percentage of Visits of Caregiver Questions about Benefits of Asthma 
Control Medications (N=295) 
 
Category Percentage of Visits (N) 
Symptom Control/Prevention 0.3% (1) 
Ease of Use 0 (0) 
Quality of Life 0.7% (2) 
Adherence 0 (0) 
Re-iteration 0 (0) 
General 0.7% (2) 
Teach-Back 0 (0) 
Potency  0 (0) 
 
Table 51 presents all of the actual questions caregivers asked providers about benefits 
during these medical visits. 
 
Table 51: Actual Caregiver Questions about Benefits of Asthma Control 
Medications  
 
Category Actual Questions from Caregivers 
Symptom Control/Prevention Ok, it just helps control what triggers? 
Quality of Life 
Would you expect that with his Advair using 
it twice a day the way you had recommended 
that at some point he would be able to run as 
hard as he wanted to? 
Should that help her too with like exercising 
and, and stuff like that? 
General 
No, you know what's made the difference in 
my opinion? 
He seems to be doing a lot better with the 
Singulair than without, you know? 
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Caregiver Statements about Benefits of Asthma Control Medications 
Table 52 presents the extent to which caregivers made statements about the benefits of 
asthma control medications for their children.  Caregivers were most likely to make 
statements about general benefits of asthma control medications (n=24) during these 
visits.  Caregivers made two statements in each of the following categories: Symptom 
Control/Prevention and Anticipating Benefit.  Caregivers made one statement in each 
about of the following categories: Quality of Life, Ease of Use, and Bronchitis.  
Caregivers made six statements in each of the following categories: Potency and 
Medication Adherence.  The range for caregiver statements about benefits of asthma 
control medications was 0-7.  In total, caregivers made 50 statements about the benefits 
of asthma control medications during 36 medical visits. 
Table 52: Percentage of Visits of Caregiver Statements about Benefits of Asthma 
Control Medications (N=295) 
 
Category Percentage of Visits (N) 
Adherence 2.0% (6) 
Potency 2.0% (6) 
General 8.1% (24) 
Teach-Back 0 (0) 
Multiple Indications 1.0% (3) 
Decreases Inflammation in Lungs 0 (0) 
Consequences of Not Treating 0 (0) 
Symptom Control/Prevention 0.7% (2) 
Quality of Life 0.3% (1) 
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Category Percentage of Visits (N) 
Pulmonary Function 0 (0) 
Reduced Need for Rescue 
Medication 0 (0) 
Acute Symptoms/Prior to Exercise 0 (0) 
Length of Time Medication Works 0 (0) 
Goals of Treatment 0 (0) 
Improvement Time-Table 0 (0) 
Ease of Use 0.3% (1) 
Dose 0 (0) 
Prevention of Bad Asthma 
Outcomes 0 (0) 
Inhalation Technique 0 (0) 
Anticipating Benefit 0.7% (2) 
Bronchitis 0.3% (1) 
  
 
Table 53 presents examples of the actual statements made by caregivers about the 
benefits of asthma control medications. 
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Table 53: Actual Caregiver Statements about Benefits of Asthma Control 
Medications 
 
Category Actual Statement from Caregivers 
Symptom Control/Prevention Um hmm…it keeps it under control Preventative 
Anticipating Benefit 
I hope it does 
It seems like a really good direction to go in 
because…when the steroids were in her…she had 
really good health 
I would love not to hear that cough 
Potency 
Well…I'm just a little worried that they didn't 
see…any improvement is what I'm trying to say 
Most of the time-well she seems to keep a cough a 
lot 
Because they put me on it because I have had 
asthma for years, and Advair don't help me, now I 
know everybody is different, but for me watching 
her and hearing her you know and everyday to me 
and I don't think it's doing any good 
 
 
 
 
Adherence 
 
 
 
 
She didn't think she needed it anymore because 
she wasn't coughing or having trouble breathing, I 
said, that's why you're not coughing 
When she, as long as she takes her medicine 
The reason with the Advair, she told him if he 
would use it everyday he that he might could 
come off the Singulair too 
Child-Related Quality of Life It won't be like he is worn out and they pull him 
out after a while 
Ease of Use Not long 
Bronchitis Well, he hasn't had anything to do with bronchitis 
since May of last year 
Multiple Indications 
Uh huh I think it is helped a lot because last year 
with his eye swelling 
They take it at night, it just helps keep those 
allergies under control 
To help your sinuses and all that in your head 
General 
I think upping the Singulair helped too 
It's better, it's getting better 
Yes, he is doing pretty good with that 
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Children’s Questions about Benefits of Asthma Control Medications 
This section will describe the extent of children’s participation in discussions about 
control medication benefits as well as describe the actual content of both questions and 
statements from the content analysis of the transcript data.   
 
Children’s questions fell into one of two categories: quality of life and general questions 
about benefits.  Children asked only two questions during the audiotaped medical visits.  
Table 54 presents the extent to which children asked questions about asthma control 
medications during these visits.  
Table 54: Percentage of Visits of Child Questions about Benefits of Asthma Control 
Medications (N=295) 
 
Category Percentage of Visits (N) 
Symptom Control/Prevention 0 (0) 
Ease of Use 0 (0) 
Quality of Life 0.3% (1) 
Adherence 0 (0) 
Re-iteration 0 (0) 
General 0.3% (1) 
Teach-Back 0 (0) 
Potency  0 (0) 
 
Table 55 presents both of the questions children asked during these medical visits. 
 
Table 55: Actual Child Questions about Benefits of Asthma Control Medications 
 
Category Actual Questions 
Quality of Life Just not that hard right? [Running] 
General Can I (unclear) if I take the medicine? 
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Children’s Statements about Benefits of Asthma Control Medications 
This section will describe the extent of children’s statements about benefits of asthma 
control medications.  Children’s statements fell into five categories: Reduced Need for 
Rescue Medication, Potency, Symptom Control/Prevention, Adherence, and General.   
 
Children made the most statements about general benefits of asthma control medications 
(n=6) as well as benefits of medication adherence (n=3).  Table 56 presents the extent to 
which children made statements about the benefits of asthma control medication 
adherence.  The range for child statements about benefits was 0-2.  Children made a total 
of 15 statements about benefits during 10 medical visits.   
 
Table 56: Types and Frequencies of Child Statements about Benefits of Asthma 
Control Medications (N=295) 
 
Category Percentage of Visits (N) 
Adherence 1.0% (3) 
Potency 0.3% (1) 
Teach-Back 1.7% (5) 
General 0.3% (1) 
Multiple Indications 0 (0) 
Decreases Inflammation in Lungs 0 (0) 
Consequences of Not Treating 0 (0) 
Symptom Control/Prevention 0.3% (1) 
Quality of Life 0 (0) 
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Category Percentage of Visits (N) 
Pulmonary Function 0 (0) 
Reduced Need for Rescue Medication 0.7% (2) 
Acute Symptoms/Prior to Exercise 0 (0) 
Length of Time Medication Works 0 (0) 
Goals of Treatment 0 (0) 
Improvement Time-Table 0 (0) 
Ease of Use 0.3% (1) 
Dose 0 (0) 
Prevention of Bad Asthma Outcomes 0 (0) 
Inhalation Technique 0 (0) 
Anticipating Benefit 0 (0) 
Bronchitis 0 (0) 
   
 
Table 57 presents the actual statements made by children about the benefits of asthma 
control medications. 
 
Table 57: Actual Child Statements about Benefits of Asthma Control Medications 
 
Category Actual Statements 
Reduced Need for Rescue 
Medication 
It helps me not to use it as much 
Nah, I probably wouldn't need it 
Potency Umm, it helps a little bit but not much 
Symptom Control/Prevention Under control, yeah 
 
 
 
Adherence 
 
 
 
Take it 
Yeah, usually when I take it, I wait a couple minutes 
and then I have no more asthma for the rest of the 
day 
Medicine that you take everyday and night for 10 
seconds 
Teach-Back To make it feel better To keep it situated 
General That's why I haven’t had as much problems probably since I started taking the Singulair 
 
 
 151
Discussions about Benefits of Asthma Control Medications Conclusion 
Asthma control medication benefits were discussed during 47% (n=140) of all medical 
visits in this sample.  Providers were most likely to ask questions about whether or not 
the asthma control medication was controlling and preventing asthma symptoms.  
Providers also attempted to engage children in these visits by directly asking questions to 
the child about the purpose of the asthma control medication, such as asking about 
benefits of asthma control medications, as well as medication adherence.  In total, 
providers asked a total of 48 questions about the benefits of asthma control medications.  
Providers also made the majority of the statements, making a total of 338 statements 
about the benefits of asthma control medications.  Providers were most likely to make 
statements about symptom control and prevention (n=66) and general statements about 
medication benefits (n=44).  Providers also had the largest breadth of statements, talking 
about a total of 20 different categories.   
 
Caregivers asked five questions about the benefits of asthma control medications in three 
different categories.  Caregivers made a total of 50 statements about benefits of asthma 
control medications in nine different categories.  Caregivers were most likely to make 
statements about general benefits of asthma control medications (n=24), while also 
discussing the medication’s lack of effectiveness in addition to the benefits of the child 
adhering to the medication regimen.   
 
Children asked a total of two questions about the benefits of asthma control medications 
in one of two different categories.  Children asked questions about quality of life and 
general benefits of asthma control medications.  Children made a total of 15 statements 
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about asthma control medications, making the most statements about general benefits of 
asthma control medications and the benefits of medication adherence.  Children also 
made statements about the reduced need for taking a rescue medication because of the 
control medication, the lack of effectiveness of the asthma control medication, and 
symptom control and prevention.   
 
Conclusion about Content Analysis of Side Effect, Risk, and Benefit Discussions 
Providers spoke the most in all three major categories: side effect discussions, risk 
discussions, and benefit discussions.  Children spoke the least in all three major 
categories as well.  Providers had a 1.4:1 ratio of their statements about side effects to the 
caregiver statements about side effects and had a 4.67:1 ratio of their statements about 
side effects to the child’s statements about side effects.  These ratios increased during 
discussions about risks.  Providers had an 8.5:1 ratio of their statements about risks to the 
caregiver statements about risks, while children did not make any statements about risks 
of asthma control medications.  Finally, providers had a 6.76:1 ratio of their statements 
about benefits of asthma control medications to caregiver statements about benefits of 
asthma control medications and had a 22.53:1 ratio of their statements to every child 
statement about benefits.  The most-discussed side effect was headaches from Singulair 
and the most-discussed specific risk was thrush.  The most-discussed specific benefit of 
asthma control medications was asthma symptom control and asthma symptom 
prevention.   
 
The next chapter will present the discussion and conclusion to this dissertation study.
CHAPTER SIX: DISCUSSION 
 
The purpose of this dissertation was to better understand communication about asthma 
control medications side effects, risks, and benefits.  This study helps address gaps in the 
literature regarding patient-provider communication between medical providers, children, 
and their caregivers about adverse effects and benefits.  While the shared decision 
making literature has stressed the importance of risk-benefit communication, this was one 
of the first studies to examine the content and predictors of actual discussions about side 
effects, risks, and benefits among providers who treat children (Makoul 2002).  Both 
qualitative and quantitative methods were used to examine the communication about 
asthma control medication side effects, risks, and benefits, as well as the impact that 
communication has on asthma control medication adherence and caregiver and child-
reported concerns about side effects.  The following sections summarize the findings and 
discuss the implications of the qualitative and quantitative results, the major limitations 
and strengths of the study, and present potential directions for future research.  
 
Summary of Findings 
Discussions of Side Effects of Asthma Control Medication  
Audiotape analysis results revealed that only four percent (n=12) of medical visits 
contained discussions about side effects of asthma control medications.  Providers rarely 
asked questions about side effects of asthma control medications, specifically asking
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children and caregivers whether they were experiencing any problems with the 
medication; providers only asked questions about side effects, however, during five total 
visits.    According to clinical practice guidelines of the National Asthma Education and 
Prevention Program of NHLBI, it is important for providers to discuss side effects with 
patients (NAEPP 2007) at every visit.   
 
The national clinical practice guidelines instruct providers to closely monitor side effects 
of asthma control medications, asking patients at every visit whether they experienced 
any side effects of the asthma control medication.  Yet, providers rarely ask questions as 
simple as: “Have you had any problems with your asthma control medication?”  
Providers need to ask children and their caregivers if they have any problems or concerns 
about side effects of asthma control medications in order for providers to alleviate 
concerns and discuss changing therapy to a more suitable control medication.  This could 
help reduce children or caregivers from under-using or discontinuing asthma control 
medications on their own.  Improved adherence to asthma control medications may result 
in fewer school days missed by children, reduced healthcare costs, and better asthma 
control (Williams et. al. 2004 and Bender and Bender, 2005).     
 
Provider demographics did not show an association with side effect communication.  
There were, however, certain child characteristics that were associated with a discussion 
about side effects.  Specifically, children who were younger were more likely to have a 
visit that included a discussion about side effects.  Future research could help determine 
why this finding occurred, but it could be that providers discuss side effects with younger 
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children and may not discuss side effects with those same children as the child ages.  It 
should be noted, however, that providers rarely discussed side effects during these visits.  
Providers should make sure to engage children of all ages in conversations about the side 
effects of their asthma control medications. If children and caregivers know what to 
expect from their medications, then they may be able to prevent and treat side effects.  
Additionally, providers need to ask the child to verbalize their thoughts and feelings 
about their concerns about medication side effects (NAEPP, 2007).  This could improve 
control medication adherence and decrease levels of concerns about side effects.   
 
Previous studies in adult patients have shown that adults do not always discuss 
medication-related symptoms with their providers (Gandhi et. al. 2003, Weingart et. al. 
2005, Wilson et. al. 2007).  Our results of side effect discussions also show that 
caregivers and children rarely discuss medication side effects with their providers.  Many 
side effects are preventable and treatable and providers should make sure to discuss side 
effects with all children and their caregivers.  One of the reasons adult patients do not ask 
their providers questions during their medical visit is because they are reluctant to ask 
their providers questions (Sleath et. al. 1999).  Sleath and colleagues (1999) also found 
that physicians perceive patient question-asking positively, rating those who asked 
questions as more interested and more assertive than patients who do not ask questions 
(Sleath et al. 1999).  Thus, providers should try to encourage children and caregivers to 
ask questions about side effects during every visit.  
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When providers did discuss side effects with children and their caregivers, they were 
most likely to ask general questions about side effects (i.e. “She didn’t have no bad 
reaction to it or anything like that?”) and make Assurance statements to children and 
caregivers.  Assurance statements were categorized as statements to attempt to put 
caregivers at ease and assure them that the symptom the caregiver thought was 
medication-related was not.  When caregivers make a statement or ask a question about a 
symptom they think is medication-related, providers should encourage a discussion about 
side effects and not cut caregivers off while the caregiver is speaking.  
 
As stated previously, discussions about side effects were found in only four percent of 
medical visits. Prior studies of provider-patient communication have found that 
discussions about side effects were rare (Sleath et. al. 2007, Sleath et. al. 1999), while 
other studies have found that discussions about side effects were very common (Young 
et. al. 2006).  The reason for such a high frequency in the Young et. al. (2006) study 
could be because that study examined new prescriptions for antidepressants in white, 
middle-aged women and those women were standardized patients.  The Young et. al. 
(2006) study may not be generalizable to this dissertation study because that study used 
standardized patients.  Also, the Young and colleagues (2006) study covertly audiotaped 
medical visit interactions (with prior provider consent), whereas in our study, the 
providers knew they were being audiotaped and no attempt was made to hide the audio 
recorder.  The Young and colleagues (2006) study was also conducted in large 
metropolitan areas in the United States, whereas our study was conducted in rural areas in 
North Carolina.  Finally, the Young et. al. (2006) study was a smaller component of a 
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randomized experiment, while in our study, there was no randomization process and 
providers delivered usual care to children.    
 
There were also no differences in characteristics of caregivers or asthma control 
medications that were associated with discussions of side effects.  The finding is 
interesting because of the general concern among the public about the safety and long-
term effects of inhaled corticosteroids.  Despite this, the finding that characteristics of the 
medication was not a significant contributor to discussions about side effects could have 
been partially due to the extremely low frequency of the discussions about side effects.   
 
It is also worth noting that side effects may still affect children whose visits did not 
include a discussion of side effects.  This study measured communication about 
medication side effects and not child or caregiver perception of side effects at the office 
visit.  It is possible that a portion of the patients not discussing side effects experienced at 
least one side effect of the medications, for example bad taste or thrush.  In fact, our 
study showed that 83 children reported at least a little concern or problem with side 
effects one month after the visit with their provider.  While this study did not examine 
specific side effects that caused children the most problems or concerns, prior research 
has found that remarkably few children use their metered dose inhaler,  diskus, and dry 
powder inhaler devices correctly, which could result in the patient experiencing side 
effects, such as unpleasant taste of the medication or oral thrush (Sleath et. al. 2011).   
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Providers could ask the following question to both children and caregivers to assess 
whether or not the child has experienced any side effects from the medication (NAEEP, 
2007): “Has your asthma medicine caused you any problems?”.  This simple, open-ended 
question can be used to gauge if the child has experienced any problems with the 
medication; in this case, side effects.  By directly asking the child about the problems in 
taking the medication, the provider is engaging the child and involving them in their own 
health care.  This begins to build autonomy in medication taking in children and initiates 
their understanding of causal relationships.  Similarly, when speaking with adolescents, 
providers can speak to teenagers akin to how they would speak with an adult (Sleath et. 
al., 2003).   
 
There were instances of communication that was not fully interactional.  For example, 
there were instances in which the caregiver was speaking to the provider about the side 
effects of asthma control medications, such as headaches, and the provider cut the 
caregiver off mid-sentence to tell them: “Not related to her asthma medicine”.  The 
provider not discussing the problematic headaches the child was experiencing may lead 
to the caregiver and child reducing or eliminating doses in order to avoid the headaches.  
In fact, statements from caregivers during these visits did confirm that caregivers stopped 
their child from taking an asthma control medication based on the side effects that were 
experienced without first consulting the child’s provider.  This type of intentional non-
adherence to asthma control medications from caregivers of asthmatic children points to 
an increased need for providers to discuss the side effects of asthma control medications 
with caregivers and children.  This discussion may prevent caregivers from having their 
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child discontinue their asthma control medication because of concerns about side effects 
of the medication.  The national asthma practice guidelines state that most non-adherence 
to medications results from concerns about the medications that the patient and/or 
caregivers have not talked about with their provider (NAEPP, 2007).  Providers can 
discuss concerns about medications in a way that both children and caregivers 
understand, thus catching potential non-adherence earlier.  Non-adherence to asthma 
control medications may result in sub-optimal asthma control and lead to increased 
healthcare costs and asthma symptoms (Williams et. al. 2004 and Bender and Bender, 
2005).   
 
Children did not ask any questions about side effects during these visits.  Children should 
be taught about their medications and providers should encourage children to ask 
questions about their medications (Bush et. al. 1999 and Bush and Sleath, 2003).   
Adolescents as young as 13 years old want to know about the side effects of their asthma 
medications and what to do about them if they experience them (Raynor et. al. 2004).   
 
Although children did not ask questions about side effects, children did make statements 
regarding side effects of their asthma control medications, but it was always anecdotal 
information after the caregiver spoke to the provider.  This study’s results found that 
discussions about side effects were more prevalent in younger children than older 
children.  These findings together confirm prior research observing that caregivers 
usually speak for their children (Tates and Meeuwesen, 2000, Wissow et. al. 1998). Prior 
studies have found that child involvement decreases the amount of time that caregivers 
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speak to the medical provider (Tates and Meeuwesen, 2000).  Providers and caregivers 
both, intentionally or not, suppress the child’s discussions during the medical visit.  
Children need to speak to their medical providers in order for providers to understand 
exactly how the child feels about using a medication, especially because children as 
young as nine years old use their asthma medications on their own (Orrel-Valente et. al. 
2008).  Younger children’s visits were more likely to include a discussion about side 
effects, but providers need to discuss side effects with older children as well, which the 
national asthma guidelines encourage (NHLBI, 2007).   
 
Children as young as seven years old can begin to learn causal relationships about their 
health (i.e. taking Singulair may result in a headache) (Sleath et. al. 2003).  Providers and 
caregivers should encourage children to participate in medical discussions by asking 
questions and discussing their experiences using an asthma control medication.  Future 
research should examine interventions that encourage children to participate in 
discussions about side effects and whether that communication impacts children’s 
concerns about using asthma control medications.   
 
Side effects were discussed during twelve distinct visits.  According to the national 
asthma practice guidelines (NAEPP 2007), providers should have discussed side effects 
as well as child and caregiver concerns about side effects during all visits.  Therefore, 
providers need to dramatically increase their performance of this behavior in order to 
achieve consistency with the guidelines.  Even when providers discuss medication risks 
with new prescriptions, an ongoing discussion about side effects should still occur at 
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every visit to monitor the medication’s efficacy and address any concerns in order to 
maximize the child’s use of the medication.  It is important to note that in order for 
discussions about side effects to have occurred, the child had to previously experience a 
side effect; they could not simply just discuss side effects.  This is a limitation of the 
study.          
 
Discussions about Risks of Asthma Control Medications 
Risks were discussed in less than one-fifth of these visits.  In both of the instances where 
the provider asked about risks of asthma control medications, the provider used those 
questions to start the discussion about risks.  While it may be counter-intuitive that 
providers would ask questions to caregivers and children about risks of asthma control 
medications, it is important for providers to assess understanding of the discussion after 
the risks were discussed.   
 
Previous studies have found that 40-80% of medical information discussed in medical 
visits is forgotten immediately and half of the information that is retained is incorrect 
(Kessels 2003).  The Teach-Back Method is a method that confirms the information the 
provider discussed during the visit is retained by the caregiver and child (DeWalt et. al. 
2010).  The Teach-Back method calls for providers to ask caregivers and children about 
the information presented during the visit to test how well the provider explained each 
concept.  Asking the child and caregiver to repeat the concepts that were discussed in the 
communication about risks could be a very strong tool that aids the provider in discussing 
a sensitive topic, such as the risk of adverse effects from asthma control medications.   
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Since retaining information is a key aspect in how caregivers and children perceive the 
safety of a medication, it is important for providers to ask questions about the risks that 
were discussed to ensure that both caregivers and children correctly understand the risks 
involved in using an asthma control medication.  The providers in these visits did not use 
the Teach-Back method when discussing the side effects and risks of asthma control 
medications.  Future research should investigate an intervention about the effect of using 
the Teach-Back Method and caregiver and child comprehension of asthma control 
medication side effects and risks.     
 
When providers made statements about the risks of asthma control medications, they 
were most likely to make General statements about risks, meaning that the provider did 
not identify a specific risk in using the medication.  Medical providers are experts on the 
treatment of diseases, such as asthma, and should discuss the salient aspects of 
pharmaceutical therapy, such as risks.  Using the phrase that was used in these medical 
visits, “And it tends not to have an effect all over the body because we don’t want to do 
that,” the provider does not tell the caregiver or child risks that (s)he should be concerned 
about.  By not discussing specific risks of using these medications, caregivers and 
children may be more susceptible to decreased adherence if they experience one of these 
risks, such as thrush.  It may be possible that providers discussed specific risks during 
previous visits.  However, national practice guidelines (NAEPP 2007) state that providers 
should address children’s and caregivers’ concerns at every visit, which may include a 
discussion about medication risks.   
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Likewise, when providers make a statement such as a Safety statement, saying, “And 
being on the daily inhaled medicine is, is quite safe,” providers are not really discussing a 
specific risk with children and their caregivers.  Saying that the medication is safe is not 
discussing risks, but the absence of risks.  This may lead to caregivers or children 
thinking that the medication will not cause any adverse effects, which is not a realistic 
perception of pharmacotherapy.  When providers did discuss specific risks, they were 
more likely to discuss Thrush and Bad Taste.   
 
When caregivers spoke about risks, they were most likely to ask questions about the 
asthma control medication causing harm to the child.  An example of this kind of 
question in these visits was: “There is not any kind of danger in that Advair is they 
(sic)?”  Caregivers also made the most statements about General risks.  An example of 
this kind of statement was: “Yeah I give it to him when, when I see that it is getting to 
that point but I don’t want to give it to him every night just because it’s a steroid but I do 
give it to him and it relieves his…”  In this example, the caregiver did not even fully 
speak the entire sentence before the provider cut the caregiver off.  The provider tells the 
caregiver to give the medication to the child every night during the allergy season after 
(s)he cut off the caregiver.  The provider misses a key opportunity to discuss the 
importance of adherence to asthma control medications and the resulting improved 
control as a result of using the medication.   
 
Confirming the results of the side effect discussions, children only spoke about risks 
during three medical visits.  It is important to note that while only three children spoke 
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any about the risks of asthma control medications, almost one-third of children reported a 
problem or concern about side effects one month after the medical visit.  This suggests 
that children do have concerns about side effects of their asthma control medications, but 
the vast majority of children are not discussing this with their medical provider.  As 
discussed earlier, children should be taught to discuss any concerns about risks or side 
effects with their provider, because this discussion may lead to providers preventing or 
treating risks before they become side effects.  However, before any discussion about 
risks can take place, providers need to explain to children specific risks that are involved 
in using asthma medications and if the risk is preventable (i.e. thrush), then how to avoid 
those risks.  Providers can then ask children directly if they are they think they are 
experiencing any side effects and also if they have any concerns about the potential side 
effects, which would fulfill the Bogardus dimension of discussion about the patient’s 
values regarding the risks (Bogardus 1999).    
 
Children should be taught how to effectively communicate during medical encounters. 
Both caregivers and medical providers should encourage children to be involved in the 
discussions, since children as young as nine years old use their asthma control 
medications without parental supervision (Eggleston et. al. 1998, Orrell-Valente et. al. 
2008).  Finding that children rarely participate in discussions during medical visits is not 
surprising, given the prior literature on child participation in medical discussions (Tates 
and Meeuwesen, 2000).  The United States Pharmacopeia suggests that children be 
included in discussions about their medications and there is literature supporting how to 
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encourage children to become involved in their medication discussions (Bush et. al. 
1999).    
 
Children around seven years old can begin to understand cause and effect relationships 
on their health (Sleath et. al. 2003).  The US Pharmacopeia (Bush et. al. 1999) takes the 
stance that children should be taught about their medications and involved in their 
medication discussions.  Further, studies have shown that even with adult patients, most 
of the information that is given during the medical consultation is forgotten (Kessels 
2003).  While children would hardly know about the risks of their medications without 
first being taught by their medical providers and caregivers, medical providers should use 
the Teach-Back method (DeWalt et. al. 2010) to aid child recall of the important points 
that are discussed during the visit.  Asking children to repeat the potential risks of their 
medications in their own words could increase their understanding of the use of their 
medications.   
 
More than one-third of caregivers also reported a problem/concern about side effects of 
their child’s asthma control medication one month after the audiotaped visit.  There were 
only 11 visits, however, in which caregivers asked a question about asthma control 
medication risks and eight visits in which caregivers made statements about the risks of 
their child’s asthma control medication.  Like children, caregivers are not discussing the 
risks and side effects of their child’s asthma control medication with providers very often.  
This could mean that providers are not fully explaining the risks of asthma control 
medications with caregivers and therefore are not lessening caregiver’s concerns.  Using 
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the Teach-Back method with caregivers as well as children when discussing risks may be 
beneficial in helping caregivers understand the risks associated with asthma control 
medication use.  This understanding may lead to a fewer percentage of caregivers 
reporting problems/concerns with side effects, but should be studied further.  
 
Also, providers rarely addressed each of the dimensions that Bogardus describes as 
essential elements of risk communication.  Specifically, providers only discussed the 
probability of the child experiencing a risk during 3% of encounters (N=8).  However, 
only one provider used numbers to convey the probability of a risk occurring.  Prior 
research has found that using words to convey probability information may be misleading 
(Berry, et. al. 2003) because consumers may not have an anchoring to a specific word 
that may be used.  When describing probability information, providers need to use a 
format that is easily understood by even those with limited numerical skills.  The use of 
numerical formats such as percentages or absolute risk reduction may be helpful to 
caregivers so they can understand the probability of their child experiencing a risk 
(Sheridan et. al. 2003).     
 
There have been previous studies that have examined how providers discuss probability 
information and how patients understand that information.  Neuner-Jehle and colleagues 
(2011) found that providers used qualitative methods of explaining risk probability, 
however patient understanding was higher when the provider used visual aids, such as 
graphs, to describe risk probability.  This study confirms Neuner-Jehle and colleagues 
finding because providers in this dissertation used qualitative expressions of probability 
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most often.  Providers could enhance patient understanding of probability by using 
graphs.   
 
Discussions of risks were significantly more likely when children were taking or 
prescribed an inhaled corticosteroid.  Inhaled corticosteroid risks, such as reduced final 
adult height, are prevalent throughout the American popular media.  In spite of the much-
publicized risks, inhaled corticosteroids are often the first line of therapy when managing 
persistent asthma.  The national asthma guidelines state that while ICS medications may 
pose risks, such as oral thrush and short-term decreased velocity of child growth, the 
benefits of using the medication outweigh those risks (NAEPP, 2007).     
 
Finally, visits that were longer were associated with a significantly increased likelihood 
of discussing asthma control medication risks.  Given the demands of a primary care 
pediatrician’s time, increasing visit time for medication risk discussions may not be an 
attractive finding.  However, shorter visit time has been cited as a barrier to effective 
healthcare communication and shorter visits are associated with worse patient outcomes 
(Cox et. al. 2007).  In this aspect, pharmacists can help educate children and caregivers 
about the risks of asthma control medications.  Additionally, pharmacists can teach 
children and caregivers how to use the asthma medication correctly to reduce the chance 
of risks occurring.  More research is needed on whether discussions of medication risks 
lead to longer medical visits and improved outcomes.   
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It is worth noting that providers who classified themselves as physician assistants, nurses, 
and nurse practitioners did not have any visits in which there was a risk discussion.  This 
is an important finding of this study.  There may be two explanations for this finding: (1) 
providers who are not physicians may lack the self-efficacy to fully discuss risks of 
asthma control medications; and (2) there may be a different type of provider-patient 
relationship between physician assistants and nurse practitioners with caregivers and 
children.  Both of these hypotheses merit further research.  The second hypothesis has 
some validity in our data because neither caregivers nor children asked any questions nor 
made any statements about medication risks with non-physician providers.   
 
Discussions of asthma control medication risks were significantly more likely to occur 
when providers were starting a new prescription for an asthma control medication.  It is 
concerning however, that risks were significantly less likely to be discussed when the 
provider continued a previous prescription without making any changes to the dose or the 
directions.  Providers need to have an ongoing dialogue with children and their caregivers 
and ask about any medication risks.  There are some medication-related risks associated 
with asthma control medications that are constant risks, such as the risk for oral thrush.  
Repeating important discussion points often and using the Teach-Back Method when 
discussing medication-related risks may increase the possibility of a child adhering to 
behaviors that may reduce the chance of a risk occurring, i.e. rinsing out the mouth after 
using an asthma control medication and using a spacer with inhalation devices.   
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Discussions about Benefits of Asthma Control Medications 
Asthma control medication benefits were discussed in less than half of the medical visits 
(47.1%).  Provider discussions about benefits were the most diverse across all 
communication areas that were studied.  Providers asked questions in eight different 
areas of benefit.  When providers made statements about benefits of asthma control 
medications, they made statements in 20 different areas. 
 
Children’s participation in the communication was highest during discussions about 
medication benefit. Nonetheless, children only spoke about asthma control medication 
benefits in four percent of visits.  Providers and caregivers need to encourage children to 
participate in the discussion because more involvement from children in medical visits 
has been associated with better health outcomes (Cox et. al. 2007). Other research shows 
that caregivers interfere when providers ask children questions (Tates and Meeuwesen, 
2000). Future research should investigate how caregivers can let children speak during 
the medical visit while at the same time allowing full interaction between the provider 
and caregiver.    
 
The GEE results showed that children who were younger were significantly more likely 
to have a visit that included a discussion about asthma control medication benefits.  
Previous studies have found that child participation in medical visits increases with age 
(Tates and Meeuwesen 2002; Cox et. al. 2009).  Providers need to discuss the role and 
benefits of asthma control medications with every child and caregiver to ensure 
understanding.     
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Asthma control medication benefits were also significantly more likely to be discussed 
when asthma control medication risks were discussed.  This could mean that when 
asthma control medication risks are discussed during a medical visit the provider also 
discusses the positive aspects of the medication, the benefits of the medication.  
Discussing and educating children and caregivers about the risks and benefits can lead to 
better child and caregiver involvement in medical decisions or shared decision-making 
(Makoul and Clayman 2006).  However, discussions of medication risks were relatively 
infrequent and approximately 12% of medical visits had discussions of both risks and 
benefits together.  Discussions of medication risks need to improve both in content and 
frequency to lead to better child and caregiver involvement. 
 
Visits that included a discussion about adherence were also significantly more likely to 
include a discussion about medication benefits.  The qualitative examination found that 
providers spoke about the benefits of medication adherence.  National practice guidelines 
for asthma encourage providers to screen for asthma medication adherence at every visit.  
There were visits in our study where providers asked children if they used their control 
medication on a consistent basis.  Providers can educate children and their caregivers that 
control medications are most effective when used daily and discuss the benefits of 
adherence more often.  This may lead to fewer misunderstandings about the role of 
asthma control medications for caregivers and children (NAEPP, 2007).   
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Finally, discussions about control medication benefits were significantly more likely 
when children were taking or prescribed an inhaled corticosteroid.  This finding could 
mean that children who take or prescribed an inhaled corticosteroid may be more likely to 
have visits that include discussions about risks and benefits.  Future research should 
investigate whether being prescribed an inhaled corticosteroid leads to discussions of 
medication risks and benefits.     
 
Benefits were significantly more likely to be discussed when a new medication was 
started.  Eighty percent of information that is discussed during medical visits may be 
forgotten immediately after the visit (Kessels, 2003) and providers need to ensure that 
both children and their caregivers understand the reason (s)he is using a certain 
medication.  Using the Teach-Back method to ensure child and caregiver comprehension 
and repeating important points often are a necessary and essential component of 
discussions about medication-related benefits.   
     
Caregiver-Reported Adherence to Asthma Control Medications 
Fifty-nine percent of caregivers reported their child as having an average adherence score 
of at least 80%.  This means that more than 40% of caregivers in this sample classified 
their child as non-adherent to asthma control medications.  The mean adherence score 
that caregivers reported was 84.6% with a range of 0%-100%.  Previous studies have 
found that adherence to asthma control medications has wide variability (Rau, 2005).  
Previous studies have also shown that self-reported medication adherence measures are 
consistently higher than when measured by more objective measures, such as pharmacy 
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refill records or electronic monitoring devices (Rau, 2005).  This study’s finding of an 
84.6% average adherence score could be at least partially due to self-report bias.  
However, since children as young as nine years old use their asthma control medications 
without adult supervision it is possible that caregivers are not fully aware of their child’s 
medication use (Orrell-Valente et. al. 2008).   Future research should determine if 
children’s self-report of adherence is related to more objective measures of adherence to 
verify the accuracy of self-reported medication use by children.      
 
Caregivers were significantly more likely to classify their child as 80% or more adherent 
to their asthma control medications when the child took a higher number of asthma 
control medications. This finding is surprising given that prior studies have found that 
medication regimen complexity, such as having more medications to take, was related to 
poorer adherence (Rau, 2005).  The result could be due to self-report bias and future 
research should use more objective measures to determine patient adherence.  The result 
could also be because caregivers of children that were more adherent to asthma control 
medications were more likely to enroll in the parent asthma study.  As stated earlier, 
future research should use more objective measures of child adherence to determine 
whether children are as adherent as they seemed to be in this study. 
 
Caregivers were also significantly more likely to classify their child as 80% or more 
adherent to their asthma control medications when the length of the visit was longer.  
Previous studies have found that shorter medical visits are associated with worse 
outcomes, a finding that this study corroborates (Cox et. al. 2007).  Also, prior research 
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has found that patient trust in their medical provider increases with the length of time the 
provider spends with the patient (Fiscella et. al. 2004).  Therefore, it is important that 
providers spend time with their patients to increase medication adherence in asthma as 
well as help build patient trust. 
 
Caregivers were significantly more likely to classify their child as 80% or more adherent 
to their asthma control medications when the child had seen the study provider more 
times.  Previous studies have found that patient trust in providers is correlated with the 
number of times the patient has seen the provider (Hall et. al. 2002).    More research 
needs to be done to examine whether caregiver trust in their child’s medical provider is 
associated with the number of times that the child has seen the provider.   
 
An interesting finding is that a discussion about control medication adherence during the 
medical visit was not associated with caregiver-reported adherence one month later.  
Simply discussing adherence of asthma control medications may not be enough of an 
intervention to improve medication adherence, based on the results of this study.   
 
Discussions about medication-related side effects, risks, and benefits were not 
significantly associated with caregiver-reported asthma control medication adherence of 
at least 80% in this study.  This could be because of the very high average adherence that 
was reported by caregivers or it could be that discussions about medication risks and 
benefits are only one aspect of a behavior (i.e. medication adherence) that is complex and 
can change on a daily basis, regardless of whether side effects, risks, or benefits were 
 174
discussed during a medical visit.  Previous research has shown that intention to adhere to 
medications is associated with discussions about medication-related risks (Thurmann 
2006).  Future research should examine whether there is a relationship between intention 
to adhere to asthma control medications and problems/concerns about side effects of 
medications to determine if patients or caregivers who score higher on an intention 
measure would be less likely to report a problem or concern about side effects.   
 
Caregiver-Reported Problems and Concerns About Side Effects with Child’s Asthma 
Control Medications 
 
A significant proportion (37%) of caregivers voiced concerns about side effects from 
their child’s asthma control medications one month after the medical visit.  However only 
11 visits included caregivers asking questions about control medication risks.  Therefore 
there are a substantial proportion of caregivers who are not voicing their concerns or 
problems with side effects to their child’s provider.  Previous research has found that 
most nonadherence originates in personal beliefs or concerns about asthma that have not 
been discussed with a medical provider (Bender and Bender 2005).  Our study confirms 
that a significant proportion of caregivers have personal concerns about side effects of 
their child’s asthma control medication, yet did not discuss these concerns during the 
medical visit.  Providers can encourage caregivers to speak about their concerns by 
asking: “What worries you most about your child’s asthma medications?” (NAEPP, 
2007).   
 
The bivariate and GEE results showed that when caregivers reported their child had 
fewer previous visits with the study provider, they were significantly more likely to 
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report a problem and concern with side effects one month after the study visit.  This 
finding is an important contribution of this study.  Prior research has shown that the 
length of time that a patient has been with a provider is significantly associated with trust 
in the provider (Hall et. al. 2002).  Our study did not examine other aspects of trust in 
physicians, but future research should in order to determine if trust is related to 
caregiver’s concerns with their child’s asthma control medications.   
 
Another interesting aspect to this study’s findings shows that caregivers were more likely 
to be adherent when the child had more visits with the study provider and less likely to 
have a problem or concern about side effects when the child had seen the provider more 
times.  These findings together add credence to the theory that trust in medical providers 
is a significant aspect of medical care.  More trust in providers may lead to better asthma 
outcomes, but this relationship needs to be studied further to assess the relationship of 
trust with less problems or concerns about side effects and medication adherence.     
 
Similar to the caregiver-reported adherence measure, discussions about side effects, risks, 
and benefits were not significantly associated with the level of caregiver-reported 
problems and concerns about side effects one month after the visit.  It could be that we 
assessed the wrong time point to understand if there was a relationship between 
caregiver-reported problems and concerns about side effects and discussions about 
medication-related side effects, risks, and benefits.  Future research should examine 
whether discussions about side effects, risks, and benefits are associated with caregiver-
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reported problems and concerns about side effects immediately after the medical visit 
(Kessels 2003). 
   
Child-Reported Problems and Concerns about Side Effects from Asthma Control 
Medications 
 
Like their caregivers, more than 32% of children reported a problem or concern about 
side effects of their asthma control medications.  Yet, only three children asked questions 
about asthma control medication risks and only three children made statements about the 
side effects of their asthma control medications during the medical visit.  Thus, a 
substantial proportion of children are not discussing their concerns or problems with side 
effects with their medical providers.  Children need to be taught to participate in their 
medical encounters, especially since their participation improves disease self-
management and increases both parent and child satisfaction with their medical care (Cox 
et. al. 2009).     
 
Providers can encourage discussions about the concerns of children in using asthma 
control medications by directly asking the child: “What concerns you most about your 
asthma medication?” (NAEPP, 2007).  National practice guidelines recommend that 
providers start each visit by asking about the patient’s asthma concerns, including 
medications (NAEPP, 2007).  It is important for providers to discuss children’s concerns 
using asthma control medications so that those concerns can be identified and addressed 
(NAEPP, 2007). 
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Children who did not take inhaled corticosteroids were significantly more likely to be 
concerned about side effects of their asthma control medication(s).  Future research 
should try to determine why this finding occurred.  One hypothesis is that children who 
are prescribed Singulair may experience more side effects than children who take inhaled 
corticosteroids or because the child could be using a rescue medication more often.  
Future research should not only determine if children have concerns about side effects, 
but also ask specifically which side effects that children are most concerned about.  
Based on this, future research also needs to examine if there are more instances of side 
effects with Singulair than with inhaled corticosteroids, as well as if children who have 
persistent asthma who do not take inhaled corticosteroids experience more side effects 
because of using rescue medications more often.   
 
Children were also significantly more likely to report a problem or concern about side 
effects from their daily asthma medications when their caregiver was not married.  
Previous research shows that married caregivers exert a positive effect on children’s 
negative attitudes toward medications.  Rhee and colleagues found that family support 
was found to reduce adolescents’ negative attitudes toward medication (Rhee et. al. 
2010), which also increased adherence.  DiMatteo (2004) found that marital status 
increased medication adherence.  Furthermore, children who are from divorced 
caregivers may experience more negative aspects of asthma medication use because of 
the child not using their asthma medication while at the other caregiver’s home.  It could 
also be that single caregivers have less time to focus on a child using an asthma control 
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medication.  Future research should investigate the problems with using asthma control 
medications that single caregivers face with their children.       
 
Finally, children whose providers were male were significantly more likely to report a 
problem or concern with side effects.  This finding is surprising and shows that provider 
characteristics may be associated with children’s concerns about side effects.  Our study 
did not find any differences in physician gender regarding visit length, and when side 
effects, risks, and benefits were discussed.  Previous studies have found that female 
providers have longer visits, engage in more social exchange and encouragement 
(Bernzweig et. al. 1997).  Caregivers may be more likely to be satisfied with female 
providers (Bernzweig et. al. 1997).  Future studies should investigate other 
communication factors that may be involved in children having concerns about side 
effects of their medications. 
 
It is important to note that discussions about asthma control medication side effects, risks, 
and benefits were not significantly associated with child-reported problems and concerns 
about side effects one month after the medical visit.  Similar to caregivers, we may have 
assessed the incorrect time point to recognize if there was a significant relationship with 
discussions about side effects, risks, and benefits and child-reported problems and 
concerns with side effects of asthma control medications.   Future research should 
examine whether discussions about side effects, risks, and benefits are significantly 
associated with child-reported problems and concerns immediately after the medical visit. 
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Implications 
Communication about medication side effects, risks, and benefits are important features 
of medical visits between children with asthma and their caregivers and their medical 
providers.  Provider-patient communication is a multifaceted concept with implications 
for patient care. 
 
Active discussion about medication side effects, risks, and benefits during the 
prescription medical visits may have several benefits.  First, it may increase the 
likelihood that providers and caregivers and children will agree on a course of treatment.  
Second, engaging patients in the side effect, risk and benefit discussions may decrease 
concerns about using asthma control medications.  Third, studies have shown that for 
children and caregivers alike, concerns and negative attitudes toward asthma control 
medication seem to influence medication use (Le et. al. 2008, Conn et. al. 2007 and Conn 
et. al. 2005).  Initiating conversations about medication use in relation to side effects, 
risks, and benefits give providers an opportunity to identify and address concerns that 
children and caregivers may have regarding using an asthma control medication.   
 
Inhaled corticosteroids were the most often used when treating children with persistent 
asthma.  The strong association between discussion of risks and benefits and the child 
taking or being prescribed an inhaled corticosteroid may indicate that there is a general 
public wariness to the safety of inhaled corticosteroids, therefore caregivers and providers 
need to discuss both the pros and the cons of the medication.   
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Encouraging medical visit communication that enables child involvement may be more 
likely to result in a better understanding of medication benefits and risks from the child’s 
point of view.  Children can learn when to take the medication, how to take the 
medication, why to take the medication (benefits), and why they should not take more of 
the medication to feel better (risks).  Emphasizing the side effects, risks, and benefits of 
the child’s asthma control medication may further help the child become acculturated to 
better provider-patient communication as the child ages.   
 
The results of this study also showed a clear association of familial support on children’s 
perception of the side effects of asthma medications.  Providers can recognize that 
children from single-caregiver families may be at a higher risk for concerns about side 
effects from their asthma control medications.  Providers should be especially vigilant 
about screening children with single-caregiver families, by not only asking the child and 
the caregiver if the child has been taking the medication, but also if the child has any 
concerns about side effects from the medication, which the national guidelines also state 
that providers should do (NAEPP, 2007).  In addition to asking the child questions about 
concerns about side effects (s)he may have, the provider can openly and thoroughly 
discuss the possibilities of side effects other than the specific concerns that the child may 
have.  Providers not only need to discuss specific risks, but also the timing of the risk, the 
permanence of the risk, the probability of getting the risk, and ensure the child is 
comfortable with the risks (Bogardus et al. 1999).  Providers also can help to prevent 
medication-related risks by teaching children better inhalation technique and prescribing 
spacers for inhalers for all children, as stated by the national guidelines (NAEPP, 2007).   
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Finally, continuity of care may be an important factor in how caregivers perceive their 
child’s medical care as well as improving health outcomes (Christakis et. al. 2002).  
Making efforts to improve continuity of care may be an essential factor in reducing 
caregiver’s concerns about their child’s asthma control medications, in addition to 
improving the perception of quality of medical care and caregiver trust in the provider.  
Improving all of these aspects of health care in the medical clinic may also improve 
medication-related outcomes, such as asthma control medication adherence.    
 
This study’s results also have implications for pharmacists.  Pharmacists are often the last 
medical provider that patients see when they obtain physical control of their medication.  
Patients can ask pharmacists in-depth questions about the medications and the 
pharmacists can discuss the medication’s risks and benefits while also monitoring 
adherence, and concerns about the medication that may lead to decreased adherence.  
Clinics may be able to employ pharmacists in medical clinics to review medications 
before children see their provider.  The pharmacist can ask about side effects and can 
discuss risks and benefits of the medication with children and their caregivers.  The 
pharmacist can then enter the  results of those discussions directly in the child’s medical 
chart so the provider can review the pharmacist consultation.     
 
When speaking with patients, pharmacists can discuss the medication’s risks and benefits 
with both caregivers and children as well as concerns about using the medication.  
Pharmacists may be able to improve adherence to asthma medications by addressing 
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concerns about the medication.  Pharmacists can also discuss ways to mitigate the onset 
of risks, such as discussing ways to prevent risks.  Pharmacists can also ask children and 
caregivers about whether the child had experienced side effects at every refill.  By 
opening lines of communication with not only the caregiver but also the child, the 
pharmacist can provide a direct link to the child’s provider if the child does experience a 
side effect that needs to be treated, such as oral thrush.    
 
Study Limitations 
This study has several limitations.  First, we examined only children with asthma and 
primary care pediatric providers.  Therefore, the results may not be generalizable to other 
patient populations or provider specialties.  Persistent asthma is, however, an excellent 
model to study medication side effects, risks, and benefits because it is both a 
symptomatic and asymptomatic condition that requires daily medications.  Second, both 
patient and provider samples were convenience samples and self-selection biases are 
possible. Third, some categories of the outcome variables of interest were smaller than 
the full sample size, because of non-responders and patients who declined to perform the 
home visit part of the study.  This study was, however, still sufficiently powered to detect 
meaningful differences.  Fourth, measurement of the full set of factors that affected 
communication and medication concerns about side effects may not have been examined 
by this study.  There may be mediating variables that affect the relationship between 
provider-child-caregiver communication as well as medication adherence and 
concerns/problems with side effects of asthma control medications.   
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Fifth, the presence of the tape recorder may have altered provider and patient behavior 
during the medical visit, although this seems unlikely to significantly affect the 
conclusions since the data were collected for another purpose.  Providers, children, and 
caregivers were blind to the research hypotheses for both the parent study and the current 
study, reducing the likelihood that they would have altered their behavior in the areas of 
medication side effect, risk, and benefit communication.   
 
Finally, previous research on attitudes toward asthma control medications has 
consistently found an association between concerns about asthma control medication 
leading to decreased adherence.  The finding that reported concerns about side effects 
was not associated with significantly decreased adherence in either caregivers or children 
may be at least partly due to social desirability bias.  Prior research has found that 
subjective measures of asthma control medication adherence such as self-report is higher 
than objective measures, such as canister weight and pharmacy records (Jentzsch et. al. 
2009).  Additionally, children use their own asthma control medications without 
supervision as young as nine years old (Eggleston 1998).  When young children supervise 
their own medication use, caregivers may be less likely to know exactly how often the 
child uses the asthma control medication, therefore limiting the complete usefulness of 
using caregiver self-report of a child’s medication adherence.  Future research should use 
objective measures of adherence, such as pharmacy refill records or electronic 
monitoring.     
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Study Strengths 
Notwithstanding the limitations, this study has several strengths and makes an important 
contribution to the knowledge base about medication side effect, risk, and benefit 
communication in pediatric medical visits.  First, this study is the first to examine 
communication about asthma control medication side effects, risks, and benefits in a 
population of children with persistent asthma.  Second, this study is the first to look 
simultaneously at medication side effect, risk, and benefit communication and asthma 
control medication adherence.  Third, the study looked at the actual medical visit 
communication about side effects, risks, and benefits, providing a deeper understanding 
of the content of such communication than has previously been reported.  The findings of 
specific categories of statements and questions add to the literature as well.  Fourth, the 
use of both qualitative methods and quantitative methods permitted examination of both 
the content of medical visit communication and predictors of communication and 
outcomes.  Finally, the study provides practical guidance for clinical practice by 
identifying a strong relationship between children taking or being prescribed inhaled 
corticosteroids and control medication risk and benefit communication.  Through open 
communication and providers engaging the child during the medical visit, medication 
adherence and concerns about side effects can be addressed in the medical visit.   
 
Directions for Future Research 
Both the implications and limitations discussed above suggest a number of future 
directions for research on medical visit communication about asthma control medication 
side effects, risks, and benefits.  First, the types of communication about medication side 
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effects, risks, and benefits may serve as a useful starting point for designing studies 
looking at the different constructs of side effects, risks, and benefits in pediatric and adult 
asthma.  Future studies examining the content of communication about asthma control 
medication side effects, risks, and benefits in a larger sample of patients with persistent 
asthma would provide insight into whether or not the concepts are consistent across 
samples.   
 
It is important to note that not all discussions about side effects and risks are equal.  
Future research should examine the quality of the discussions about side effects and risks.  
Future research could use a weighted scoring method to evaluate the quality of the 
discussions based on a theoretical framework, such as Bogardus.  Higher scores would be 
reflective of better quality discussions.  The quality of the discussions could then be used 
in a multivariate model to determine whether the quality of the discussion is related to 
asthma control medication adherence as well as caregiver- or child-reported problems 
and concerns about side effects of asthma control medications. 
 
Another feature that is related to quality of discussions is the amount of time that is spent 
discussing medication-related side effects and risks.  While this study did not examine the 
amount of time that providers spent discussing side effects and risks, this aspect should 
be examined in order to understand if the amount of time that is spent discussing side 
effects and risks is associated with appropriate asthma control medication adherence as 
well as caregiver- and child-reported problems and concerns about side effects of asthma 
control medications.  Future research should also focus on the amount of time that 
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providers spend discussing medication-related benefits.  Future research should examine 
whether providers spend more time discussing benefits than side effects and/or risks as 
well as if this difference is associated with adherence and problems/concerns about side 
effects.      
 
Next, an intervention that would be beneficial in improving discussions of medication-
related risks and shared decision-making could be designed following Elwyn and 
colleagues 2004 study in Great Britain (Elwyn et. al. 2004).  This study showed that 
providers were able to increase their use of shared decision making as well as risk 
communication by providers attending a shared decision making workshop and a risk 
communication workshop. 
 
An intervention that followed Elwyn’s study design could be applied to providers who 
treat children for persistent asthma.  A study could be designed to audiotape a particular 
number of providers who treat children with asthma.  After a group of children were 
initially enrolled into the study, providers could be randomly assigned to a risk 
communication workshop.  The providers who were not randomly selected into the 
workshop would continue to treat their patients with usual care.  In the workshop, 
particular attention would be paid to increasing provider awareness of Bogardus’ 
dimensions of risk communication.  Providers would be taught to discuss specific risks, 
their probabilities, timing, and permanence of the risks.  Providers would also be taught 
to ask caregivers and children their feelings about the risks of each asthma control 
medication.  An outcome measure could be the amount of providers who increased the 
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frequency of risk discussions among their patients as well as examining adherence in the 
study group versus the usual care group using pharmacy refill records. 
 
Also, future studies could examine which risks children want to discuss in medical visits 
as well as the risks that caregivers want to discuss in medical visits.  A promising study 
that was led by Raynor and colleagues (Raynor et. al. 2004) showed that children as 
young as 12 years old had certain medication information needs that providers should 
address when talking about asthma medications: (1) name and the purpose of the 
medication; (2) when to take it, how to take it, and how long to take it; (3) side effects 
and what to do about them; (4) interactions with other medications; and (5) how to tell if 
the medication is not working.  Incorporating those five sections of medication 
discussions into an intervention could be beneficial in enhancing risk communication.   
 
An intervention that incorporated Raynor’s 2004 study could be audiotape recording 
pharmacist discussions with children who have persistent asthma.  The pharmacist would 
have a checklist of each important topic area from Raynor and colleagues (2004) each 
time they interacted with a study patient.  By randomly selecting pharmacists into a 
discussion using Raynor’s topic areas and comparing with pharmacists who continue to 
see their patients as usual care, researchers could examine child adherence among the 
study arm pharmacists and the control group pharmacists.   
 
Next, the audiotaped medical visit that was used in the present study provided only a 
snapshot of the provider-child-caregiver relationships.  Using a longitudinal study design 
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would permit the assessment of investigating side effect, risk, and benefit communication 
on medication adherence over multiple medical visits.  Longitudinal study designs in 
future research should attempt to identify important mediators and moderators of 
communication about side effects, risks, and benefits of asthma control medications and 
the impact of these communications on patient outcomes.  Caregiver’s and children’s 
trust in their providers, provider attitudes with side effect, risk, and benefit 
communications, and caregiver’s and children’s assessments of their willingness to take a 
medication given certain risks and benefits are just some of the factors that may mediate 
or moderate the relationship between communication and patient outcomes.   
 
Future studies should include both observational and perception measures of 
communication.  Direct observation of communication permits reliable assessment of the 
content and time spent discussing certain topics, but it fails to capture whether children 
and caregivers understood the information provided.  Given that prior research has found 
that most patients forget the information their provider discussed during the medical visit 
and those who remember the content are incorrect when they have to recall the 
information (Kessels 2003), it is important for researchers to understand if both children 
and caregivers understand the side effect, risk, and benefit communication that providers 
may give them during a medical consultation.  An intervention that included the Teach-
Back method would be especially beneficial in helping children and caregivers 
understand the information that is presented during a medical visit.   
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Providers could incorporate the Teach Back method in their discussions about 
medication-related risks and benefits.  A study that could be designed would be where 
providers are audiotape recorded and there would be a nurse in the room to act as a health 
advocate.  There would be providers who would continue to treat children as usual 
without the health advocate in different practices.  The health advocate could ensure that 
providers use the Teach Back method during the clinic visits.  Researchers could then 
assess if using the Teach Back method resulted in more accurate recall of what was 
discussed during the medical visit.     
 
 Future studies should also examine provider attitudes toward discussing side effects, 
risks, and benefits with a particular focus on self-efficacy.  Related to self-efficacy, future 
research should focus on the knowledge that primary care providers have about 
medication-related side effects and risks of asthma control medications.  Our results 
showed that providers who were not physicians did not have visits in which asthma 
control medication-related risks were discussed.  Future research should try to determine 
if there is a difference in self-efficacy and knowledge among providers who are not 
physicians and providers who are physicians.  
 
Additionally, future research should also examine how children can be taught to 
effectively participate in their medical encounters, especially in discussing medication 
risks and benefits.  Interventions should be aimed at children that take into account a 
child’s cognitive stage as well as their age.  Since there is a high prevalence of adults 
with low numeracy in the United States, interventions that can be tailored for low 
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numerate adults have the potential to be used in children as well.  An example of an 
intervention that has the potential to be used by children and their caregivers could be 
teaching a medical provider to discuss each of Raynor’s five areas of medication 
information (Raynor et. al. 2004), with both children and their caregivers, using the 
Teach-Back method.  A randomized controlled trial that compares usual care with this 
intervention may be useful in not only making children and their caregivers aware of their 
asthma medication and the risks and benefits associated with using it, but also increase 
comprehension of that information.     
 
An intervention should also be tested that examines how pharmacists can discuss 
medication-related risks and benefits to children and caregivers.  Pharmacists have a 
limited time to counsel patients on their medications.  Utilizing Raynor and colleagues 
framework to discussing asthma medications may be beneficial for pharmacists (Raynor 
2004).  The intervention could be a simple workshop that teaches pharmacists to counsel 
patients by discussing: (1) name and the purpose of the medication; (2) when to take it, 
how to take it, and how long to take it; (3) side effects and what to do about them; (4) 
interactions with other medications; and (5) how to tell if the medication is not working.   
Another possible intervention that could be directed at pharmacists is a course that 
specifically targets pharmacy rotation students and teaches important communication 
aspects, incorporating Raynor and colleagues’ findings of talking points when discussing 
medications with children and caregivers and using the Teach-Back method to ensure 
understanding.  The intervention could end with simulated patients and discussions of 
ways in which pharmacists can enhance their discussions with children and caregivers.      
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Conclusion 
This study helps address gaps in the literature regarding communication between 
providers and children and their caregivers about asthma control medication side effects, 
risks, and benefits.  While the literature has stressed the importance of provider-patient 
communication about medication risks, this was the first study to examine the content 
and predictors of actual discussions about asthma control medication side effects, risks, 
and benefits.  Our results show that providers rarely discuss side effects and risks of 
asthma control medications with children and caregivers.  Our results also show that 
discussions about asthma control medication benefits do not occur in every visit, but 
comparatively more so than side effects and risks.  Physicians were the only providers 
who had visits in which asthma medication risks were discussed and asked questions 
about asthma control medication benefits.  
 
Study results indicate that medication side effects, risks, and benefit communication are 
complex topics that take many different forms in routine medical visits.  The study results 
may facilitate the development of interventions that focus on children, caregivers, and 
providers to encourage discussions about asthma control medication side effects, risks, 
and benefits in primary care medical practice.  Interventions utilizing technologies to 
bring child-reported concerns about side effects and medication adherence to the point of 
care may go a long way to improving the communication about asthma control 
medication side effects, risks, and benefits.  This study may also help provide a 
framework for providers to start discussing the potential risks that children face in other 
chronic diseases that require daily medication management.  
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Appendix A: Asthma Control Medications 
 
         Generic (Brand name) 
 
 
Inhaled Corticosteroids 
 
 
Beclomethasone (Vanceril®, Beclovent®, Qvar®)  
         Triamcinolone (Azmacort®) 
 
Flunisolide (Aerobid®)   
 
Fluticasone (Flovent®)  
         Budesonide (Pulmicort®)  
  
       Mometasone (Asmanex®) 
 
Anti-inflammatory: Mast-cell stabilizer 
 
 
Cromolyn (Intal®)  
 
Nedocromil (Tilade®)  
 
Long-acting beta agonist 
 
 
Salmeterol (Serevent®)  
 
Formoterol (Foradil®)  
 
 
Inhaled corticosteroid and long-acting beta agonist 
 
 
Salmeterol and fluticasone (Advair® diskus)  
                  
 
Methylxanthines 
 
 
Theophylline (Slo-bid®, Theo-Dur®, Uniphyl®)  
 
 
Leukotriene Modifiers 
 
 
Zileuton (Zyflo®)  
 
Zarfirlukast (Accolate®) 
 
Montelukast (Singulair®)  
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Appendix B: Supplemental Coding Instrument 
Supplemental Coding Instrument 
Patient ID: ____________      Coder ID: __________ 
Date of Coding: __________ 
 
 
Asthma Proposal – Supplemental Coding Instrument 
 
i). Is there more than one caregiver present      Y N 
     during the audiotaped medical visit? 
 
1.  
 
a. Name of Control 
Medication Discussed 
b. End of 
Visit Plan 
c. Risks 
Discussed 
d. Side 
Effects 
Discussed 
e. Benefits 
Discussed 
1 ________________ 
Start     Cont     
 
D/C 
Y             N        
 
N/A 
Y             N        
 
N/A 
Y           N        
 
N/A 
2 _ ______________ 
Start     Cont     
 
D/C 
Y            N        
 
N/A 
Y             N        
 
N/A 
Y           N        
 
N/A 
3 
_____________________
_ 
Start     Cont     
 
D/C 
Y            N        
 
N/A 
Y             N        
 
N/A 
Y           N        
 
N/A 
4 
_____________________
_ 
Start     Cont     
 
D/C 
Y            N        
 
N/A 
Y             N        
 
N/A 
Y            N        
 
N/A 
 
 
2.  
 
 Side Effects Yes No     
a. Are side effects 
discussed? Y N     
b. If yes, for what asthma 
control medication(s)? 1  2 3 4 
c. If yes, who initiates the 
discussion? C P  D N/A 
d. Does caregiver or 
patient state experience of 
side effects? C P D  N/A 
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Name of Side Effect Discussed 
1 _____________________________________________________________________ 
2 _____________________________________________________________________ 
3 _____________________________________________________________________ 
4 _____________________________________________________________________ 
5 _____________________________________________________________________ 
6 _____________________________________________________________________ 
7 _____________________________________________________________________ 
8 _____________________________________________________________________ 
9 _____________________________________________________________________ 
 
2e. Number of caregiver questions about side effects? _________ 
 
2f. Number of caregiver statements about side effects _________ 
 
2g. Number of child questions about side effects? _________ 
 
2h. Number of child statements about side effects _________  
 
2i. Number of provider questions about side effects? __________ 
 
2j. Number of provider statements about side effects __________ 
 
 
 
3.  
 
Risks YES NO     
a. Are risks discussed? Y N     
b. If yes, who initiates? C P D N/A 
 
 
c. Identity of risk discussed 
d. Is 
Permanence 
Discussed 
e. Is 
Timing 
Discussed 
f. Is 
Probability 
Discussed 
g. Are 
Values 
Discussed 
h. Is 
Severity of 
Risk 
Discussed 
1 
____________________
_ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
2 
____________________
_ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
3 
____________________
_ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
4 
____________________
Y        N        
 
Y       N        
 
Y       N        
 
Y       N        
 
Y       N        
 
 195
_ N/A N/A N/A N/A N/A 
5 
____________________
_ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
6 
____________________
_ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
7 
____________________
_ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
8 
____________________
_ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
9 
____________________
__________ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
 
 
3i. Does provider discuss probability qualitatively?  Y N N/A 
 
3j. Does provider discuss probability numerically?  Y N N/A 
 
3k. Number of caregiver questions about risks? ________________ 
 
3l. Number of caregiver statements about risks _______________ 
 
3m. Number of child questions about risks? _______________ 
 
3n. Number of child statements about risks _______________ 
 
3o. Number of provider questions about risks? ________________ 
 
3p. Number of provider statements about risks ________________ 
 
4.  
 
Benefits Discussed YES NO     
a. Are benefits discussed Y N     
b. If yes, who initiates? C P D N/A 
 
c. Names of Benefits Discussed 
1 ______________________________ 
2 ______________________________ 
3 ______________________________ 
4 ______________________________ 
5 ______________________________ 
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6 ______________________________ 
7 ______________________________ 
8 ______________________________ 
9 ______________________________ 
 
 
4d. Number of provider statements about benefits of asthma control medications _________ 
 
4e. Number of provider questions about benefits of asthma control medications ________ 
 
4f. Number of caregiver statements about benefits of asthma control medications _________ 
 
4g. Number of caregiver questions about benefits of asthma control medications ________ 
 
4h. Number of patient statements about benefits of asthma control medications ________ 
 
4i. Number of patient questions about benefits of asthma control medications ________ 
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Appendix C: Coding Rules for Supplemental Coding Instrument (SCI) 
 
Coding Rules for Supplemental Coding Instrument (SCI) 
 
All questions contained in the SCI about risks, side effects, and benefits of 
medication are for asthma control medications only.  Follow these rules for coding 
of the instrument in the order directed by this document.   
 
Notes about Medications:  
• For the purposes of this study, we are interested in medications that are used to treat 
persistent asthma. 
o You have been provided with a sheet that contains all of the asthma control 
medications that are used to treat persistent asthma. 
• Medication conversations that are of interest include medications the child is taking, has 
taken, or may take.   
o This includes medications that the patient should have been taking since their last 
visit, medications the patient has stopped taking, new medications that are being 
prescribed during the visit, and medications that are to be started that is 
contingent on a certain circumstance, medications that are being considered, 
and/or medications that are mentioned. 
o This also includes medications that the patient is taking regardless of whether or 
not they were prescribed by the provider that was recorded in the transcript. 
 
Asthma Control Medication Side Effects, Risks, and Benefits:  
• Conversations about asthma control medication side effects, risks, and benefits includes 
direct communication about these concepts.  Direct communication involves explicit 
communication about the side effects, risks, and benefits that the patient may be or has 
experienced as a result of using the medication.   
 
• For the purposes of this study, we have defined side effects, risks, and benefits that are to 
be followed CLOSELY:  
 
o Side Effects: Side effects are defined as adverse effects that the patient HAS 
experienced as a result of using the asthma control medication.   
 Side effects’ definition DOES NOT include adverse effects that the 
patient may experience, regardless of whether the provider, child, or 
caregiver uses the direct words “side effects.” 
 Example: C-I took his Singulair away he has not complained to me about 
headaches. 
 
o Risks: Risks are defined as adverse effects that the patient HAS NOT 
experienced yet or MAY experience as a result of using the asthma control 
medication. 
 Risks’ definition DOES NOT include adverse effects that the patient has 
already experienced.   
 Example: D: The steroids don’t make you grow hair and muscles it’s just 
anti-inflammatory, just for lungs. 
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o Benefits: Benefits are defined as ANY positive effects that the provider, child, or 
caregiver discusses that are results of using the asthma control medication.  This 
includes discussions of prior benefits or benefits that have not been experienced 
yet  
 Example: D-…We should be able to get him on enough medicine that 
you are able to play soccer and run and to not get that short of breath 
 
 
When Coding:  
1. Use your computer’s Microsoft Word software to code the information on the coding tool 
1.  
2. Please have the asthma control medications sheet during the entire coding process.   
2.  
3. Read the transcript at least 3 times in order to correctly code the visit 
a. Use the first time as a way to get acquainted with the transcript and learn how the 
communication process works 
b. Use the second time to code information that is contained in the following pages.  
There is a high likelihood that you will not be able to capture all the information 
during the second reading. 
c. Use the third time to capture the information you may have missed during the second 
reading, and to verify that you have followed the rules for coding. 
 
4. Make sure that each item and category is coded (highlighted in Microsoft Word) 
appropriately.  Please double-check your work. 
 
5. Generally, more information is always preferred.  If you are unsure about how to code an 
interaction, record as much detail about the encounter and record any notes or questions that 
may be helpful in determining why a particular decision was made. 
 
To Code: 
Header: Transcript Identification, Coder Initials, and Coding Date 
3.  
• Transcript/Patient Identification Number: Be sure to type the patient’s 5-digit 
identification number.  The format should be:  
o Example: 010101 
 010101 is the patient ID number for the project.   
• The first two digits identify the clinic, the second two digits 
identify the provider, and the last two identify the patient.   
• In this case, at clinic 01, provider 01 is seeing patient 01. 
• Coder Initials: Type your initials here. 
• Date Coded: Record the current date on which you are coding the transcript. 
4.  
 
 
Initial Page Content 
Legend 
Y = ‘yes’ 
N = ‘no’ 
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D = ‘doctor’ 
P = ‘patient/child’ 
C = ‘caregiver’ 
Ne = ‘neither’ 
N/A = ‘not applicable’ 
 
Question i – Code this question as ‘Yes’ if the top right hand side of the transcript 
indicates that there was more than one caregiver present during the visit.  This includes O 
for other, but not for siblings.   
 
Name of Control 
Medication Discussed 
End of Visit 
Plan 
Risks 
Discussed 
Side Effects 
Discussed 
Benefits 
Discussed 
1 
_____________________
_ 
Start     Cont     
 
D/C      
Y            N        
 
 
Y            N        
 
N/A 
Y            N        
 
 
2 
_____________________
_ 
Start     Cont     
 
D/C      
Y            N        
 
 
Y             N        
 
N/A 
Y           N        
 
 
3 
_____________________
_ 
Start     Cont     
 
D/C      
Y            N        
 
 
Y             N        
 
N/A 
Y           N        
 
 
4 
_____________________
_ 
Start     Cont     
 
D/C      
Y            N        
 
 
Y             N        
 
N/A 
Y            N        
 
 
  
For Name of Control Medication box above, write the name of each of the asthma 
control medications discussed during the medical visit.   
 
Then, for the End of Visit Plan box code whether the provider Started, Continued, or 
Discontinued (D/C) the medication.  If the provider changes the dose of a medication but 
the medication name stays the same, then the coder will code this action as a medication 
that has been Started.  If a medication was restarted by the provider (if discussed this way 
in the medical visit), then the coder should code this as Start. 
 
Next, for the Risks Discussed box, circle whether or not there was a discussion of risks 
for that asthma control medication.  Code ‘Yes” (Y) if there was ANY discussion of risks 
(regardless of who speaks) or ‘No’ (N) if there is not any discussion of risks for that 
asthma control medication.  
 
The Side Effects Discussed box is next and code whether or not there was a discussion 
of the side effects for that asthma control medication.  Code this question as ‘Yes’ (Y) if 
there was ANY discussion of side effects (regardless of who speaks) during the medical 
visit for that asthma control medication or ‘No’ (N) if there was not any discussion of 
side effects for that asthma control medication.  This box can also be coded “N/A” if the 
medication is a new medication, since children have not experienced any side effects of a 
medication they have not taken before.   
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Lastly, the Benefits Discussed box is next to code.  Code whether or not there was a 
discussion of benefits for that asthma control medication.  Code ‘Yes’ (Y) if there was a 
discussion of benefits for each asthma control medication discussed and code ‘No’ (N) if 
there was not a discussion of asthma control medications.   
 
Discussions about Side Effects 
 
Side Effects Yes No     
Are side effects discussed? Y N     
If yes, for what asthma 
control medication(s)? 
 1 2 3 4 
If yes, who initiates the 
discussion? C P  D N/A 
Does caregiver or patient 
state experience of side 
effects? C P D  N/A 
 
For the first row in this table, code whether or not side effects were discussed during the 
medical visit.  Code ‘Y’ if side effects were discussed during the visit and code ‘N’ if 
side effects were not discussed during the visit.   
 
For the second row in the above box, code the corresponding number(s) from the first 
table of the asthma control medications.   
 
For the third row in the above box, code who started the discussion about side effects.  If 
there was not a discussion of side effects (‘N’ is coded in the first row) then code ‘N/A.’  
 
For the final row in the above box, code who states that the child is currently or has 
previously experienced side effects.  Code ‘C’ if the caregiver states the child has 
experienced a side effect and code ‘P’ if the patient states s/he has experienced a side 
effect.  Code ‘D’ if it is the provider that states the child has or is experiencing side 
effects.  Code N/A if side effects were not discussed.         
 
 
Name of Side Effect Discussed 
1 _____________________________________________________________________ 
2 _____________________________________________________________________ 
3 _____________________________________________________________________ 
4 _____________________________________________________________________ 
5 _____________________________________________________________________ 
6 _____________________________________________________________________ 
7 _____________________________________________________________________ 
8 _____________________________________________________________________ 
9 _____________________________________________________________________ 
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For each row in the above table, copy EACH question and EACH statement that was 
made about side effects for all applicable medications.  The following table is an actual 
table from the Principal Investigator’s coding of a side effect discussion:  
 
Name of Side Effect Discussed 
1 _ MD:  You’re so funny.  You did great on your spirometry and it’s normal.  It looks 
good.  Alright, so you’re taking your Advair?  No problems with that?  Doing it in the 
inhaler with your spacer? 
____________________________________________________________________ 
2 _____________________________________________________________________ 
3 _____________________________________________________________________ 
4 _____________________________________________________________________ 
5 _____________________________________________________________________ 
6 _____________________________________________________________________ 
7 _____________________________________________________________________ 
8 _____________________________________________________________________ 
9 _____________________________________________________________________ 
 
2e. Number of caregiver questions about side effects? _________ 
 
2f. Number of caregiver statements about side effects _________ 
 
2g. Number of child questions about side effects? _________ 
 
2h. Number of child statements about side effects _________  
 
2i. Number of provider questions about side effects? __________ 
 
2j. Number of provider statements about side effects __________ 
 
For each question above, count and sum each participants’ respective questions and 
statements from the box above and place the answer in the provided space.   
 
 
 
 
 
 
Discussions about Risks 
 
Risks YES NO     
a. Are risks discussed? Y N     
b. If yes, who initiates? C P D N/A 
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For the first row in the above box, code whether there is ANY discussion of risks during 
the medical visit, regardless of who participates in the discussion.  Code “Y” (yes) if 
there is a discussion about risks of an asthma control medication.  Code “N” (no) if there 
is not any discussion about the risks of using an asthma control medication.   
 
For the second row in the above box, code who started the conversation about risks.  
Code “C” if the caregiver starts the discussion, “P” if the child starts the conversation, 
and “D” if the provider starts the discussion.  Code “N/A” if there is not a discussion of 
risks.   
 
 
c. Identity of risk discussed 
d. Is 
Permanence 
Discussed 
e. Is 
Timing 
Discussed 
f. Is 
Probability 
Discussed 
g. Are 
Values 
Discussed 
h. Is 
Severity of 
Risk 
Discussed 
1 
_____________________ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N         
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
2 
_____________________ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N         
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
3 
_____________________ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N         
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
4 
_____________________ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N         
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
5 
_____________________ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N         
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
6 
_____________________ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N         
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
7 
_____________________ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N         
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
8 
_____________________ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N         
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
9 
_____________________ 
Y        N        
 
N/A 
Y       N        
 
N/A 
Y       N         
 
N/A 
Y       N        
 
N/A 
Y       N        
 
N/A 
 
 
For each row in the above box, code each asthma control medication risk that is discussed 
during the visit.  Each column from the above table needs to be coded in addition to the 
name of each risk that is stated.  The concepts for each column is defined below: 
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 Risk Identity: The name of the risk.  Examples of names of risks are: shorter stature, 
glaucoma, oral thrush, etc. 
5.  
 Permanence: The duration of the risk.  The duration of the risk may be temporary (e.g. 
oral thrush from using an inhaled corticosteroid) or permanent (e.g. shorter adult stature) 
 
 Timing: When the risk is likely to occur.   
 
 Probability: The likelihood of experiencing the risk.  This includes quantitative 
probability discussions, such as 1%, 1 in 1,000 etc. to describe the likelihood of a risk 
occurring.  This dimension also includes qualitative probability discussions that use 
words such as rare, common, not common, frequent, etc. to describe the likelihood of a 
risk occurring.   
 
 Value: The caregiver’s and/or the child’s perception of the importance of the risk for 
him/herself (how much does the risk matter to the caregiver or child?). 
 
 Severity: The gravity of the risk.  Can the risk result in blindness (from glaucoma after 
using inhaled corticosteroids) or death (as a result of only using a long-acting beta-
agonist in treating persistent asthma)? 
 
 
3i. Does provider discuss probability qualitatively?  Y N N/A 
 
3j. Does provider discuss probability numerically?  Y N N/A 
   
The above two questions are only applicable IF there is a discussion about the probability 
of a risk occurring.   
 
Question 3i should be coded “Y” (yes) if there is a discussion about probability that used 
words (as described above) to communicate the likelihood of a risk occurring and “N” 
(no) if there is not a discussion that used words to describe the likelihood of a risk 
occurring.  The coder should code “N/A” if there is not any discussion about the 
probability of a risk occurring.  
 
Question 3j should be coded “Y” (yes) if there is a discussion about probability that used 
numbers (as described above) to communicate the likelihood of a risk occurring and “N” 
(no) if there is not a discussion that used numbers to describe the likelihood of a risk 
occurring.  The coder should code “N/A” if there is not any discussion about the 
probability of a risk occurring.   
 
3k. Number of caregiver questions about risks? ________________ 
 
3l. Number of caregiver statements about risks _______________ 
 
3m. Number of child questions about risks? _______________ 
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3n. Number of child statements about risks _______________ 
 
3o. Number of provider questions about risks? ________________ 
 
3p. Number of provider statements about risks ________________ 
  
 
For each question above, count and sum each participant’s respective questions and 
statements about risks and place the answer in the space provided.  
 
Discussions about Benefits 
 
Benefits Discussed YES NO     
a. Are benefits discussed Y N     
b. If yes, who initiates? C P D N/A 
 
For the first row in the above box, code whether there was ANY discussion about the 
benefits of using an asthma control medication, regardless of who speaks in the 
discussion.  Code “Y” (yes) if there is a discussion about benefits of using an asthma 
control medication and code “N” (no) if there is not a discussion about the benefits of 
using an asthma control medication.   
 
For the second row in the above box, code the participant that started the conversation 
about the benefits of the asthma control medication.  Code “C” if the caregiver started the 
conversation about benefits, code “P” if the child started the conversation about benefits, 
and code “D” if the provider started the conversation about benefits.  Code “N/A” if there 
is not a discussion about benefits of using asthma control medications.   
 
 
c. Names of Benefits Discussed 
1 ______________________________ 
2 ______________________________ 
3 ______________________________ 
4 ______________________________ 
5 ______________________________ 
6 ______________________________ 
7 ______________________________ 
8 ______________________________ 
9 ______________________________ 
  
For each row in the above box, copy and paste each question and statement from the 
transcripts of the medical visit.  The following table is an actual table from the Principal 
Investigator’s coding of a benefit discussion: 
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c. Names of Benefits Discussed 
1 _ MD You are so much better than you were. _______________________ 
2 MD But it’s that medicine, honey, that prevents you from having trouble. 
______________________________ 
3 MD I mean it’s that medicine that does it. 
 
4 ______________________________ 
5 ______________________________ 
6 ______________________________ 
7 ______________________________ 
8 ______________________________ 
9 ______________________________ 
 
4d. Number of provider statements about benefits _________ 
 
4e. Number of provider questions about benefits ________ 
 
4f. Number of caregiver statements about benefits _________ 
 
4g. Number of caregiver questions about benefits ________ 
 
4h. Number of patient statements about benefits ________ 
 
4i. Number of patient questions about benefits _________ 
 
 
For each question above, count and sum each participant’s respective questions and 
statements about benefits and place the answer in the space provided.  
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